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ABSTRACT 
 
JASMINE A. TALAMEH: Genetic and Pharmacogenetic Associations with  
Heart Failure Patient Survival 
(Under the direction of J. Herbert Patterson) 
 
 
Heart failure (HF) is an enormous public health problem. Survival and beta-
blocker response rates in HF patients are highly variable and cannot be accurately 
predicted by clinical characteristics alone. The sympathetic nervous system (SNS) and 
the renin-angiotensin-aldosterone system (RAAS) dually contribute to HF 
pathophysiology, and inhibition of these systems by beta-blockers, on average, 
significantly prolongs HF patient survival. Common, functional genetic variants affect 
the activity of the SNS and RAAS, but their association with HF patient outcomes has not 
been fully characterized. Therefore the collective objective of this doctoral dissertation 
research was to determine the association of common, functional genetic variants in the 
SNS and RAAS with HF patient survival and beta-blocker survival benefit. Eleven 
variants from nine genes in the SNS and RAAS were genotyped in 722 HF patients with 
fluorescent, electrophoretic, and mass spectrometric methods. No variants were 
independently associated with HF patient survival, but ADBR1 Ser49Gly was 
significantly associated with beta-blocker survival benefit.   Beta-blocker use at baseline 
was associated with a statistically significant 46% reduction in mortality in Ser49-
homozygotes and a non-significant 38% increase in Gly49-carriers. Simple and 
internally-weighted genetic risk scores were used to assess the additive association of the 
iv 
 
SNS and RAAS variants with HF patient survival and beta-blocker survival benefit. The 
genetic risk scores were not associated with either outcome, did not add to the 
predictability of clinical risk factors, or reclassify HF patients into new mortality risk 
categories. A recursive partitioning data mining method was used to detect gene-gene 
interactions associated with HF patient survival and beta-blocker survival benefit. No 
gene-gene interactions were associated with outcome in all of the patients or specifically 
the African-Americans, but in the non-African-Americans ADRB1 Ser49-Arg389/ Gly49-
Arg389 diplotype interacted with AGTR1 A1166C. In the patients aged less than 60 and 
treated with beta-blockers, the mortality rate was approximately 3-fold higher if patients 
had the ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype and carried AGTR1 1166C. The 
findings in this dissertation research have profound clinical implications. HF patients 
with a genetic predisposition for high mortality risk or beta-blocker ineffectiveness could 
be targeted for closer clinical monitoring and/or additional/alternative pharmacologic 
therapies.  
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CHAPTER I: 
INTRODUCTION 
 
Summary 
 Heart failure (HF) is an enormous public health problem. Hyperactivity of the 
sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) 
plays a major role in HF pathophysiology. Direct pharmacologic inhibition of the SNS 
and indirect inhibition of the RAAS with beta-blockers significantly improves survival in 
patients with HF, on average, but the individual patient responses to beta-blockade 
widely vary. Genetic variation, affecting the functional activity of the SNS and RAAS, 
may be a possible explanation for variation in HF patient survival and beta-blocker 
response. The aims of this dissertation research were to determine if genetic variants in 
the SNS and RAAS, individually, additively, or with interactions between, are associated 
with survival and beta-blocker survival benefit in patients with HF. 
 
The Problem of Heart Failure 
 HF is an enormous public health problem, with immense cost, incidence, 
prevalence, morbidity, and mortality.  In 2010, HF cost the United States an estimated 
$39.2 billion (1), and in 2015 the projected cost is $44.6 billion (2). Although only 13% 
of Medicare beneficiaries have HF, they accounted for 37% of all Medicare spending and 
50% of Medicare inpatient costs (3). The development of HF is very common. The 
lifetime risk for developing HF is 20% at age 40, and an estimated 5.7 million Americans 
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have HF (2). This burden of HF is expected to increase as the population ages, acute 
mortality from myocardial infarction (MI) declines, and the survival of patients with HF 
is prolonged.  HF continues to have high morbidity and mortality rates.  One out of four 
HF patients admitted to the hospital will be readmitted within 30 days (4). Overall, 20% 
of HF patients will die within one year, and 50% will die within five years (2). For end-
stage HF, the one-year mortality rate with optimal medical management is 75%, which is 
higher than many types of cancer (5).  Heart transplant is the only cure for HF, which 
improves end-stage HF one-year survival to approximately 88% and five-year survival to 
approximately 75% (6). However in 2010, there were only 2,406 hearts donated (6), and 
the low donation rate has remained constant with no substantive increase anticipated in 
the near future (6). 
 Despite these striking statistics, the treatment of HF has significantly improved 
over the past few decades, owing to the introduction of effective pharmacologic and 
mechanical device therapies. Several classes of drugs have been developed that improve 
HF symptoms and/or survival (7), but this comes at the expense of increasing the number 
of drugs that HF patients take chronically. For example, Medicare beneficiaries with HF 
have an average of 61 prescriptions written in one year; the typical beneficiary had 29 
(3). The resulting polypharmacy can lead to problems including economic burden, patient 
adherence, and drug interactions (8).  Left ventricular assist devices (LVAD) are 
becoming more common as either bridge-to-transplant or destination therapies; however 
the survival rates with LVAD are not as great as with heart transplant: 74% at one year 
and 55% at two years (9).  The use of LVAD results in serious adverse events, 
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predominately caused by infection, bleeding, neurologic dysfunction, and device 
malfunction (10). 
 The current therapies for HF do not distinguish among the complex types of HF, 
in which there are many potential etiologies, diverse clinical features, and numerous 
clinical subsets. For example, patients with HF caused by MI, chemotherapy, or no 
known identifiable cause (i.e. idiopathic dilated cardiomyopathy which could possibly be 
viral or inherited) are generally treated the same (7), even though the source and 
manifestation of myocardial damage are grossly different. Also, there is not unequivocal 
evidence for pharmacotherapies in patients with HF and preserved left ventricular 
ejection fraction (LVEF).  Although the syndromes under the moniker of HF are diverse, 
a final common pathway among the heterogeneous HF patient population is 
neurohormonal activation. The major neurohormonal systems that are activated in HF are 
the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone (RAAS) 
system. 
 
The Sympathetic Nervous System 
 The purpose of the SNS, as part of the autonomic nervous system, is to elicit the 
fight-or-flight response. In a healthy person, the SNS responds to stress with a wide 
variety of physiologic responses such as vasoconstriction, cardiac inotropy and 
chronotropy, and release of renin from the kidney. Sympathetic outflow to the heart and 
peripheral circulation is regulated by cardiovascular reflexes originating from aortic and 
carotid baroreceptors, cardiopulmonary baroreceptors, and peripheral chemoreceptors 
(11). The SNS mediates cardiovascular action via four pathways: 1) norepinephrine (NE) 
 4 
 
release at the sinus and atrioventricular nodes and left ventricle; 2) epinephrine (EPI) 
released in the circulation by the adrenal cortex; 3) local release of EPI and NE in the 
peripheral vessels; and 4) circulating NE which can act in multiple locations (12).  Both 
NE and EPI exert their biological actions via activation of nine different adrenergic 
receptor subtypes: alpha-1 (1A, 1B, and 1D), alpha-2 (2A, 2B, and 2C), and beta (1, 2, 
and 3). Adrenergic receptors are members of the super-family of seven transmembrane 
receptors that signal primarily via interaction with heterotrimeric G proteins. These 
healthy SNS responses may have evolved to compensate for non-specific, short-term loss 
of blood volume and/or pressure. However in HF, cardiac output is persistently affected, 
for example due to myocardial infarction, ventricular hypertrophy, or idiopathic dilated 
cardiomyopathy.  Thus, HF results in long-term activation of the SNS, which in turn 
leads to abnormalities in SNS function and adverse consequences (Figure 1).   
 SNS hyperactivity in HF.  In HF, the SNS is hyperactive with the goal of 
maintaining cardiac output. Plasma NE concentration is significantly higher in patients 
with HF compared to healthy controls (13). Despite the reduced organ blood flows 
caused by HF that can elevate plasma NE concentration, methods have determined that 
the increased plasma NE concentration in HF is due to both increased release and 
decreased clearance of NE from plasma (14). The exaggerated release of NE in HF at rest 
is similar in magnitude to the release of NE in healthy persons during exercise (15). 
Increased central sympathetic outflow has also been demonstrated in HF by direct 
measurement of sympathetic nerve activity using microneurography (16).  Several 
possible mechanisms can explain SNS hyperactivity in HF, such as abnormalities in 
cardiovascular reflexes and circulating and central hormones. The sympatho-inhibitory 
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cardiovascular reflexes, such as the arterial baroreceptor reflex, are significantly 
suppressed (17), whereas the sympatho-excitatory reflexes, such as the cardiac 
sympathetic afferent reflex (18), are augmented.  Angiotensin II levels are also increased 
in HF, which can facilitate sympathetic neurotransmission via several mechanisms 
described in detail below (See: Interaction with SNS).  
 Consequences of SNS hyperactivity in HF.  SNS hyperactivity in HF has 
adverse consequences at molecular, physiologic, and clinical levels.    There are multiple 
alterations in the beta-adrenergic receptor signaling pathway, including down-regulation 
of receptors (decreased beta receptor density) (19), desensitization via uncoupling from 
Gs (stimulatory G protein) (20), and an increase in Gi (inhibitory G protein) (21). 
Notably, receptor down-regulation in HF is specific to beta-1 receptors, and beta-2 
receptor density remains unchanged (22).  Down-regulation and desensitization of beta-
receptors is thought to be a protective adaptation in HF because persistent sympathetic 
stimulation is toxic to the cardiac myocyte (23). Persistent SNS activation also leads to 
the pathophysiologic cardiac remodeling process, in which the heart goes through 
maladaptive changes in size, shape, and function after an injury (24). The degree of SNS 
hyperactivity is also correlated with hemodynamic abnormalities (25), symptoms (26), 
and survival (27) in patients with HF (25). 
 
The Renin-Angiotensin-Aldosterone System 
 The RAAS is both a circulating and local hormonal system with the purpose of 
maintaining blood pressure and fluid homeostasis. When blood pressure or volume is 
lowered in a healthy person, renin is secreted from the juxtaglomerular cells of the kidney 
 6 
 
into the circulation, which converts angiotensinogen (synthesized in the liver) to 
angiotensin I. Angiotensin I is converted to angiotensin II by the angiotensin-converting 
enzyme. Angiotensin II elicits the majority of its actions via the angiotensin II type 1 
receptor, which includes vasoconstriction, sodium and water retention, and aldosterone 
secretion. Notably, the release of renin is the rate-limiting step in the RAAS activation 
(28).  
 RAAS hyperactivity in HF. Like the SNS, the RAAS is hyperactive in HF to 
compensate for the persistent decrease in cardiac output, which has been demonstrated in 
experimental HF (29) and HF patients (30,31) by increased plasma levels of renin, 
angiotensin II, and aldosterone. Also like the SNS, there are several mechanisms that can 
account for the loss of the counter-regulatory balance in the RAAS. Baroreceptor 
dysfunction is a common mechanism for RAAS and SNS hyperactivity. In a healthy 
person, under- and over-filling of the vasculature initiates afferent signals from various 
sensory receptors (e.g. atrial and arterial baroreceptors), aiming ultimately to restore 
perfusion pressures with sodium and water retention or induce natriuresis to relieve 
circulatory congestion. However in HF, there are disturbances in the afferent signaling 
from volume-sensing sites resulting in blunted natriuresis in the face of venous 
congestion and elevated cardiac filling pressures (32). In addition, the suppression of 
renin release and renal excretion responses to natriuretic peptide are attenuated in HF 
(33).   
 Consequences of RAAS hyperactivity in HF. Similar to the SNS, RAAS 
hyperactivity in HF has adverse consequences at molecular, physiologic, and clinical 
levels.  Angiotensin II plays a critical role in pathophysiologic cardiac remodeling via 
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several mechanisms: increasing DNA, protein, and collagen synthesis in cardiac 
fibroblasts (34,35); mediating stretch-induced hypertrophy (36);  and cardiac myocyte 
necrosis (37).  Therefore it is not surprising that RAAS activity is associated with left 
ventricular dysfunction (13). Other physiologic consequences of RAAS hyperactivity in 
HF include peripheral vasoconstriction, sodium retention, and hence, circulatory 
congestion. RAAS activity is associated with the progression to HF from asymptomatic 
left ventricular dysfunction (13) and HF morbidity and mortality (38-40).  
 Interaction with SNS. Although discussed separately, the SNS and RAAS 
mutually facilitate each other’s hyperactivity (Figure 2). Specifically, angiotensin II can 
facilitate sympathetic neurotransmission via several mechanisms: stimulatory action on 
sympathetic ganglia (41); increasing neurotransmitter release at sympathetic nerve 
endings (42); preventing NE uptake at sympathetic nerve terminals (43); centrally 
stimulating angiotensin II type 1 receptors in the brain (44);  increasing central 
sympathetic nerve activity (45); the release of catecholamines from the adrenal medulla 
(46); facilitation of NE release from sympathetic nerve terminals (47); and modulation of 
baroreflex control of heart rate (48). In turn, SNS stimulation of beta-1 adrenergic 
receptors in the kidney results in renin release (49).  
 
Beta-Blockers in Heart Failure 
 Beta-blockers are one of the greatest advances in HF therapy, resulting in a 35% 
reduction in mortality when added to angiotensin-converting enzyme (ACE) inhibitors. 
Although the use of beta-blockers in HF was once contraindicated because of their 
negative inotropic effects, multiple large, placebo-controlled clinical trials demonstrate 
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significant reductions in morbidity and mortality with the use of beta-blockers in HF 
(50,51). The long-term benefits of inhibition of the adverse effects of SNS hyperactivity 
greatly outweigh the negative inotropic effects of beta-blockers. Metoprolol CR/XL, 
carvedilol, and bisoprolol are the three beta-blockers that significantly reduced mortality 
in large HF trials, and hence, are recommended for HF in the treatment guidelines (7). 
Despite the success of these three beta-blockers, a class effect cannot be assumed because 
bucindolol failed to significantly reduce mortality in a large clinical trial (52). Bucindolol 
is a non-selective β-1and β-2 adrenergic receptor antagonist, but bucindolol also has the 
unique pharmacologic property of marked sympatholysis. Metoprolol and bisoprolol are 
selective β-1 receptor antagonists, whereas carvedilol also blocks β-2 and α-1. Although, 
the pharmacologic differences between metoprolol, bisoprolol, and carvedilol have not 
translated into differences in efficacy.  
 Importantly, these results from large beta-blocker trials demonstrate an average 
benefit, but the individual patient responses to beta-blockers vary. For example, long-
term optimal dosing of beta-blockers fails to improve LVEF over 5% in as many as 43% 
of HF patients (53). In a randomized, double-blind trial of metoprolol versus carvedilol in 
150 HF patients, the 95% CI for change in LVEF was -8.2% to +22.6% for metoprolol 
and -11.1% to +32.9% for carvedilol (54). In a study of 171 chronic HF patients treated 
with metoprolol or carvedilol for 9 to 12 months, only 22% of patients had an increase in 
LVEF ≥ 15% (55).  Controversy exists over whether there is racial and regional variation 
in beta-blocker efficacy. The large beta-blocker clinical trials enrolled mostly Caucasian 
men. In a meta-analysis of the large beta-blocker trials, the point estimate for reduction in 
mortality in African-Americans (AA) (RR = 0.67) was similar to Caucasians (RR = 
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0.63), but the estimate was not statistically significant in 545 AAs (56). Less than half of 
the patients enrolled in the large beta-blocker trials were from the United States, and the 
relative risk reduction for each beta-blocker was of smaller magnitude and not 
statistically significant in Americans compared to the rest of the world (57). 
  
Genetic Variation within the SNS and RAAS 
 Genetic variation is differences in DNA sequences between individuals and 
populations, and it can take on a variety of forms, frequencies, and functions. The most 
common form of genetic variation is the single nucleotide polymorphism (SNP), which 
occurs every 100 to 300 base-pairs along the 3 billion base-pair human genome. Other 
common forms of genetic variation are insertion/deletions (indels) and copy number 
variations (CNVs). Genetic variation can be common, i.e. occurring in greater than 5% of 
the general population, or an extremely rare mutation. Most genetic variation is believed 
to be random mutation and have neutral effect, but some genetic variation could have 
profound effect on phenotype, in which a single genetic variant is sufficient to cause 
disease. The functional effect of genetic variation on phenotype can be easily seen for 
some human phenotypic traits, such as eye, hair, and skin color, but genetic variation also 
affects traits that are not readily visible, such as the SNS and RAAS (58,59).   
 Indeed, there is a large amount of variation within genes relevant to the SNS and 
RAAS, including receptors, enzymes, neurotransmitters, and hormones. For example, in 
the National Center for Biotechnology Information (NCBI) and National Library of 
Medicine Database of Single Nucleotide Polymorphisms (dbSNP) (60), there are 112 
variants reported within the human beta-1 adrenergic receptor gene (ADRB1), and 536 
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variants reported within the angiotensin-converting enzyme gene (ACE). There are both 
uncommon and common genetic variants identified within the SNS and RAAS.  For 
example, an indel in the alpha-2C adrenergic receptor gene (ADRA2C) occurs in only 4% 
of Caucasians, while an indel in ACE occurs in 44% of Caucasians. Importantly, the 
frequencies of genetic variants in the SNS and RAAS can differ between races.  For 
comparison, the same ADRA2C indel that is 4% frequent in Caucasians is ten times more 
common in AAs (frequency 43%), but the ACE indel has nearly identical frequency in 
Caucasians (44%) and AAs (43%).  This genetic variation in the SNS and RAAS is not 
merely random mutation; these genetic variants can have profound effects on protein 
function or expression. For example, the ACE indel mentioned above explains 50% of the 
variation in serum ACE levels (61). Another example is that the beta-1 adrenergic 
receptor has agonist-stimulated activity that is three times higher with an arginine at 
amino acid 389 compared to glycine (62).    
 Data on how the functional genetic variation within the SNS and RAAS can 
translate into effects on the HF clinical phenotype is developing. Because the SNS and 
RAAS are integral for HF development, progression, and pharmacotherapy, it is logical 
that functional genetic variants could affect the HF clinical phenotype at any or all of 
those stages (See references 63 and 64, Appendices I & II, for review articles). For 
example, a glycine at amino acid 49 in the beta-1 adrenergic receptor, which results in 
increased receptor down-regulation compared to a serine, resulted in an odds ratio of 14.7 
for the risk of developing idiopathic dilated cardiomyopathy in a small study (65).  In 
patients with established HF, a serine at amino acid 49 in the beta-1 adrenergic receptor 
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was associated with decreased survival (adjusted risk ratio 2.03) (66). This same genetic 
variant was also associated with survival benefit of beta-blockers in HF patients (67).   
 The relationship between SNS and RAAS genetic variation and HF clinical 
outcomes, such as survival and beta-blocker response, has not been fully characterized. 
The genetic and pharmacogenetic association literature for HF is still in very early stages 
and subject to several limitations. For example, many of the previous HF genetic and 
pharmacogenetic studies were low power due to short follow-up (most < 5 years) and/or 
small sample size (most n < 400), which could lead to falsely negative results. Positive 
associations from small, single-center HF genetic and pharmacogenetic studies could be 
false due to selection bias or chance, and those associations have not yet been replicated 
in larger, multicenter HF patient cohorts to rule out those possibilities. Most of the 
previous studies only tested one to three variants; therefore they are unable to determine 
the association of multiple variant combinations or interactions. Previous studies are also 
limited by retrospective design, the exclusion of HF patients with preserved ejection 
fraction, and poor or no representation of AAs. Retrospective studies were often not 
initially designed for genetic and pharmacogenetic research, and hence they often lack 
power. The inclusion of HF patients with preserved ejection fraction in pharmacogenetic 
studies is important because of differences in the HF phenotype and drug response 
compared to HF patients with reduced ejection fraction. Including AAs in genetic and 
pharmacogenetic HF studies is important because, as exemplified above, there are racial 
discrepancies in allele frequencies.  
Specific limitations of the HF pharmacogenetic literature include 100% beta-
blocker treatment rates, only intermediate phenotypic endpoints, lack of beta-blocker 
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dose analysis, lack of specific beta-blocker analysis, and the analysis of the non-FDA 
approved beta-blocker bucindolol. Falsely negative or the reverse pharmacogenetic 
associations could stem from 100% beta-blocker treatment rates present in some of the 
previous HF pharmacogenetic literature. Hypothetical scenarios demonstrating the need 
for an untreated portion of patients in pharmacogenetic studies are shown in Figure 3. 
Many previous HF pharmacogenetic studies only evaluated intermediate phenotypes such 
as ventricular remodeling and not clinical outcomes such as survival, and ventricular 
remodeling is not a perfect surrogate for beta-blocker survival benefit. Many previous HF 
pharmacogenetic studies also lacked beta-blocker dose, which is important because 
genetic effects could vary by dose. For example, ADRB1 Ser49-homozygous patients 
treated with a high dose of beta-blockade had a greater survival benefit as compared with 
a low dose. Whereas ADRB1 Gly49-carriers had a similar survival rate regardless of beta-
blocker dose (67). Many previous HF pharmacogenetic studies lacked specific beta-
blocker data or did not test for beta-blocker specific interactions. However in vitro data 
suggests that pharmacogenetic interactions may be beta-blocker specific (68), which may 
translate into clinical differences. The most robust HF pharmacogenetic data comes from 
sub-studies of the Beta-Blocker Evaluation of Survival Trial (BEST) (52). However the 
beta-blocker tested in BEST is bucindolol, which has unique pharmacologic properties 
including marked sympatholysis (69), and bucindolol did not significantly reduce 
mortality like other FDA-approved beta-blockers (52). Therefore the pharmacogenetic 
data on bucindolol may not be applicable to metoprolol CR/XL, carvedilol, or bisoprolol. 
Because of the many limitations of the previous HF genetic and pharmacogenetic 
literature, more definitive and comprehensive research is needed to characterize the 
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relationship between SNS and RAAS genetic variants and HF survival and beta-blocker 
survival benefit. This dissertation research addresses the limitations described above by 
using a well-powered, HF patient cohort and the novel application of advanced analytical 
methods to determine the individual (Specific Aim I), additive (Specific Aim II), and 
interactive (Specific Aim III) association of multiple SNS and RAAS variants with HF 
patient survival and beta-blocker survival benefit.  
 
Perspective 
 HF is an enormous public health problem. Although there have been great 
advances in the therapy for HF in the past few decades, morbidity and mortality still 
remain high. The progression to death and response to a cornerstone of HF 
pharmacotherapy, beta-blockade, are highly variable among HF patients. Two objectives 
are critical in abating the HF epidemic, and this dissertation research takes steps towards 
achieving these objectives: 1) improve the use of current HF therapies and 2) improve the 
identification of HF patients with high risk of death. Because the SNS and RAAS are 
integral in HF pathophysiology, and genetic variation affects these systems, the aims of 
this dissertation research were to determine if genetic variants in the SNS and RAAS, 
individually (Specific Aim I), additively (Specific Aim II), or with interactions between 
(Specific Aim III), are associated with survival and beta-blocker response in patients with 
HF. This dissertation research could have profound clinical implications, as it could lead 
to more tools for identifying high risk HF patients and HF patients that are most likely to 
respond to beta-blockers. 
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Specific Aims 
I. Determine if functionally annotated genetic variants within the SNS & RAAS are 
independently associated with survival and beta-blocker response in patients with 
HF. Hypothesis: Genetic variants causing increased activity of the SNS or RAAS in vitro 
and in vivo will be independently associated with higher risk of all-cause mortality in 
patients with HF, but patients with the higher activity genotypes will have a greater 
reduction in mortality with beta-blockers.  
  
II. Determine if a genetic risk score, composed of a panel of functionally annotated 
SNS & RAAS genetic variants, is associated with survival and beta-blocker response 
in patients with HF. Hypothesis: The SNS & RAAS genetic variants individually will 
have a modest association with survival and beta-blocker response, but patients 
possessing a combination of high activity variants will have additive risk for all-cause 
mortality and beta-blocker response.  
 
III. Determine if gene-gene interactions among functionally annotated SNS & RAAS 
genetic variants are associated with survival and beta-blocker response in HF 
patients. Hypothesis: Because gene-gene interactions are a ubiquitous component of 
complex diseases such as HF, and the SNS and RAAS dually contribute to HF 
pathophysiology, gene-gene interactions between variants in these systems will be 
associated with HF patient survival and beta-blocker response. 
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Figure legends 
Figure 1. A comparison of healthy SNS activation (left half of figure) and in HF (right 
half of figure) is shown. When a decrease in cardiac output occurs in an otherwise 
healthy person, the SNS is activated, resulting in increased inotropy, chronotropy, 
vasoconstriction, and the release of renin. Once cardiac output is restored, the SNS 
resumes baseline activity. However in a person with HF, cardiac output is only 
maintained with continuous SNS activation, which leads to adverse consequences such as 
cardiac myocyte apoptosis, disrupted adrenergic receptor signaling, and cardiac 
remodeling. 
 
Figure 2.  The interaction between the SNS and RAAS is shown. Sites labeled AII are 
sites in which angiotensin II facilitates the SNS, and those labeled SNS are sites in which 
the SNS facilitates the RAAS. 
 
Figure 3. Hypothetical scenarios demonstrating the need for an untreated portion of 
patients in pharmacogenetic studies. Values are hypothetical mortality rates in ADRB1 
Ser49-homozygous (Ser49/Ser49) or Gly49-carrying (Gly49-car) patients either treated 
with beta-blockers (+BB) or not (-BB) and the reality and appearance if 100% of patients 
were treated with beta-blockers in the study.  
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Figure 1. Comparison of healthy SNS activation and in heart failure. 
 
 
 
 
 
 
 
 
 
 
 
 17 
 
Figure 2. Interaction between SNS and RAAS. 
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Figure 3. Hypothetical scenarios demonstrating need for untreated patients in 
pharmacogenetic studies. 
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CHAPTER II:  
IDENTIFICATION OF CANDIDATE GENETIC VARIANTS 
 
Summary 
 Chapter I introduced the severity of the HF public health problem and the roles 
that the SNS and RAAS play in HF pathophysiology and clinical outcomes. The goal of 
this chapter was to identify candidate genetic variants within the SNS and RAAS that 
have in vitro and in vivo evidence to support an association with HF survival and beta-
blocker response. A final list of eleven candidate genetic variants was identified in the 
literature and will be used for analyses. A comparison of the candidate gene approach to 
other genetic association approaches was introduced, and the limitations of the candidate 
gene approach used herein were discussed. 
 
Introduction 
 Because there are approximately three million differences in DNA sequences 
between individuals, deciding which genetic variants to test and how many to test is an 
extreme challenge for investigators. Genetic association study designs fall on an 
enormous spectrum. On one extreme, an investigator may test a single genetic variant. On 
the other extreme, an investigator may scan the entire genome. When an investigator 
decides to only test one or a few variants, this is referred to as a “candidate gene 
approach” because the investigator has a strong a priori hypothesis for the best 
candidates to find an association. The a priori hypothesis for the candidate genetic 
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variants is ideally based on substantial pre-existing evidence for an association with the 
trait (e.g. molecular, physiologic, pre-clinical, or clinical evidence). When pre-existing 
evidence for particular candidate genes is lacking, an investigator may test all of the 
common variation in the genome. This is referred to as a genome-wide association study 
(GWAS), which has been referred to as “hypothesis-free,” or the broad hypothesis that 
there are variants somewhere within the genome that will be associated with the trait. 
Many genetic association study designs fall somewhere in the middle of the two 
extremes, with intermediate numbers of genetic variants tested for a general hypothesis. 
For example, if the trait is drug response, the hypothesis could be that any genetic 
variation within pharmacokinetic genes (e.g. drug metabolizing enzymes and 
transporters) will be associated with drug response. This hypothesis is narrower than 
testing the entire genome, but it also does not make the hypothesis for specific variants. 
Instead of 1 variant or 3 million variants, this hypothesis falls in the middle range with a 
few thousand variants. 
 Of course each end of the genetic association spectrum (i.e. candidate gene 
association versus GWAS), has its advantages and disadvantages. When only selecting a 
few genetic variants, obviously genetic association from other genes will be missed. The 
primary limitation of candidate gene association studies is that they are limited to known 
or hypothesized biologic relevance. However there may be yet undiscovered genes 
important for a trait, which would be detected in the GWAS.  For example, in another 
common, complex disease, age-related macular degeneration, candidate gene studies 
failed to find any genetic variants that accounted for a large proportion of the overall 
prevalence, but GWAS did (1).  However a disadvantage of testing many genetic variants 
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is the potential for false positives. For example, if testing 1 million variants, and using an 
alpha = 0.05, the investigator may find 50,000 variants associated with the trait by chance 
alone. Therefore to control for the potential false positives, stringent levels for statistical 
significance must be set, and therefore very large sample sizes are required to have the 
power to detect true associations. In this sense, candidate gene studies have the advantage 
of being flexible and having power to test few variants. Another advantage of candidate 
gene studies is coverage of uncommon or rare variants. GWAS typically only cover 
common genetic variation (minor allele frequency [MAF] > 5%). Cost is also a 
significant factor when deciding on the number of variants to test, as genotyping costs 
and sample sizes must increase with the number of variants. GWAS are typically 
hypothesis generating and therefore require validation samples as well. In addition, the 
data generated in GWAS are computationally intensive and often require more elaborate 
IT infrastructure and statistical support than a candidate gene study.  
 The candidate gene approach was chosen for this dissertation research for several 
reasons. The sample size of the HF patient cohort (n = 720) was not amenable for 
GWAS, which requires thousands of patients for power to meet the stringent statistical 
significance thresholds. And also the lower cost of only genotyping a few variants was 
another reason. There is also good data in the literature to support an a priori hypothesis 
for certain variants. Specifically, it is well-established that the SNS and RAAS are 
involved with HF pathophysiology and pharmacology. There are known genetic variants 
in these systems that are known to affect these systems at molecular, physiologic, and 
clinical levels, and hence a “hypothesis-free” GWAS approach was not required. 
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 The rationale for candidate variant selection is as follows: Because the SNS and 
RAAS are so closely associated with HF pathophysiology and pharmacology (See 
Chapter I: Introduction), variants affecting those systems were chosen. Variants also 
known to affect gene expression or function were chosen because they are more likely to 
translate into clinically relevant outcomes. Much variation in the genome is thought to be 
random mutation and have a neutral effect; this variation would not be expected to 
translate into clinically meaningful outcomes. Because the best candidates for an 
association with HF clinical outcomes (survival and beta-blocker response) wanted to be 
chosen, variants that had effects further translating from molecular effects to physiologic 
or clinical outcomes (e.g. ventricular remodeling or beta-blocker response) were chosen. 
Only common variants (e.g. MAF >5% in Caucasian-Americans or AAs) were chosen 
due to statistical power and generalizability of the results to large numbers of patients.  
Herein the methods for finding candidate genetic variants that meet these criteria were 
described and the literature supporting the candidate variant list was summarized. 
 
Methods 
 Selection criteria. Candidate genetic variants must be part of the SNS or RAAS, 
have a MAF of greater than 5% in Caucasian-Americans or AAs, affect gene expression 
or function, and are associated with HF patient clinical outcomes or relevant physiologic 
processes (i.e. ventricular remodeling). When linkage disequilibrium exists, the true 
functional variant was chosen if known. 
 Search strategy. Candidate genetic variants were identified in the PubMed 
database from 1966 to May 2009 by combining the following search terms: heart failure, 
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sympathetic adrenergic system, renin-angiotensin-aldosterone system, genetic, 
polymorphism, beta-blocker, pharmacogenetic, survival, and left ventricular ejection 
fraction. Once variants were identified to have an association with HF relevant outcomes 
such as drug response, ventricular remodeling, or survival, then functional and pre-
clinical data was searched for using the specific variant name or rsID (reference sequence 
identifier). Variant population frequencies were found in published literature, the 
HapMap database (2), or NCBI (3). Studies were limited to those published in English. 
 
Results 
 Twelve candidate variants met the selection criteria. However one candidate 
variant, M235T in the gene for angiotensinogen (AGT), was excluded because it was 
found to be in complete linkage disequilibrium with G-6A in AGT, which was later 
determined to be the causal functional variant (4). Table 1 summarizes the identification 
and location information for the candidate genetic variants. Table 2 summarizes the MAF 
of the variants in populations of Caucasian and African descent. Tables 3 & 4 summarize 
the gene function within SNS or RAAS, respectively, and the molecular and clinical HF 
phenotypes of the variants. 
 
Discussion 
 Eleven candidate genetic variants in the SNS and RAAS were chosen for this 
dissertation research based on candidate frequency and molecular/clinical phenotypes. It 
is important to point out the limitations of this candidate gene approach. Given the 
complexity of the SNS and RAAS, it is somewhat surprising that only 11 candidate 
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genetic variants met the selection criteria. Therefore important genetic variation in these 
systems may be missed in this dissertation research simply because they have not been 
previously studied. This also highlights the fact that genetic variation in systems other 
than the SNS and RAAS, such as inflammatory, that affect the HF phenotype are also not 
being tested as part of this dissertation research.   Importantly, when looking at beta-
blocker response in HF, no pharmacokinetic (PK) genes were selected for this 
dissertation. However the few studies testing for an association between PK genetic 
variants and beta-blocker response have not found an association with 
pharmacodynamics (5,6). Publication bias, in which the effects of a variant may be false 
positive or exaggerated (7), is also an important consideration because the variant 
selection was based on previously published literature. The genetic and pharmacogenetic 
literature for HF is still in very early stages, as there is not a great deal of literature 
available, and the current literature covers only a few variants in small sample sizes. Of 
course the candidate gene approach is not the only method for finding genetic 
association. An alternative method would be to use tag SNPs to cover all common 
genetic variation in the SNS or RAAS genes, instead of just picking only one or two 
variants. Of course GWAS is another alternative, because in a complex disease such as 
HF, many genetic variants are probably involved. However, a large HF patient population 
would be required. The strengths of the 11 candidate genetic variants for the dissertation 
research are low cost, low computational demand, improved statistical power, frequency, 
and substantial background in vitro and in vivo data. 
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Table 1. Identification and location information of candidate genetic variants 
 
Gene rsID Nucleotide 
substitution  
Amino acid 
Substitution 
Chromosome Chromosome 
position 
(GRCh37.p5 
assembly) 
Variant 
type 
ADRB1 rs1801252 A1231G Ser49Gly 10 115804036 missense 
SNP 
ADRB1 rs1801253 C1251G Arg389Gly 10 115805056 missense 
SNP 
ADRB2 rs1042713 A285G Arg16Gly 5 148206440 missense 
SNP 
ADRB2 
rs1042714 C318G Gln27Glu 5 148206473 missense 
SNP 
ACE rs1799752 287-bp 
deletion 
n/a 17 61565890 intronic  
indel 
ADRA2C rs61767072 12-bp 
deletion 
322GlyAla-
GlyPro325 
4 3769297 frameshift 
indel 
GRK5 rs17098707 A355T Gln41Leu 10 121086097 missense 
SNP 
AGT rs5051 G-6A n/a 1 230849872 5’ UTR 
SNP 
 
AGTR1 rs5186 A1166C n/a 3 148459988 3’ UTR 
SNP 
 
CYP11B2 rs1799998 C-344T n/a 8 143999600 5’ UTR 
SNP 
 
BDKRB2 n/a 9-bp 
deletion 
n/a 14 n/a non-
coding 
exon indel 
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Table 2. Minor allele frequencies (MAF) of candidate genetic variants 
Gene rsID Minor allele MAF Caucasian MAF African 
ADRB1 rs1801252 G 0.17 0.25 
ADRB1 rs1801253 G 0.27 0.38 
ADRB2 rs1042713 A 0.40 0.50 
ADRB2 rs1042714 G 0.42 0.20 
ACE rs1799752 Ins 0.44 0.43 
ADRA2C rs61767072 Del 0.04 0.43 
GRK5 rs17098707 T 0.02 0.24 
AGT rs5051 A 0.42 0.82 
AGTR1 rs5186 C 0.25 0.05 
CYP11B2 rs1799998 C 0.43 0.29 
BDKRB2 n/a Del 0.50 0.40 
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Table 3. Gene function and molecular and clinical phenotypes of candidate SNS genetic  
 
variants 
 
 
  
SNS 
Gene Gene function Variant 
(common 
notation)  
Molecular 
phenotype 
Clinical phenotype 
ADRB1 Mediates 
cardiac 
inotropy and 
chronotropy 
Ser49Gly Gly49 ↑ 
desensitization 
(8,9) 
Gly49 ↑ survival (9) 
Arg389Gly Arg389 ↑ 
function (10) 
Arg389 ↓ survival (11) 
ADRB2 Mediates 
cardiac 
inotropy and 
chronotropy 
Gly16Arg Gly16 ↑ 
desensitization 
(12,13) 
Gly 16 ↑ survival (13) 
Gln27Glu Glu27  
desensitization 
resistant (12,13) 
Gln27 ↓ risk of worsening HF 
(14) 
ADRA2C Pre-synaptic 
auto-inhibition 
of NE release 
Codon 322-
325 Ins/Del 
Del ↓ function 
(15) 
Del ↓ survival (16) 
GRK5 Desensitization 
of beta-
adrenergic 
receptors 
Gln41Leu Leu41 ↑ 
desensitization 
(17) 
Leu41 ↑ survival (17) 
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Table 4. Gene function and molecular and clinical phenotypes of candidate RAAS 
genetic variants 
 
 
 
  
RAAS 
Gene Gene 
function 
Variant 
(common 
notation)  
Molecular 
phenotype 
Clinical phenotype 
ACE Conversion 
of 
angiotensin I 
to 
angiotensin 
II 
Intron 16 
Ins/Del 
Del ↑ plasma 
ACE (18) 
Del ↓ survival (19) 
AGT Substrate for 
renin, 
converted 
into 
angiotensin I 
G-6A -6A ↑ 
transcription rate 
(4) 
-6A ↓ survival (20) 
 
AGTR1 Mediates 
major CV 
effects of 
angiotensin 
II 
A1166C 1166C ↑ 
sensitivity (21) 
1166C ↓ survival (22) 
CYP11B2 Synthesizes 
aldosterone 
T-344C -344C ↑ plasma 
aldosterone (23-
25) 
-344C ↓ survival (24) 
BDKRB2 Mediates CV 
actions of 
bradykinin 
Exon 1 
Ins/Del 
Ins ↓ 
transcription rate 
(26,27) 
Ins ↑ LV growth (27) 
35 
 
 
REFERENCES 
(1) Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement 
factor H polymorphism in age-related macular degeneration. Science 2005 Apr 
15;308(5720):385-389.  
(2) International HapMap Consortium. A haplotype map of the human genome. Nature 
2005 Oct 27;437(7063):1299-1320.  
(3) National Center for Biotechnology Information and National Library of Medicine. 
Database of Single Nucleotide Polymorphisms. Available at: 
http://www.ncbi.nlm.nih.gov/snp/, 2012.  
(4) Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, et al. A 
nucleotide substitution in the promoter of human angiotensinogen is associated with 
essential hypertension and affects basal transcription in vitro. J Clin Invest 1997 Apr 
1;99(7):1786-1797.  
(5) Sehrt D, Meineke I, Tzvetkov M, Gultepe S, Brockmoller J. Carvedilol 
pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB 
pharmacogenetics. Pharmacogenomics 2011 May 23.  
(6) Baudhuin LM, Miller WL, Train L, Bryant S, Hartman KA, Phelps M, et al. Relation 
of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, 
carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol 2010 
Aug 1;106(3):402-408.  
(7) Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic 
associations with complex outcomes. Lancet 2003 Mar 8;361(9360):865-872.  
(8) Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-
protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity 
and increased desensitization and down-regulation. J Biol Chem 2002 Aug 
23;277(34):30429-30435.  
(9) Borjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in 
the gene coding for the beta(1)-adrenergic receptor associated with survival in patients 
with heart failure. Eur Heart J 2000 Nov;21(22):1853-1858.  
(10) Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in 
a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999 
Apr 30;274(18):12670-12674.  
(11) Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A, et al. Impact 
of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, 
36 
 
 
arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 2008 
Sep 15;102(6):726-732.  
(12) Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the 
human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. 
Biochemistry 1994 Aug 16;33(32):9414-9419.  
(13) Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, et al. Relation of 
beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with 
heart failure. Am J Cardiol 2007 Jan 15;99(2):250-255.  
(14) Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V, et al. Association 
of beta-adrenergic receptor polymorphisms and progression to heart failure in patients 
with idiopathic dilated cardiomyopathy. Am J Med 2004 Oct 1;117(7):451-458.  
(15) Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid 
deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic 
receptor confers impaired coupling to multiple effectors. J Biol Chem 2000 Jul 
28;275(30):23059-23064.  
(16) Kardia SL, Kelly RJ, Keddache MA, Aronow BJ, Grabowski GA, Hahn HS, et al. 
Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence 
heart failure survival. BMC Med Genet 2008 Oct 23;9:93.  
(17) Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 
polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart 
failure. Nat Med 2008 May;14(5):510-517.  
(18) Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An 
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting 
for half the variance of serum enzyme levels. J Clin Invest 1990 Oct;86(4):1343-1346.  
(19) Andersson B, Sylven C. The DD genotype of the angiotensin-converting enzyme 
gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 
1996 Jul;28(1):162-167.  
(20) Pilbrow AP, Palmer BR, Frampton CM, Yandle TG, Troughton RW, Campbell E, et 
al. Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the 
risk of mortality in heart failure. Hypertension 2007 Feb;49(2):322-327.  
(21) Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW. 
Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C 
polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000 
Sep;36(3):411-416.  
37 
 
 
(22) Amir O, Amir RE, Paz H, Attias E, Sagiv M, Lewis BS. Relation between AT1R 
gene polymorphism and long-term outcome in patients with heart failure. Cardiology 
2009;112(2):151-157.  
(23) White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995 Feb-
May;21(1-2):437-442.  
(24) McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, et 
al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans 
with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 2006 Sep 
19;48(6):1277-1282.  
(25) Pojoga L, Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, et al. Genetic 
determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 
1998 Jul;11(7):856-860.  
(26) Braun A, Kammerer S, Maier E, Bohme E, Roscher AA. Polymorphisms in the gene 
for the human B2-bradykinin receptor. New tools in assessing a genetic risk for 
bradykinin-associated diseases. Immunopharmacology 1996 Jun;33(1-3):32-35.  
(27) Brull D, Dhamrait S, Myerson S, Erdmann J, Woods D, World M, et al. Bradykinin 
B2BKR receptor polymorphism and left-ventricular growth response. Lancet 2001 Oct 
6;358(9288):1155-1156.  
 
 
 
 
 
 
 
CHAPTER III:  
CHARACTERIZATION OF CANDIDATE GENETIC VARIANTS 
 
Summary 
 The previous chapter covered the methods and results for the candidate gene 
search. This chapter describes genotyping technologies and the methods used for 
genotyping the eleven selected candidates. Three platforms were used:  TaqMan® 
fluorescent allelic discrimination, QIAxcel® capillary electrophoresis, and Sequenom® 
MALDI-TOF mass spectrometry. These methods were accurate and reproducible when 
subject to a series of quality control measures except for the ADRA2C indel, which 
significantly deviated from Hardy-Weinberg Equilibrium (HWE). Preferential 
amplification of the ADRA2C deletion allele must have occurred, and therefore analyses 
of the ADRA2C indel must be performed as insertion-homozygous versus deletion-carrier 
and not as the three individual genotypes.  
 
Introduction 
 Rapid advances in genomic technology have yielded a panoply of genotyping 
methods to choose from. However with the large amount of genotyping methods 
available comes a host of factors to consider when choosing the optimal method (Table 
5). Genotyping technologies can be broadly classified into an allele discrimination step 
and then the allele detection step (1). Almost all genotyping methods require an initial 
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PCR amplification step, and then allele discrimination is commonly achieved using 
primer extension, hybridization, ligation, or enzymatic cleavage.  Primer extension relies 
on the highly accurate DNA polymerase enzyme to incorporate allele-specific 
nucleotides, and hence it is very reliable. Assay designs are simple, fast, flexible, 
customizable, multiplex, and widely commercially available (e.g. Sequenom® 
MassEXTEND™).  Hybridization techniques rely on the thermal stability of perfectly 
complementary DNA probes at the variant loci. Therefore the major disadvantages of this 
technique are non-specific binding to other loci in the genome or cross-hybridization. The 
advantage of hybridization techniques is increased throughput because of the lack of an 
enzymatic reaction requirement. Ligation relies on the high accuracy of the DNA ligase 
enzyme to join two oligonucleotides only when there is perfect complementarity with the 
DNA template. With appropriate tags and divergent oligonucleotides, ligation methods 
can be successfully scaled up to high throughput. Enzymatic cleavage methods rely on 
the specificity of certain enzymes for certain DNA sequences. For example, restriction 
fragment length polymorphism (RFLP) utilizes restriction enzymes that cleave double-
stranded DNA at unique sites consistently. RFLP is one of the earliest genotyping 
methods, but it has limited throughput and multiplex capacity. Notably, allele 
discrimination could involve a combination of any of the above approaches (e.g. 
TaqMan® uses a combination of hybridization and 5’ nuclease activity of DNA 
polymerase). 
 Allelic detection methods generally fall under four broad categories: gel 
electrophoresis, mass-based, fluorescence, and chemiluminescence (1). Gel 
electrophoresis is the longest used detection method, but traditional agarose gel 
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electrophoresis is low resolution, labor-demanding, and time-demanding. More recently 
these disadvantages have been overcome by capillary gel electrophoresis (e.g. Qiaxcel®) 
(2). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) is a commonly used mass-based technique for detecting 
oligonucleotides. A major advantage of MALDI-TOF MS is that a mixture of 
oligonucleotides can be rapidly separated and accurately analyzed simultaneously. This 
method is commonly used for detecting products of primer extension reactions (e.g. 
Sequenom®). The genotype for each allele-specific extension product is determined by 
its unique mass. A major limitation of this method is reduced peak resolution due to 
similar masses of the extension products. Fluorescence is a commonly used detection 
method because it is simple, fast, and accurate. TaqMan® is an example of fluorescent 
detection, in which probes with a quencher on one end and the fluorescent dye on the 
other end are used. When the probes are intact, the fluorescent signal is quenched. 
However, the fluorescent signal is emitted when the fluorescent dye is cleaved from the 
quencher by a DNA polymerase with 5’ exonuclease activity. The alleles have specific 
fluorescent dyes which reveal genotype. Chemiluminescence utilizes a cascade of 
enzymatic reactions that generate light. This method is fast, automatable, and has a high 
signal-to-noise ratio.  A method that uses chemiluminescence is Pyrosequencing™. 
When a template nucleotide is complementary to the nucleotide being extended, DNA 
polymerase incorporates the nucleotide initiating the cascade of reactions to emit light. A 
disadvantage of this method is the lack of multiplex capacity. 
 A combination of three platforms was necessary for genotyping the 11 candidate 
variants identified in Chapter II: Identification of Candidate Genetic Variants. Because of 
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availability, cost efficiency, customizability, flexibility, and multiplex capacity, a 
Sequenom® assay genotyping all 11 variants simultaneously was initially assessed for 
compatibility. The Sequenom® assay design only allowed 6 of 11 variants into the assay 
design, presumably because of the inability to design extension products with clearly 
distinguishable masses. The remaining five variants were rs1042713 (ADRB2 Arg16Gly), 
rs1799998 (CYP11B2 T-344C), and the three indels (BDKRB2 9-bp, ADRA2C 12-bp, and 
ACE 287-bp). TaqMan® was chosen for the two remaining SNPs due to cost efficiency, 
flexibility, ease-of-use, availability, and reliability. The indels were genotyped using 
Qiaxcel® capillary electrophoresis due to availability, cost-efficiency, ease-of-use, and 
rapidity. Qiaxcel® capillary electrophoresis is very compatible with genotyping indels 
because the PCR products are separated with high resolution (down to 2 bp indel) and the 
genotypes are determined based on the size of the PCR products.         
 
Methods 
 DNA samples. The DNA samples on which genotyping was performed are 
described in detail in Chapter IV. Briefly, the Unified Investigators to Evaluate Heart 
Failure (UNITE-HF) began enrollment of HF patients into the UNITE-HF registry from 
U.S. outpatient HF specialty clinics in 2000. All patients had a history of HF defined as 
dyspnea on exertion or edema due to cardiac cause. Patients were enrolled without regard 
to LVEF, symptoms, or new/return patient status. Patients were only excluded if death 
due to comorbidity was expected within one year. Patients in the UNITE-HF registry that 
also consented to provide a DNA sample composed the UNITE-DNA cohort studied 
herein. 
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Quality control. To ensure genotyping accuracy, the following quality control 
measures were performed: one negative control per 96-well plate (i.e. water used in place 
of DNA); all samples without an initial genotype call were re-analyzed; comparison of 
UNITE-DNA allele frequencies to published frequencies of the same race; repeat 
genotyping of 10% of samples, randomly chosen and verification of concordance 
between calls; visual inspection of all genotype calls by one individual; visual inspection 
of genotype calls for 10% of samples selected at random by a separate individual; the χ2 
test for deviation from the Hardy-Weinberg equilibrium (HWE); blinding to patient 
characteristics and outcome; comparison of genotype calls for at least two samples of 
each genotype to calls from an independent laboratory.  
 DNA sample preparation. Peripheral blood (25 mL) was drawn from each 
patient using ethylenediaminetetraacetic acid tubes as an anticoagulant. Genomic DNA 
was extracted from peripheral blood samples using standard methods (3). The stock DNA 
concentration was determined using the Quant-iT™ PicoGreen® dsDNA kit (Invitrogen, 
Molecular Probes, OR, USA). Working stock DNA (1 ng/μL) was made by normalizing 
aliquots of stock DNA in molecular-grade water (Mediatech, VA, USA) using a 
Biomek® 3000 laboratory automated workstation (Beckman Coulter, CA, USA). 
 TaqMan® fluorescent allele discrimination. Genomic DNA was amplified in a 
10 μL volume using TaqMan® genotyping assay kits (C_8896484_10 for rs1799998 
[CYP11B2 T-344C] and C_2084764_20 for rs1042713 [ADRB2 Arg16Gly], Applied 
Biosystems, Foster City, CA, USA) on a DNA Engine Tetrad® 2 Peltier thermal cycler 
(BioRad, CA, USA). Briefly, the reaction mixture contained 2 μL of genomic DNA 
(1ng/μL), 0.5 μl TaqMan® probes (10x), 5 μL GTXpress Master Mix (2x), and 2.5 μL of 
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molecular grade water.  The reaction mixture was incubated at 95
o
C for 20 seconds for 
DNA polymerase activation followed by 39 cycles of 95
o
C for 15 seconds for 
denaturation and 60
o
C for 60 seconds for annealing/extension. Allelic discrimination was 
performed on the post-PCR product with a CFX96
TM
 (Bio-Rad, CA, USA) with allelic 
discrimination software supplied by the manufacturer. 
 QIAxcel® capillary electrophoresis for BDKRB2 9-bp indel. For PCR 
amplification of the BDKRB2 9-bp indel, the following forward and reverse primers were 
used: 5’- GCCCTTGAAAGATGAGCTG -3’ and 5’-AACTCCCCACGACCACAG -3’ 
based on the exon 1 9 bp insertion/deletion polymorphism in BDKRB2 reported by Braun 
et al (4). The expected PCR product size with the insertion allele was 275 bp and the 
deletion allele was 266 bp. The PCR mixture contained 10 µL of HotStarTaq® Plus 
Master Mix (2X) (Qiagen, Hilden, Germany), 4 µL of Q solution (5X) (Qiagen), 2 µL of 
each primer (10 µM), and 2 µL of working stock DNA (1 ng/µL) in a final volume of 20 
µL. A DNA Engine Tetrad® 2 Peltier thermal cycler (BioRad, Hercules, CA, USA) was 
used with the following conditions based on Braun et al (4): initial incubation at 95°C for 
5 minutes followed by 40 amplification cycles (1 minute at 94°C, 1 minute at 53°C, and 1 
minute at 72°C) and a final elongation at 72°C for 10 minutes.  
 High-resolution capillary electrophoresis was performed using a QIAxcel® DNA 
high-resolution gel cartridge (Qiagen) on a QIAxcel system (Qiagen), as per the 
manufacturer’s instructions. A QX DNA Size Marker (Qiagen) with 17 fragment sizes 
ranging in size from 25 to 450 bp was used to size PCR products. A QX Alignment 
Marker (Qiagen), which consisted of 15 bp and 500 bp fragments, was injected onto the 
cartridge with each sample. The 0M700 method in the BioCalculator® software (Qiagen) 
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was used for all analyses; this corresponds to a 10 second sample injection time at 5 kV, 
and 700 second separation time at 3 kV. The QIAxcel® system injected less than 0.1 μL 
of 20 μL PCR products onto the cartridge for analysis. The retention time of the PCR 
fragments relative to the 15 bp and 500 bp QX Alignment Marker fragments was 
calculated using the BioCalculator® software (Qiagen). The PCR product sizes were then 
determined by comparing the retention time with the QX DNA Size Marker. The 
BioCalculator® software produces a digital gel image and an electropherogram for 
fragment analysis.  
 QIAxcel® capillary electrophoresis for ADRA2C 12-bp indel. For the 
ADRA2C 12-bp indel, the following forward and reverse primers were used (5): 5’- 
GTGGAGCCGGACGAGAGC - 3’ and 5’ – GGCGCGACAGGAAGAACTC – 3’. The 
expected PCR product size with the insertion allele was 232 bp and the deletion allele 
was 220 bp. The PCR mixture was the same as for the BDRKB2 9-bp indel. A DNA 
Engine Tetrad® 2 Peltier thermal cycler (BioRad, Hercules, CA, USA) was used with the 
following conditions: initial incubation at 95°C for 5 minutes followed by 44 
amplification cycles (1 minute at 94°C, 1 minute at 60°C, and 1 minute at 72°C) and a 
final elongation at 72°C for 10 minutes. The PCR product was run on the QIAxcel 
capillary electrophoresis system similar to the BDKRB2 9-bp indel, except the 0H700 
method in the BioCalculator® software (Qiagen) was used for all analyses; this 
corresponds to a 20 second sample injection time at 2 kV, and 700 second separation time 
at 3 kV. 
 QIAxcel® capillary electrophoresis for ACE 287-bp indel. Two stages of PCR 
amplification were required for genotyping the ACE 287-bp indel due to known 
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preferential amplification of the deletion allele (6). The first stage of PCR used the 
following forward and reverse primers: 5’ - CTGGAGACCACTCCCATCCTTTCT - ‘3 
and 5’ - GATGTGGCCATCACATTCGTCAGAT -3’. The expected first-stage PCR 
product size with the deletion allele was 191 bp and the insertion allele was 478 bp. The 
first-stage PCR mixture contained 10 µL of AmpliTaq Gold® PCR Master Mix (Applied 
Biosystems, Foster City, CA), 0.5 µL of each primer (10 µM), 1 µL of working stock 
DNA (1 ng/µL), and 8 µL of molecular grade water in a final volume of 20 µL. A DNA 
Engine Tetrad® 2 Peltier thermal cycler (BioRad, Hercules, CA, USA) was used with the 
following conditions: initial incubation at 93°C for 20 minutes followed by 50 
amplification cycles (30 seconds at 94°C, 30 seconds at 58°C, and 30 seconds at 72°C) 
and a final elongation at 72°C for 5 minutes.  
 Unlike the much smaller BDKRB2 9-bp and ADRA2C 12-bp indels, the ACE 287-
bp indel did not require the use of a high resolution QIAxcel cartridge. Instead, a 
QIAxcel® DNA screening cartridge (Qiagen) was used. A QX DNA Size Marker 
(Qiagen) with 11 fragment sizes ranging in size from 50 to 800 bp was used to size PCR 
products. A QX Alignment Marker (Qiagen), which consisted of 15 bp and 1000 bp 
fragments, was injected onto the cartridge with each sample. The AL320 method in the 
BioCalculator® software (Qiagen) was used for all analyses; this corresponds to a 20 
second sample injection time at 8 kV, and 320 second separation time at 6 kV. The 
QIAxcel® system injected less than 0.1 μL of 20 μL PCR products onto a cartridge for 
analysis. The retention time (and hence bp size) of the PCR fragments relative to the 15 
bp and 1000 bp QX Alignment Marker fragments was calculated using the 
BioCalculator® software (Qiagen). 
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 All patients who were genotyped as deletion homozygotes in the first stage were 
subject to a second, independent PCR amplification with forward and reverse primers 
that recognize an insertion-specific sequence (7): 5’ – 
TGGGACCACAGCGCCCGCCACTAC – 3’ and 5’ – 
TCGCCAGCCCTCCCATGCCCATAA – ‘3. The reaction yields a 335-bp amplicon only 
in the presence of an insertion allele, and no product in samples homozygous for deletion. 
The PCR mixture and thermal cycling conditions were the same as for the ADRA2C 12-
bp indel, except for a 68
o
C annealing temperature. The second-stage PCR products were 
similarly run to the first-stage PCR except the AH320 method in the BioCalculator® 
software (Qiagen) was used for all analyses; this corresponds to a 20 second sample 
injection time at 2 kV, and 320 second separation time at 6 kV. 
 Sequenom® MALDI-TOF mass spectrometry. The multiplex SNP assay was 
designed using Sequenom® iPLEX® Assay Design software version 3.1. The primers 
used are shown in Table 6. All reagents used were from the Sequenom® Complete 
Genotyping Reagent Set (Sequenom, Inc., San Diego, CA, USA). Briefly, the PCR 
reaction mixture consisted of 0.5 µL PCR buffer, 0.4 µL magnesium chloride, 0.1 µL 
dNTPs, 0.2 µL Taq polymerase, 1.0 µL forward and reverse primer mix (0.5 μM), 1.8 µL 
molecular grade water, and 1.0 µL genomic DNA (10ng/µL) to a final volume of 5.0 µL. 
The thermal cycling conditions were as follows: 94
o
C for 2 minutes, followed by 45 
cycles of 94
o
C for 30 seconds, 56
o
C for 30 seconds, 72
o
C for 1 minute, with a final 
extension at 72
o
C for 5 minutes. After PCR amplification, the PCR product is incubated 
with shrimp alkaline phosphatase (SAP) enzyme to neutralize any free dNTPs. The SAP 
reaction mixture consists of 0.3 µL SAP enzyme, 0.17 µL SAP buffer, and 1.53 µL 
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molecular grade water to create a final volume of 2.0 µL added to the PCR product. The 
SAP reaction mixture + PCR product is incubated at 37
o
C for 40 minutes followed by 
85
o
C for 5 minutes.  After the SAP reaction is the extension reaction. The extension 
reaction mixture contains 0.2 µL extension buffer, 0.2 µL termination mix, 0.084 µL 
extension primer (7-14 µM), 0.041 µL extension enzyme, and 0.755 µL molecular grade 
water to create a final volume of 2.0 µL which is added to the PCR product. The thermal 
cycling conditions for the extension reaction are as follows: 94
o
C for 30 seconds 
followed by 40 cycles of 94
o
C for 5 seconds, 52
o
C for 5 seconds, 80
o
C for 5 seconds, and 
a final extension at 72
o
C for 3 minutes. After the extension reaction, salt adducts are 
removed by adding 25 µL of molecular grade water and 6 mg of resin to each PCR 
product. PCR product is then spotted onto a 384 SpectroCHIP using a MassARRAY® 
nanodispenser and analyzed using MALDI-TOF MS platform (Sequenom, Inc., San 
Diego, CA, USA). 
 Linkage disequilibrium. Linkage disequilibrium, calculated as r
2
 and D’, was 
determined using SAS® version 9.2 (SAS Institute, Inc., Cary, NC, USA). Haplotypes 
for the ADRB1 and ADRB2 variants were estimated using the open access software 
PHASE version 2.1.1 (University of Washington, Seattle, WA, USA) (8,9).  
 
Results 
 All genotyping assays were reliable (call rates greater than 99%), accurate (100% 
concordance with genotypes from an independent laboratory, similar allele frequencies to 
the literature, and within HWE), and reproducible (100% concordance of subsequent run 
for 10% randomly chosen samples), except for the ADRA2C 12-bp indel as shown in 
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Tables 7 and 8. Like the ACE indel, it is likely that preferential amplification of the 
deletion allele must have been occurring because the number of expected heterozygotes 
was much higher than the observed number (Table 9). Therefore (assumed) heterozygous 
samples were incorrectly genotyped as deletion homozygotes. Linkage disequilibrium, 
diplotypes identified, and frequencies by race for the ADRB1 and ADRB2 genetic variants 
are shown in Table 10. 
 
Discussion 
 The genotyping methods for the 11 candidate genetic variants were reliable, 
accurate, and reproducible, except for the ADRA2C 12-bp indel that significantly 
deviated from HWE. HWE is the preservation of allele and genotype distributions from 
generation to generation. Considering a diallelic locus with alleles A and B and 
population frequencies of 1-q and q respectively, the probabilities for the three possible 
genotypes (AA, AB, and BB) will follow the Hardy-Weinberg law: (1 - q)
2
, 2q(1 - q), and 
q
2
 (10). Reporting violations from HWE in genetic association literature is extremely 
important because the conclusions made from the genetic association study could be 
false. Violations from HWE signals important problems, errors, or peculiarities in the 
dataset and may explain failed replication of genetic associations in subsequent studies. 
Failure to test and report HWE is common in the literature, even in high profile genetics 
journals (11), and this has led to the call for retraction of at least one genetic association 
publication (12).  
 HWE depends on a series of assumptions about the population: the population is 
infinitely large, no new mutation, no selection, no migration, and random mating. 
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Therefore violations of HWE can be due to 1) violations of these assumptions, 2) chance, 
or 3) genotyping errors.  All of the HWE assumptions cannot be directly verified in 
UNITE-DNA, although they seem very reasonable. UNITE-DNA is not infinitely large, 
but the population is large enough that a chance deviation from HWE due to sampling 
bias is highly unlikely (13). Additionally, the ADRA2C indel has been known for years, 
and hence it is not a new mutation. However selection bias may play a role because the 
ADRA2C indel has been previously associated with mortality in HF patients (14,15), but 
the data are conflicting and not confirmed herein (see Chapter V). Migration is an 
unlikely issue because the patients are 21
st
 century Americans, where no large migration 
into or out of the U.S. has occurred for centuries. Migration effects were also not evident 
for any of the other 10 variants, and the patients come from geographically diverse areas 
across the U.S. The selection of mates is rarely random; individuals may preferentially 
select one another because of physical and behavioral characteristics that are influenced 
by genetics. However most traits that contribute to non-random mating are controlled by 
many loci.  
 Because UNITE-DNA generally meets the assumptions of HWE, that leaves 
chance and genotyping errors to explain the HWE violation for the ADRA2C 12-bp indel. 
Because the p-values for HWE in both the Caucasian and AA patients were less than 
0.0001, the result is not due to chance. Therefore, the most likely explanation for the 
violation of the ADRA2C 12-bp indel from HWE would be genotyping error. The 
ADRA2C 12-bp indel passed all genotyping quality control checks until the final HWE 
check. However looking at the expected and observed genotype frequencies and 
electropherograms, preferential amplification, like the ACE indel, must have been 
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occurring. The following are potential mechanisms for preferential amplification (16): 1) 
The two alleles in a heterozygous sample denature at different temperatures, and the 
allele that denatures less efficiently will not be detected. 2) Differential priming, in which 
the primer anneals more efficiently to one of the alleles. This is possibly due to a SNP 
that is in linkage disequilibrium with the allele of interest that lies underneath the primer 
annealing site. However, there are no reported SNPs under the primers used for ADRA2C 
indel genotyping.  3) Under conditions of limiting enzyme, as is the case with high 
concentrations of PCR product, the probability of a complete primer extension may be 
greater for the shorter products.  
 There are several different approaches to reduce or manage preferential 
amplification. If any of the three mechanisms above are suspected, the following 
adjustments could be made: 1) Use a denaturing temperature at which both alleles are 
completely denatured. 2) Ensure that there are no polymorphisms underlying the primer 
annealing sites. 3) Use high concentrations of DNA polymerase. If these adjustments do 
not work, two-stage PCR could be used like in the ACE indel assay.  The first stage of 
PCR uses primers that flank the entire indel, and all samples that are genotyped as 
deletion homozygotes in the first stage of PCR are subject to a second stage of PCR. The 
second stage of PCR uses insertion-specific primers, so that a PCR product is only 
amplified in the presence of an insertion allele. Hence, those samples with detectable 
PCR products are truly heterozygotes. The simplest way to cope with preferential 
amplification, and the method chosen herein, is to analyze the data as insertion-
homozygotes versus deletion-carriers. Although this method does not require any further 
labor, the disadvantage is the inability to detect differences between heterozygotes and 
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deletion homozygotes. This disadvantage is minimal in the Caucasian UNITE-DNA 
patients because the deletion frequency is so low (MAF = .04) there would be very few 
deletion homozygotes, and therefore very little power to analyze that genotype group. 
However the ADRA2C deletion is much more common in AAs (MAF = 0.4); therefore a 
large proportion of the AA patients are expected to be deletion homozygotes, but we are 
unable to analyze them separately.       
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Table 5. Factors to consider when selecting genotyping methods. 
Factor Description 
Throughput The number of samples that can be genotyped per unit of time 
Reliability The number of samples with successful genotype calls 
Reproducibility Yielding identical genotype calls in subsequent runs 
Accuracy The method provides the true genotype call, usually assessed by 
genotyping the same variant with different methods or by an 
independent laboratory 
Availability The equipment is already present in the laboratory or part of the 
campus resource or core genotyping facility 
Cost-efficiency The method is productive relative to the cost 
Ease-of-use Less time for technician training and fewer errors made 
Number of samples Large sample sizes may require high throughput methods 
Number of variants Large numbers of variants may require microarray chip technology 
Type of variants Some genotyping platforms are incompatible or unreliable with 
indels or CNVs 
Multiplex capacity Multiple variants can be genotyped in a single reaction 
Technical support Availability of manufacturer for trouble-shooting system failures 
Automation 
capacity 
To minimize human error 
Turn-around-time Some genotype calls, such as for making therapeutic decisions, 
require a rapid return of results 
Customization The ability to design a unique assay to meet the investigator’s 
needs 
Flexibility The ability to genotype many different variants using the same 
equipment and reagents 
Quality of DNA 
available 
Some genotyping methods are more robust when the DNA quality 
is poor 
 
Amount of DNA 
available 
Some genotyping methods require only minute amounts of DNA 
when DNA is scarce 
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Table 6. Primers used in Sequenom® genotyping assay. 
 
rsID Forward Reverse Extension 
rs1042714  ACGTTGGATGACATGACG
ATGCCCATGCC 
ACGTTGGATGAGCGCCTTC
TTGCTGGCAC 
ACACCTCGTCCCTT
T 
rs1801253 ACGTTGGATGCCTTCAAC
CCCATCATCTAC 
ACGTTGGATGAGCCCTGC
GCGCGCAGCAGA 
CGCAAGGCCTTCC
AG 
rs17098707  ACGTTGGATGAGCTTACC
TATGGTCCTTCG 
ACGTTGGATGAGCGCAAA
GGGAAAAGCAAG 
TCGGAGGTCTTCA
CAC 
rs5051  ACGTTGGATGTGTAGTAC
CCAGAACAACGG 
ACGTTGGATGAGCCTGGG
AACAGCTCCATC 
ACGGCAGCTTCTT
CCCC 
rs1801252 ACGTTGGATGGTCGCCGC
CCGCCTCGTT 
ACGTTGGATGATGAGCGC
CATCAGCAGAC 
TTCTGCCTCCCGCC
AGCGAA 
rs5186  ACGTTGGATGCCACATAA
TGCATTTTCTCC 
ACGTTGGATGAGAACATT
CCTCTGCAGCAC 
TCAATTCTGAAAA
GTAGCTAA 
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Table 7. Concordance and call rates for 11 candidate variants. 
Gene Variant 
(Minor Allele) 
Method Concordance 
with independent 
lab  
Concordance with 
10% random repeat 
Call rate 
ADRB1 Ser49Gly (Gly) Sequenom 100% 100% 99.5% 
Arg389Gly(Gly) Sequenom 100% 100% 99.8% 
ADRB2 Gly16Arg(Arg) TaqMan 100% 100% 99.5% 
Gln27Glu(Glu) Sequenom 100% 100% 99.8% 
ACE Ins/Del (Ins) QIAxcel 100% 100% 99.2% 
ADRA2C Ins/Del (Del) QIAxcel 100% 100% 99.5% 
GRK5 Gln41Leu(Leu) Sequenom 100% 100% 99.8% 
AGT G-6A (A) Sequenom 100% 100% 99.4% 
AGTR1 1166C(C) Sequenom 100% 100% 99.8% 
CYP11B2 T-344C (T) TaqMan 100% 100% 99.8% 
BDKRB2 Ins/Del (Ins) QIAxcel 100% 100% 99.3% 
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Table 8. Allele frequencies in the literature and UNITE-DNA and HWE p-value by race 
for 11 candidate variants. 
Gene Variant 
(Minor 
Allele) 
UNITE-
DNA 
Published 
Cauc 
UNITE-
DNA 
Cauc 
Caucasian 
HWE  
p-value* 
Published 
AA 
UNITE-
DNA 
AA 
AA 
HWE  
pvalue* 
ADRB1 Ser49Gly 
(Gly) 
0.18 0.17  0.14  0.2287 0.25  0.25  0.0504 
 
Arg389Gly 
(Gly) 
0.31 0.27  0.25  0.4071 0.38  0.41  0.1160 
ADRB2 Gly16Arg 
(Arg) 
0.42 0.40  0.36  0.0940 0.50  0.52  0.4502 
 
Gln27Glu 
(Glu) 
0.33 0.42  0.43  0.9714 0.20  0.18  0.1463 
ACE Ins/Del 
(Ins) 
0.43 0.44  0.43  0.0307 0.43  0.42  0.8386 
ADRA2C Ins/Del 
(Del) 
0.24 0.04  0.09  <.0001 0.43  0.50  <.0001 
GRK5 Gln41Leu 
(Leu) 
0.09 0.02  0.01  0.0011 0.24  0.21  0.1958 
AGT G-6A (A) 0.59 0.39  0.42  0.3467 0.83 0.85  0.1384 
AGTR1 1166C (C) 0.20 0.28  0.29  0.1222 0.05  0.07  0.7322 
CYP11B2 T-344C 
(C) 
0.36 0.43  0.46  0.4654 0.15  0.20  0.0548 
BDKRB2 Ins/Del 
(Del) 
0.47 0.50  0.49  0.4793 0.40  0.45  0.1164 
 
Cauc = Caucasian; *Bonferroni-corrected alpha = .002 
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Table 9. Expected and observed genotype distributions for the ADRA2C indel by race. 
ADRA2C genotype 
Caucasian 
Expected Observed 
Insertion homozygotes 361 373 
Heterozygotes 69 45 
Deletion homozygotes 3 15 
ADRA2C genotype  
AA 
Expected Observed 
Insertion homozygotes 67 91 
Heterozygotes 134 86 
Deletion homozygotes 66 90 
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Table 10. Linkage disequilibrium, diplotypes identified, and frequencies by race for the 
ADRB1 and ADRB2 genetic variants. 
ADRB1 linkage disequilibrium White patients (n = 429) Black patients (n = 270) 
r
2
 0.24 0.47 
D’ 1.00 1.00 
ADRB1 haplotypes 
Ser49/Arg389 519 (60%) 187 (35%) 
Ser49/Gly389 215 (25%) 219 (41%) 
Gly49/Arg389 124 (14%) 134 (25%) 
ADRB2 linkage disequilibrium White patients (n = 432) Black patients (n = 269) 
r
2
 0.65 0.48 
D’ 1.00 1.00 
ADRB2 haplotypes 
Gly16/Glu27 370 (43%) 94 (17%) 
Gly16/Gln27 184 (21%) 163 (30%) 
Arg16/Gln27 310 (36%) 281 (52%) 
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CHAPTER IV:  
CLINICAL FACTORS ASSOCIATED WITH HF PATIENT SURVIVAL  
AND BETA-BLOCKER RESPONSE 
 
Summary 
 The previous chapter described the genotyping methods and results for the 11 
candidate genetic variants. The objectives for this chapter were to characterize the 
UNITE-DNA patient population and determine the clinical characteristics associated with 
HF survival and beta-blocker (BB) survival benefit. UNITE-DNA has good 
representation of groups that have been under-represented in the landmark HF clinical 
trials (e.g. women and AA) and a large BB untreated portion of patients, giving power to 
test for statistical interactions with BB treatment. Baseline age, diabetes, NYHA class, 
systolic BP, LVEF, and GFR were independently associated with HF survival. BB use at 
baseline was significantly associated with an approximate 30% lower mortality after 
rigorous control for clinical covariates, and no clinical characteristics were significantly 
associated with BB survival benefit. 
 
Introduction 
 The survival of patients with HF is highly variable, with one-year survival rates 
ranging from 93% (1) to 25% (2).  The ability to accurately estimate the risk of death in 
patients with HF is extremely important, enabling informed decisions by providers, 
patients, and patients’ families on medications, devices, transplantation, and end-of-life 
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care. Many clinical and demographic factors have been associated with survival in HF 
patients: gender (3), race (4), age (5,6), NYHA class (6), etiology (6), diabetes (5,6), 
history of hypertension (6), heart rate (1), BP (7), LVEF (5), and renal function (8).  
Several models combining these clinical risk factors have been developed in various HF 
patient settings with variable accuracy (1,9,10).  One of the most commonly used and 
accurate mortality risk prediction models is the Seattle HF model (11). The Seattle HF 
model consists of easily obtainable characteristics relating to clinical status, therapy 
(pharmacological as well as devices), and laboratory parameters, and the overall receiver 
operating characteristic area under the curve was 0.729 (95% CI 0.714-0.744). Evidence 
is emerging for genetic risk factors in HF mortality (12-20) (for details see Chapter II: 
Identification of Candidate Genetic Variants), but it is unclear whether the addition of 
genetic factors to established clinical models improves risk prediction. 
 Like survival, BB response in patients with HF is also highly variable (for 
detailed examples see Chapter I: Introduction). However, there are no established clinical 
or demographic characteristics that predict BB efficacy in HF. There is some evidence for 
gender (21), racial (21), regional (22), baseline BP (23), and etiologic differences (23) in 
BB response, but currently the HF treatment guidelines recommend that all patients with 
an LVEF < 40% be treated with the same target doses of BB (24).  Moreover, no large-
scale studies have demonstrated that BB improves outcomes in HF patients with 
preserved LVEF (LVEF > 40%) (24). Also like survival, evidence is emerging for 
genetic determinants of BB response in HF (Appendices I & II) (25,26).    
 Robust modeling of the clinical characteristics associated with HF survival and 
BB response is not only important for patients, but it is also critically important for 
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genetic and pharmacogenetic research.  Over- or under-estimation of the true genetic or 
pharmacogenetic association with outcome can result, depending on the direction and 
magnitude of relationships between the clinical covariates and between the clinical 
covariates and the genetic variant. Population stratification, which is systematic 
differences in allele frequencies between subpopulations due to different ancestry, is a 
major source of confounding in genetic association studies. Confounding can be 
prevented using a randomized study design, but when this is not possible (such as in the 
non-randomized, observational UNITE-DNA registry described herein) strategies to 
control for the confounding factors must be used. Three general approaches can be used 
to control for confounding factors when there are a small number of genetic variants 
genotyped (27): 1) stratify the sample according to the confounding factors so that the 
comparison groups are relatively homogenous, 2) use regression modeling adjustment so 
that the association between the genetic variant and outcome can be assessed at fixed 
values of the covariates, or 3) use propensity score matching to balance the comparison 
groups (28). Regression adjustment is the most commonly used method presumably 
because of its simplicity. All three methods are introduced in this chapter, and each 
method will be used when testing the genetic and pharmacogenetic associations in this 
dissertation research. Specifically, stratification by race will be used in all analyses 
because of the differences in allele frequencies between races. The clinical models that 
will be used for regression adjustment of genetic and pharmacogenetic associations are 
developed in this chapter. And because UNITE-DNA was not randomized to BB 
treatment, propensity matching was used to balance known covariates in the BB 
untreated and BB treated patients. Overall, the objectives for this chapter are to 1) 
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thoroughly describe the UNITE-DNA patient population overall and in relevant strata, 2) 
determine the independent clinical factors associated with survival in UNITE-DNA, 3) 
determine the independent association of BB treatment with survival in UNITE-DNA, 
and 4) determine the clinical factors associated with BB response in UNITE-DNA.   
 
Methods 
 Registry. The Unified Investigators to Evaluate Heart Failure (UNITE-HF) 
network of dedicated and like-minded investigators was founded in 1999 by the UNC 
Heart Failure Program, Dr. Kirkwood F. Adams, Jr. PI, to promote clinical registry, 
biomarker, and genomic research in HF (29). The list of study sites and investigators that 
contributed subjects for this research is shown in Table 11, and UNC-Chapel Hill has 
served as the network coordinating center since its founding. The network began 
enrollment of HF patients into the prospective, multicenter, and observational UNITE-HF 
registry in early 2000. Patients that enrolled into the UNITE-HF registry that also 
consented to give a DNA sample composed the UNITE-DNA sample described herein. 
The inclusion criteria were broad: All patients had a history of HF defined as dyspnea on 
exertion or edema due to cardiac cause. New or return adult outpatients seen in HF 
specialty clinics were eligible. There was no specific LVEF requirement and patients 
could be asymptomatic at enrollment. The exclusion criteria were minimal: Patients were 
excluded if death due to comorbidity was expected within one year. At baseline, the 
following data were collected on a common form set: demographics, pertinent past 
medical history including ventricular function and HF signs/symptoms, detailed 
information on cardiovascular medications including specific type and dose of BB. Race 
64 
 
was self-reported. During follow-up, vital status was collected initially from the study 
sites, then periodically by Social Security Death Index. Forms were faxed to the UNITE-
HF Coordinating Center and processed to a final SAS analysis dataset using standard 
methods for data entry and query for data verification. All statistical analyses were 
performed in Statistical Analysis Software (SAS) version 9.2 (Cary, NC, USA). 
 Baseline analysis. Continuous baseline characteristics were summarized using 
mean and standard deviation, and categorical baseline characteristics were summarized 
using counts and percentages. Baseline characteristics were compared by race (AA versus 
Non-AA), BB treatment (on BB versus off BB at baseline), etiology (ischemic versus 
non-ischemic), and vital status (currently alive versus died during follow-up) using chi-
square, Fisher’s exact, or student’s t-test as appropriate. Race was not known for two 
subjects so they were excluded from race-stratified analyses, and etiology was not known 
for 16 subjects so they were excluded from etiology-stratified analyses.  
 Survival analysis. To assess the association of clinical characteristics with the 
primary endpoint, all-cause mortality, a series of univariate proportional hazards 
regression models were fit, one model for each of 11 pre-defined clinical factors: gender, 
race, age, etiology (ischemic vs. non-ischemic), history of hypertension, history of 
diabetes, NYHA class, systolic blood pressure, resting heart rate, LVEF, and GFR. A 
significance level of p < 0.10 was prospectively defined for inclusion of clinical factors in 
the multivariable analysis. Given n = 722, alpha = 0.1, and 8.9 years of follow-up, there 
was 80% power to detect a hazard ratio of 1.19 for a dichotomous variable in the 
univariate analysis. Final inclusion in the multivariable model was determined using 
stepwise selection with a significance level of p < 0.05. The assumption of proportional 
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hazards was confirmed by testing time-dependent covariates in the model (e.g. 
variable*time interaction term). The influence of missing data was assessed by repeating 
analyses with simple imputation for missing data (replacement of missing values with 
mean value of variable from UNITE-DNA overall).  
 BB response analysis. To assess the association between BB treatment and the 
primary endpoint, all-cause mortality, BB treatment (yes versus no at baseline), BB dose 
(in 25mg metoprolol equivalents), and specific BBs (metoprolol tartrate or succinate and 
carvedilol) were tested in the multivariable clinical model derived from UNITE-DNA 
described above (the “reduced model”). For more conservative estimates of the BB 
treatment association with survival, BB treatment was also tested in models using all 11 
candidate variables (the “full model”) and the multivariable clinical model derived from 
the overall UNITE-HF registry using the same methods as UNITE-DNA described above 
(n = 1304; the “UNITE-HF registry model,” which includes all candidate variables in the 
full model except heart rate and history of hypertension). Potential non-linearity of BB 
dose response was tested using polynomial terms (e.g. BB dose*BB dose) in the 
multivariable model.  
 Because UNITE-DNA is not a BB randomized clinical trial, any significant 
results for BB response were subject to propensity matching (30). Propensity matching 
was based on the probability of UNITE-DNA patients being treated with BB based on the 
11 candidate variables in the full clinical model plus anti-RAAS treatment. Patients 
treated and un-treated with BB were matched 1:1 using a greedy 8→1 matching 
algorithm (31).  Because sample size is decreased with propensity matching, the 
propensity score was also used as a covariate in modeling the entire UNITE-DNA cohort. 
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Because propensity matching only balances groups based on known covariates, a 
sensitivity analysis was performed to evaluate the effect of a possible unknown or 
unmeasured confounder (32,33). HRs for BB versus no BB adjusted for an unknown 
binary confounder were derived assuming different hazards and distributions of the 
unmeasured confounder in the two treatments.  To determine if any of the 11 candidate 
clinical variables are associated with BB response, a multiplicative interaction term 
(clinical variable*BB) was introduced in the full clinical model. A statistically significant 
interaction was defined as alpha = 0.1/11 = 0.0091. 
 
Results 
 Baseline characteristics and follow-up. The UNITE-DNA cohort consists of 
722 patients. The mean length of follow-up for patients that are still living is 8.9 years, 
and the number of events for the primary endpoint, all-cause mortality, was 336 (47%). 
Baseline characteristics are shown in Tables 12, 13, 14 and 15 in UNITE-DNA overall 
and stratified by race, BB treatment status, etiology, and vital status, respectively. In 
UNITE-DNA overall, there was good representation of women (37%), AAs (38%), wide 
age range (57 ± 13 years), wide LVEF range (32% ± 15%), and characteristics that are 
typical of a community HF patient population. The BB treatment rate was low (67%), but 
anti-RAAS treatment was high (ACE inhibitor or ARB = 90%). The baseline 
characteristics for the propensity-matched dataset (n = 406) are well balanced between 
BB-treated (n= 203) and BB-untreated (n = 203) patients as shown in Table 16, and they 
are similar to the entire UNITE-DNA dataset (n = 722). The baseline characteristics 
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compared between the patients that remained in the propensity-matched dataset and the 
patients without matches, and hence excluded from the dataset, are shown in Table 17.  
 Survival analysis. The Kaplan-Meier survival curve for UNITE-DNA is shown 
in Figure 4. The results for the univariate and final multivariable model are shown in 
Tables 18 and 19. Six variables remained in the final multivariable clinical model: age, 
history of diabetes, NYHA class, systolic blood pressure, LVEF, and GFR. There were 
669 patients with complete data for these six covariates for the survival analysis. 
However, the results were similar when using imputed mean data for any missing 
covariates, and thus, including all UNITE-DNA patients in the survival analysis. The 
proportional hazards assumption was met for the clinical variables. 
 BB response analysis. BB treatment was significantly associated with an 
approximately 30% reduction in mortality (Figure 5), and the results were similar 
regardless of the adjustment model used (reduced model [HR = 0.72; 95% CI = 0.57-
0.90; p = 0.0046] vs. full model [HR = 0.69; 95% CI = 0.54-0.88; p = 0.0031] vs. 
UNITE-HF registry model [HR = 0.68; 95% CI = 0.54-0.86; p = 0.0012]), in the 
propensity-matched dataset (HR = 0.74; 95% CI = 0.56-0.98; p = 0.0346), and in the 
propensity-adjusted model (HR = 0.73; 95% CI = 0.57-0.93; p = 0.0180). An unknown 
binary confounder with a HR = 2 would have to be present in 40% more of the BB 
untreated patients than the BB treated patients to render the BB association non-
significant. There was no statistically significant interaction between BB and any of the 
candidate clinical variables (Table 20).  BB dose was also associated with a reduction in 
mortality (Figure 6), although it only reached nominal significance (reduced model for 
every 25mg increase in metoprolol equivalent dose [HR = 0.96; 95% CI = 0.92-0.99; p = 
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0.0240] vs. full model [HR = 0.95; 95% CI = 0.92-0.99; p = 0.0161] vs. UNITE-HF 
registry model [HR = 0.95; 95% CI = 0.91-0.99; p = 0.0077]), in the propensity-matched 
dataset (HR = 0.95; 95% CI = 0.90-0.1.01; p = 0.0732), and in the propensity-adjusted 
model (HR = 0.96; 95% CI = 0.93-0.1.00; p = 0.0476). Polynomial terms for non-linear 
dose response were not statistically significant, indicating that dose response is 
approximately linear on the ln(HR) scale. The majority of patients were on metoprolol 
(tartrate 21%; succinate 20%) or carvedilol (51%). The reduced model adjusted results 
were similar for the specific BBs: metoprolol (tartrate or succinate) HR = 0.71; 95% CI = 
0.52-0.96; p = 0.0270; and carvedilol HR = 0.74; 95% CI = 0.56-0.98; p = 0.0357. The 
results were similar when using imputed mean data for any missing covariates, and thus, 
including all UNITE-DNA patients in the BB response analysis. The proportional hazards 
assumption was met for the BB treatment variables. 
 
 
Discussion 
  
Objective #1: Thoroughly describe the UNITE-DNA patient population 
overall and relevant strata. Among published genetic and pharmacogenetic studies, 
UNITE-DNA is one of the largest with the longest follow-up. The UNITE-DNA sample 
also has the advantages of a high event rate, geographical diversity, and a large 
proportion of BB untreated patients. Although it is very unfortunate that there is a high 
mortality rate in UNITE-DNA, for research purposes it permits more power to test for 
associations with all-cause mortality. And although low BB treatment rate would appear 
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to be a poor characteristic of this patient sample, it is actually an advantage because it 
provides power to test for statistical interactions with BB treatment. The low BB 
treatment rate is most likely a reflection of the time of enrollment relative to the 
publication of the major HF BB clinical trials. In contrast to the large HF clinical trials 
and other HF registries (34), UNITE-DNA includes patients with preserved LVEF, a 
large proportion of women and AA, and wide age range. The landmark HF randomized 
clinical trials have mostly been conducted in patients that are younger, with systolic 
dysfunction, Caucasian, and male compared to the general HF patient population (21). 
The heterogeneity of UNITE-DNA is an advantage for the generalizability of results, but 
heterogeneity could also be a disadvantage and limit power for detecting genetic 
associations. UNITE-DNA enrollment took place exclusively in outpatient HF specialty 
clinics, which may lead to selection bias and limit generalization of results to other HF 
patient care settings. Another limitation of the UNITE-DNA registry design is the mode 
of death is not known, which may limit the power to detect associations of cardiovascular 
variables (e.g.. systolic BP, HR, and etiology) with mortality if the patient died from 
something other than HF. On the other hand, all-cause mortality is a gold standard 
endpoint in clinical practice.    
 Interestingly, the HF phenotype in the UNITE-DNA AA patients was very 
different compared to the Non-AA. The AA UNITE-DNA patients had a higher 
percentage of women, were younger, had a lower percentage of ischemic etiology, higher 
percentage with a history of hypertension, increased diastolic BP, increased GFR, and 
increased BB dose compared to the Non-AA patients. The younger age, increased rate of 
hypertension, and decreased rate of ischemic etiology are consistent with findings in the 
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literature (35). Recent data is encouraging and demonstrates that AA HF patients have 
similar or better in-hospital mortality rates, and HF care is equitable in racial/ethnic 
groups (36). Although beyond the scope of this dissertation, future research should focus 
on HF in AA because 1) the disease burden of HF in the U.S. is expected to grow (37), 2) 
the AA population is expected to double by 2050 (38), and 3) AA have a disproportionate 
greater burden of HF (39).  
 The HF phenotype was also drastically different in ischemic versus non-ischemic 
UNITE-DNA patients. UNITE-DNA patients with an ischemic etiology had a higher 
percentage of males, Non-AA, diabetes, hypertension, increased age, decreased HR, 
GFR, and anti-RAAS use, and more deaths compared to the patients with non-ischemic 
disease. The increased age, percentage of males, diabetes, and deaths are consistent with 
previous findings in the literature (40). Although not confirmed in the analysis herein, 
data in the literature suggests that prognosis and drug response differs by HF etiology 
(41). These drastic differences in the HF phenotype, prognosis, and drug response by 
etiology may reflect underlying genetic differences between the ischemic and non-
ischemic HF etiologies. Risk stratification and the tailoring of pharmacotherapeutic 
regimens according to HF etiology may provide future opportunities for personalization 
of HF medicine. 
  
Objective #2: Determine the independent clinical factors associated with 
survival in UNITE-DNA. The significant, independent clinical risk factors for all-
cause mortality found in UNITE-DNA were increased age, the presence of diabetes, 
increased NYHA class, decreased systolic blood pressure, decreased LVEF, and 
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decreased GFR. The direction and magnitude of association for these clinical risk factors 
are similar to other HF patient populations published in the literature. Increased age is not 
surprising, as studies in the very elderly with HF have demonstrated they have extremely 
high risk for mortality (6). The micro- and macro-vascular complications accompanied 
with diabetes possibly explain the increased risk of mortality in the HF patients with 
diabetes, although evidence also demonstrates that diabetes independently contributes to 
myocardial damage, hypertrophy, and fibrosis (42). Symptomatic HF is probably one of 
the most important predictors of mortality, as even a crude measurement such as NYHA 
class consistently predicts mortality (6). The relationship of systolic blood pressure with 
mortality in HF may seem paradoxical, as decreased systolic blood pressure would be 
protective in hypertensive patient populations. However low systolic blood pressure is 
consistently a poor prognostic sign in HF (7). Low systolic blood pressure may be a sign 
of poor systolic capacity of the heart coupled with poor vascular responses and declining 
renal function, but low blood pressure also prevents the use and titration of life-saving 
HF medications such as ACE inhibitors. Decreased LVEF is also consistently associated 
with poor prognosis, and in UNITE-DNA it may reflect non-response to ventricular 
remodeling drugs such as ACE inhibitors, aldosterone antagonists, and BB.  Poor renal 
function may contribute to increased mortality risk in HF due to the resulting electrolyte 
abnormalities and dose-limiting consequences for life-saving HF medications such as 
aldosterone antagonists. 
 Several established mortality risk factors in the literature (e.g. gender, race, heart 
rate, etc.) were not confirmed in UNITE-DNA. However this was probably due to lack of 
power as opposed to underlying differences in the UNITE-DNA patient population 
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because the estimates for the risk factors were similar to those in the literature. This is 
also evident because more clinical risk factors were statistically significant in the overall 
UNITE-HF registry (n = 1304).    
   
Objective #3: Determine the independent association of BB treatment with 
survival in UNITE-DNA. The major limitation to evaluating BB treatment response in 
UNITE-DNA is non-randomization to treatment groups. Randomization (in large sample 
sizes) ensures balancing of known and, perhaps more importantly, unknown 
characteristics between the treatment groups and therefore true BB effects can be 
concluded. However, it is reasonable to suspect that certain biases are present in an 
observational study such as UNITE-DNA. Specifically, the UNITE-HF providers may 
have been hesitant to prescribe BB in the more severe HF patients because of the 
negative inotropic effects.  Indeed, BB were once contraindicated in HF. This type of bias 
would falsely increase the BB response estimate. However there could also be competing 
bias, in that over the course of UNITE-DNA follow-up, BB were becoming adopted as 
standard of care in HF. There may have been crossover of the untreated patients at 
baseline to the BB treated group, which would falsely decrease the BB response estimate. 
Adjustment with covariates in regression modeling helps controlling some of the bias for 
known confounding factors, but it still does not control enough of the bias to equal the 
balance achieved with a randomized, controlled trial. A further step toward balancing 
treatment groups is propensity matching. Indeed the UNITE-DNA propensity-matched 
sub-group was well-balanced, but statistical power is sacrificed when decreasing the 
UNITE-DNA sample size for propensity-matching (which is why the propensity score 
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was also used as a covariate). Also, propensity matching only balances the treatment 
groups based on known factors, leaving unknown factors that could possibly bias the 
results. This is where the unmeasured confounders analysis is valuable to help determine 
how large of an effect from an unmeasured confounder would have to be in order to 
change the result. Despite all of these analysis methods, BB was still associated with 
decreased mortality, and therefore conclusions made on pharmacogenetic interactions 
will still be meaningful.  
  
Objective #4: Determine clinical factors associated with BB response in 
UNITE-DNA. Previous data in the literature demonstrates that certain clinical factors are 
possibly associated with BB response in patients with HF, such as gender (21), race (21), 
and etiology (23). However this was not confirmed in UNITE-DNA, even in unadjusted 
analyses (data not shown). This does not seem to be an issue of low power because even 
when the entire UNITE-DNA sample was included in the analyses (with simple 
imputation for missing covariates), the results were still negative. There is biologic 
plausibility for difference in BB response among these groups. For example, patients with 
ischemic cardiomyopathy may have irreversible damage to the myocardium, prohibiting 
the beneficial ventricular remodeling conferred by BB. Moreover, ischemic etiology is 
more common in males, which could possibly explain the decreased BB responsiveness 
by gender. In the overall UNITE-HF registry, the statistical interaction between race and 
BB was significant, indicating decreased BB responsiveness in AA. A possible 
explanation for decreased responsiveness in AA is the difference in HF phenotype 
between AA and Non-AA. Racial differences in drug response are also often attributed to 
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differences in care, socioeconomic status (43), and genetics. As mentioned above, data is 
encouraging that care is equivalent in racial groups (36), and certainly in UNITE-DNA 
the BB utilization and doses were similar between races. Although UNITE-DNA did not 
collect data on socioeconomic status, the next chapter begins to elucidate the association 
between genetic factors and BB response.   
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Table 11. UNITE-HF study sites and investigators that contributed subjects for this 
research. 
 
Site Investigator(s) 
University of North Carolina  
(Coordinating center) 
 
Kirkwood Adams, Carla Sueta, Amanda Garrand, J. 
Herbert Patterson 
Duke University Christopher O’Connor, Wendy Gattis 
University of Iowa Ron Oren 
Cardiac Center LA Jalal Ghali 
University of Illinois-Chicago Stephanie Dunlap 
Case Western Reserve Ileana Pina 
Medical University of South 
Carolina 
 
Adrian Van Bakel, Grady Hendrix 
University of Florida Alan Miller, Jun Chung 
Stern Cardiovascular Frank McGrew 
University of Texas Medical 
Branch 
Daniel Lenihan 
Tulane University Hector Ventura 
University of Cincinnati Lynne Wagoner, Ginger Conway 
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Table 12. Baseline characteristics in pooled UNITE-DNA and by race. 
Baseline characteristics Pooled 
n = 722 
Non-AA 
n = 450 
(62.5%) 
AA 
n = 270 
(37.5%)  
p-value  
  
male gender 455 (63%) 317 (70%) 136 (51%) <.0001 
age (years)  57 (13) 60 (13) 53 (13) <.0001 
NYHA class 2.50 (0.64) 2.51 (0.64) 2.50 (0.63) 0.6535 
ischemic etiology  314 (44%) 222 (50%) 90 (34%) <.0001 
Hx of hypertension  488 (68%) 272 (61%) 215 (80%) <.0001 
Hx of diabetes 233 (33%) 140 (31%) 91 (34%) 0.4024 
SBP (mmHg) 119 (22) 118 (20) 121 (24) 0.1192 
DBP (mmHg) 70 (13) 69 (12) 72 (14) 0.0002 
HR (beats/min) 75 (14) 75 (14) 76 (14) 0.1046 
LVEF (%)  32 (15) 32 (15) 32 (17) 0.7141 
Estimated GFR (mL/min) 66 (27) 63 (23) 71 (31) <.0001 
BB 484 (67%) 304 (68%) 179 (67%) 0.6851 
BB dose (mg metoprolol CR equivalents) 112 (85) 105 (82) 124 (88) 0.0170 
ACE inhibitor  577 (81%) 365 (82%) 211 (79%) 0.3248 
ACE inhibitor or ARB  639 (90%) 402 (90%) 235 (88%) 0.3285 
Loop diuretic 603 (84%) 367 (82%) 234 (87%) 0.1219 
Spironolactone 172 (24%) 107 (24%) 65 (24%) 0.9628 
Digoxin 516 (72%) 330 (74%) 185 (69%) 0.1321 
Follow-up characteristics  
Days of follow-up 2410 (1288) 2475 (1285) 2302 (1290) 0.0808 
Deaths 336 (47%) 204 (45%) 131 (49%) 0.4068 
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Table 13. Baseline characteristics in pooled UNITE-DNA and by BB treatment status. 
Baseline characteristics Pooled 
n = 722 
BB yes 
n = 484  
(67%) 
BB no 
n = 238 
(33%) 
p-value  
  
male gender 455 (63%) 307 (64%) 144 (62%) 0.5991 
race (AA) 270 (38%) 179 (37%) 143 (39%) 0.6851 
age (years) 57 (13) 56 (13) 59 (13) 0.0133 
NYHA class 2.50 (0.64) 2.43 (2.67) 2.65 (0.57) <.0001 
ischemic etiology  314 (44%) 211 (45%) 100 (44%) 0.8322 
Hx of hypertension  488 (68%) 325 (67%) 160 (69%) 0.5966 
Hx of diabetes 233 (33%) 152 (32%) 156 (67%) 0.7112 
SBP (mmHg) 119 (22) 119 (22) 121 (23) 0.2826 
DBP (mmHg) 70 (13) 70 (13) 71 (12) 0.1614 
HR (beats/min) 75 (14) 73 (13) 80 (14) <.0001 
LVEF (%)  32 (15) 32 (15) 31 (16) 0.5475 
Estimated GFR (mL/min) 66 (27) 68 (26) 64 (27) 0.0603 
BB dose (mg metoprolol CR equivalents) 112 (85) 112 (85) 0 (0) N/A 
ACE inhibitor  577 (81%) 403 (84%) 173 (75%) 0.0034 
ACE inhibitor or ARB  639 (90%) 441 (92%) 197 (85%) 0.0058 
Loop diuretic 603 (84%) 412 (85%) 191 (82%) 0.2069 
Spironolactone 172 (24%) 119 (25%) 52 (23%) 0.5238 
Digoxin 516 (72%) 344 (71%) 172 (74%) 0.5234 
Follow-up characteristics  
Days of follow-up 2410 (1288) 2475 (1244) 2272 (1369) 0.0479 
Deaths 336 (47%) 194 (40%) 140 (60%) <.0001 
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Table 14. Baseline characteristics in pooled UNITE-DNA and by etiology. 
Baseline characteristics Pooled 
n = 722 
Ischemic 
n = 314 
(44%) 
Non-ischemic 
n = 392 
(56%) 
p-value  
  
male gender 455 (63%) 227 (72%) 218 (56%) <.0001 
race (AA) 270 (38%) 90 (29%) 174 (44%) <.0001 
age (years)  57 (13) 62 (11) 53 (13) <.0001 
NYHA class 2.50 (0.64) 2.62 (0.58) 2.43 (0.66) <.0001 
Hx of hypertension  488 (68%) 231 (74%) 247 (63%) 0.0031 
Hx of diabetes 233 (33%) 126 (40%) 101 (26%) <.0001 
SBP (mmHg) 119 (22) 120 (23) 119 (22) 0.3849 
DBP (mmHg) 70 (13) 70 (12) 70 (13) 0.5483 
HR (beats/min) 75 (14) 73 (13) 78 (15) <.0001 
LVEF (%)  32 (15) 31 (15) 33 (16) 0.0876 
Estimated GFR (mL/min) 66 (27) 62 (23) 70 (29) <.0001 
BB 484 (67%) 211 (68%) 263 (67%) 0.8322 
BB dose (mg metoprolol CR equivalents) 112 (85) 105 (86) 113 (84) 0.3175 
ACE inhibitor  577 (81%) 242 (78%) 324 (83%) 0.0941 
ACE inhibitor or ARB  639 (90%) 267 (86%) 360 (92%) 0.0079 
Loop diuretic 603 (84%) 264 (85%) 328 (84%) 0.6611 
Spironolactone 172 (24%) 66 (21%) 103 (26%) 0.1115 
Digoxin 516 (72%) 214 (69%) 294 (75%) 0.0604 
Follow-up characteristics  
Days of follow-up 2410 (1288) 2198 (1292) 2566 (1271) 0.0002 
Deaths 336 (47%) 180 (57%) 149 (38%) <.0001 
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Table 15. Baseline characteristics in pooled UNITE-DNA and by vital status. 
Baseline characteristics Pooled 
n = 722 
Alive 
n = 386  
(53%) 
Deceased 
n = 336 
(47%) 
*p-value  
  
male gender 455 (63%) 236 (61%) 219 (65%) 0.2400 
race (AA) 270 (38%) 139 (36%) 131 (39%) 0.4068 
age (years)  57 (13) 54 (13) 61 (13) <.0001 
NYHA class 2.50 (0.64) 2.37 (0.69) 2.67 (0.53) <.0001 
ischemic etiology  314 (44%) 134 (36%) 180 (55%) <.0001 
Hx of hypertension  488 (68%) 246 (64%) 242 (72%) 0.0218 
Hx of diabetes 233 (33%) 94 (25%) 139 (41%) <.0001 
SBP (mmHg) 119 (22) 120 (22) 119 (22) 0.3549 
DBP (mmHg) 70 (13) 71 (13) 69 (12) 0.0035 
HR (beats/min) 75 (14) 75 (15) 75 (13) 0.7670 
LVEF (%)  32 (15) 34 (16) 30 (15) 0.0006 
Estimated GFR (mL/min) 66 (27) 72 (25) 59 (27) <.0001 
BB 484 (67%) 290 (76%) 194 (58%) <.0001 
BB dose (mg metoprolol CR equivalents) 112 (85) 117 (88) 105 (80) 0.1388 
ACE inhibitor  577 (81%) 320 (84%) 257 (78%) 0.0456 
ACE inhibitor or ARB  639 (90%) 351 (92%) 288 (87%) 0.0439 
Loop diuretic 603 (84%) 309 (80%) 294 (88%) 0.0059 
Spironolactone 172 (24%) 98 (26%) 74 (22%) 0.3140 
Digoxin 516 (72%) 261 (68%) 255 (77%) 0.0105 
Follow-up characteristics  
Days of follow-up 2410 (1288) 3260 (807) 1438 (1021) <.0001 
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Table 16. Baseline characteristics of propensity-matched dataset 
 
Baseline characteristics Pooled 
n = 406 
BB yes 
n = 203 (50%) 
BB no 
n = 203 (50%) 
p-value  
male gender 243 (60%) 129 (59%) 129 (61%) 0.7613 
race (AA) 135 (36%) 68 (34%) 77 (38%) 0.3321 
age (years) 58 (13) 59 (13) 58 (12) 0.5530 
NYHA class 2.63 (0.56) 2.63 (0.53) 2.63 (0.59) 1.0000 
ischemic etiology  173 (43%) 86 (43%) 87 (44%) 0.8507 
Hx of hypertension  284 (70%) 147 (72%) 137 (69%) 0.3892 
Hx of diabetes 126 (31%) 60 (30%) 66 (33%) 0.5411 
SBP (mmHg) 120 (23) 119 (23) 120 (23) 0.6464 
DBP (mmHg) 71 (13) 71 (14) 71 (12) 0.9816 
HR (beats/min) 79 (14) 78 (14) 79 (14) 0.5504 
LVEF (%)  31 (16) 31 (16) 31 (16) 0.7945 
Estimated GFR (mL/min) 64 (26) 64 (24) 64 (28) 0.9970 
BB dose (mg metoprolol CR equiv) 100 (82) 100 (82) 0 (0) <.0001 
ACE inhibitor  315 (78%) 158 (78%) 157 (77%) 0.9053 
ACE inhibitor or ARB  357 (88%) 177 (87%) 180 (89%) 0.6476 
Loop diuretic 345 (85%) 178 (88%) 167 (82%) 0.1265 
Spironolactone 100 (25%) 51 (25%) 49 (24%) 0.8399 
Digoxin 293 (72%) 145 (71%) 148 (73%) 0.7397 
Follow-up characteristics  
Days of follow-up 2369 (1332) 2420 (1287) 2317 (1376) 0.4390 
Deaths 210 (52%) 90 (44%) 120 (59%) 0.0029 
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Table 17. Baseline characteristics of propensity-matched patients and unmatched. 
Baseline characteristics Pooled 
n = 722 
Propensity-matched 
n =  406 (56%) 
Unmatched 
n = 316(44%) 
p-value  
  
male gender 455 (63%) 243 (60%) 212 (67%) 0.0398 
race (AA) 270 (38%) 145 (36%) 125 (40%) 0.2860 
age (years)  57 (13) 58 (13) 55 (14) 0.0023 
NYHA class 2.50 (0.64) 2.63 (0.56) 2.34 (0.69) <.0001 
ischemic etiology  314 (44%) 173 (43%) 141 (46%) 0.4536 
Hx of hypertension  488 (68%) 284 (70%) 204 (65%) 0.1037 
Hx of diabetes 233 (33%) 126 (31%) 107 (34%) 0.4253 
SBP (mmHg) 119 (22) 120 (23) 119 (21) 0.3974 
DBP (mmHg) 70 (13) 71 (13) 69 (12) 0.1965 
HR (beats/min) 75 (14) 79 (13) 71 (13) <.0001 
LVEF (%)  32 (15) 31 (16) 33 (15) 0.1805 
Estimated GFR (mL/min) 66 (27) 64 (26) 69 (27) 0.0104 
BB 484 (67%) 203 (50%) 281 (90%) <.0001 
BB dose (mg meto CR equiv) 112 (85) 100 (82) 118 (87) 0.0243 
ACE inhibitor  577 (81%) 315 (77%) 262 (85%) 0.0120 
ACE inhibitor or ARB  639 (90%) 357 (88%) 282 (92%) 0.1174 
Loop diuretic 603 (84%) 345 (85%) 258 (83%) 0.4083 
Spironolactone 172 (24%) 100 (25%) 72 (23%) 0.6669 
Digoxin 516 (72%) 293 (72%) 223 (72%) 0.8911 
Follow-up characteristics  
Days of follow-up 2410 (1288) 2369 (1332) 2465 (1230) 0.3204 
Deaths 336 (47%) 210 (52%) 126 (40%) 0.0015 
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Table 18. Univariate proportional hazards analysis of 11 candidate clinical variables. 
Variable HR 95% CI p-value 
Gender (Male) 1.23 (0.98-1.54) 0.0762 
Race (AA) 1.14 (0.92-1.42) 0.2321* 
Age (10 years) 1.42 (1.30-1.55) <.0001 
Etiology (ischemic) 1.74 (1.40-2.17) <.0001 
Hx HTN (yes) 1.27 (1.00-1.62) 0.0473 
Hx DM (yes) 1.75 (1.40-2.17) <.0001 
NYHA class (1 class) 1.77 (1.46-2.13) <.0001 
SBP (5 mmHg) 0.97 (0.95-0.99) 0.0350 
HR (5 bpm) 0.98 (0.95-1.02) 0.3476* 
LVEF (5%) 0.93 (0.89-0.97) 0.0002 
GFR (10 mL/min) 0.85 (0.81-0.89) <.0001 
 
*Did not meet < 0.1 level of significance and was not entered into multivariable model 
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Table 19. Final multivariable clinical model. 
Variable HR 95% CI p-value 
Age (10 years) 1.32 (1.20-1.46) <.0001 
Hx DM 1.62 (1.28-2.03) <.0001 
NYHA class 1.60 (1.30-1.95) <.0001 
SBP (5 mmHg) 0.96 (0.94-0.99) 0.0072 
LVEF (5%) 0.96 (0.92-0.99) 0.0363 
GFR (10 mL/min 0.91 (0.87-0.96) 0.0008 
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Table 20. Adjusted interaction between 11 candidate clinical variables and BB response. 
Variable *p-value 
Gender (Male) 0.1005 
Race (AA) 0.1471 
Age (10 years) 0.6225 
Etiology (ischemic) 0.1357 
Hx HTN 0.2166 
Hx DM 0.1058 
NYHA class 0.3073 
SBP (5 mmHg) 0.9385 
HR (5 bpm) 0.1706 
LVEF (5%) 0.3647 
GFR (10 mL/min 0.8958 
 
*Bonferroni-adjusted level of statistical significance = 0.0091  
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Figure legends 
Figure 4. The Kaplan-Meier estimated survival distribution function for all UNITE-DNA 
patients is shown over 10 years of follow-up. Censored observations are represented by 
small circles. 
 
Figure 5. Survival curves for UNITE-DNA derived from the Cox proportional hazards 
model adjusted for age, diabetes, systolic blood pressure, NYHA class, LVEF, and GFR 
and stratified by patients treated with beta-blockers (n = 483) and patients not treated 
with beta-blockers (n = 232) at baseline. 
 
Figure 6. The linear association between BB dose and reduction in mortality derived 
from the Cox proportional hazards model adjusted for age, diabetes, SBP, NYHA class, 
LVEF, and GFR is shown by 25, 50, 100, 150, and 200mg of metoprolol dose 
equivalents.   
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Figure 4. Kaplan-Meier survival curve for UNITE-DNA 
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Figure 5. Adjusted survival curves by BB treatment in UNITE-DNA 
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Figure 6. Adjusted BB dose associated survival benefit in all UNITE-DNA patients. 
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CHAPTER V:  
INDIVIDUAL GENETIC VARIANTS ASSOCIATED WITH  
HF PATIENT SURVIVAL AND BETA-BLOCKER RESPONSE 
 
Summary 
 The previous chapter described the UNITE-DNA HF patient population and the 
clinical characteristics that are associated with survival and BB survival benefit. This 
chapter covers the individual, candidate genetic variants that are independently associated 
with HF patient survival and BB survival benefit. Although none of the 11 variants or 
diplotypes was significantly associated with survival, Ser49Gly in ADRB1 was 
significantly associated with BB response after rigorous control for clinical covariates 
and multiple comparisons. BB treatment was associated with a statistically significant 
46% reduction in mortality in Ser49-homozygotes but a non-significant 38% increase in 
Gly49-carriers.  
 
Introduction 
 The clinical characteristics described in the previous chapter do not entirely 
explain the variability in HF survival and BB response, but data is emerging for genetic 
factors that may play a role (see Chapter II: Identification of Candidate Genetic Variants). 
When studying and interpreting genetic associations in common, complex diseases such 
as HF, the small effect sizes of common variants in common diseases and the potential 
for false positives must be considered.  The common disease common variant hypothesis 
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(1) predicts that multiple common genetic variants contribute to common, complex 
diseases, and each variant has a small effect (e.g. odds ratios typically in the range of 1.2 
to 1.5). The small effect sizes expected for common genetic variants in common diseases 
requires large sample sizes for the power to detect genetic associations, especially in 
comparison to and when controlling for clinical risk factors with large effects. However 
genetic variants have the potential for effect sizes similar to and independent of their 
clinical risk factor counterparts. For example, a single insertion/deletion variant in ACE 
accounts for half of the variance in plasma ACE levels (2). HF patients who possess the 
deletion allele have significantly higher plasma ACE levels and significantly higher risk 
of mortality (3). The odds ratio for the ACE genetic variant in the multivariable model 
was 1.69, which was higher than any other significant clinical variable in a study of 194 
patients with idiopathic HF. For comparison, the other significant predictors of mortality 
in the multivariable analysis were New York Heart Association functional class (odds 
ratio = 1.42) and left ventricular end-systolic diameter (odds ratio = 1.07).   
 Because the genetic contribution to variability in HF outcomes is most likely 
polygenic, genetic association studies often test multiple genetic variants in multiple 
genetic models resulting in multiple statistical tests. Multiple statistical testing inflates 
Type I error (rejecting the null hypothesis when it is actually true). An extreme example 
would be GWAS, in which one million genetic variants could be tested for an 
association. If a GWAS investigator used alpha = 0.05, then 50,000 of the genetic 
variants could be reported as positive by chance alone. It has been speculated that 19 out 
of every 20 genetic marker-disease associations in the literature are false (4), which is 
supported by the pervasive lack of replication for many genetic markers (5) (Appendix 
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IV). Several reasons could possibly explain the lack of replication, such as true variation 
of the underlying association in different populations, misclassification of outcome, 
population stratification, or lack of power, but the failure to exclude chance is purported 
to be the number one cause of false discoveries (6).  False discoveries can lead to wasted 
time and resources on leads that are eventually proven worthless, and the repeated lack of 
replication of genetic associations also leads to a loss of confidence in this type of 
research by the scientific community. Therefore, several methods have been developed to 
control for false discoveries when making multiple comparisons in genetic association 
studies. 
 Multiple comparison control methods can be broadly defined into two categories 
(4,6): those that control the family wise error rate (FWER) and those that control the false 
discovery rate (FDR).  The family wise error rate is the rate of Type I error for a family 
of statistical tests, and the false discovery rate is the proportion of rejected null 
hypotheses that are false. Methods that control the FWER are more conservative than 
FDR methods, and FWER methods become increasing conservative with the number of 
statistical tests. For example, one of the most commonly used FWER controlling 
methods, presumably because of its simplicity, is the Bonferroni correction in which 
alpha is divided by the number of comparisons. Therefore, for a GWAS of 500,000 
variants, the alpha = 10
-7
. The Bonferroni correction for multiple comparisons can be 
overly conservative because achieving such low levels of Type I error increases Type II 
error (failing to reject the null hypothesis when in fact it is false), and hence extremely 
large sample sizes are required for the power to meet statistical significance. The incurred 
loss of power, even in medium-sized studies, has led many investigators to neglect 
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multiplicity control all together. FWER controlling methods assume independence of the 
statistical tests, which is unlikely in genetic association studies of many variants.  Also, 
the FWER correction is dependent on the number of tests, which in genetic association 
studies can be arbitrary and based on factors such as budget, publication strategy, and 
genotyping capacity. The context of the genetic association study is also important. For 
example, exploratory studies may prefer less conservative methods and therefore permit a 
number of false discoveries in order to ensure the power for detecting true discoveries. 
On the other hand, validation studies may use more conservative methods since the 
genetic association has been previously reported, and the implications for the genetic 
association may be great (e.g. the conduct of a large, expensive, prospective clinical trial 
or change in clinical practice).   
 Both FWER and FDR methods were used for this chapter. The more conservative 
FWER controlling Bonferroni method was used as control for the primary hypotheses of 
this chapter: an independent association of the individual genetic variants or diplotypes 
with 1) survival and 2) BB survival benefit in an autosomal dominant inheritance model. 
The more conservative method was chosen for the two primary hypotheses because these 
hypotheses have been tested before, and thus UNITE-DNA is serving as a validation 
population. Also, the implications for the results are large because they concern HF 
patient survival and pharmacotherapy that is firmly entrenched in the HF treatment 
guidelines. For exploratory analyses of other inheritance models and sub-groups (i.e. 
racial and etiologic), a FDR of 5% modified for dependency was used. This is because 
the analyses are exploratory, and hence a small amount of false discoveries are permitted 
to allow for the power to detect other important leads.      
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Methods 
 Statistical analysis. The autosomal dominant inheritance model (major allele 
[most frequent] homozygotes versus heterozygotes plus minor allele homozygotes) was 
used to test the two primary hypotheses. The purpose of using the dominant inheritance 
model was two-fold. First, it maximizes the sample sizes of the comparison groups. 
Second, it improves potential future generalizability in clinical practice (e.g. if BB 
response differed only in a minor allele homozygotes sub-group, then it would only apply 
to a small percentage of patients). To assess the independent association of the 11 
candidate variants and two diplotypes (diplotypes in ADRB1 and ADRB2; see Chapter III: 
Characterization of Candidate Genetic Variants) with survival, each was tested in the Cox 
proportional hazards reduced model developed in Chapter IV: Characterization of Patient 
Population. The model was developed for the risk alleles determined in Chapter II, so that 
the expected HR would be >1 based on previous literature. Given n = 722, alpha = 0.1, 
and 8.9 years of follow-up, there was 80% power to detect a HR = 1.19 for a 
dichotomous variable in the univariate analysis. To assess the independent interaction 
between genotype and BB survival benefit, each of the 11 candidate variants and two 
diplotypes was tested for a multiplicative statistical interaction (variant*BB) within the 
reduced clinical model. If the interaction term was statistically significant, then the 
adjusted BB survival benefit within the genotype sub-groups was determined using 
stratified and contrast analysis. BB dose-associated survival benefit was assessed by 
including BB dose (in 25mg metoprolol equivalents) in the model as a continuous 
variable. Possible non-linearity of BB dose-associated survival benefit was assessed by 
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including polynomial terms in the model. The Bonferroni-adjusted alpha for the 
independent association of variants with survival was 0.05/13 = 0.0038 and for the 
genotype*BB interaction term was 0.1/13 = 0.0077 (multiplicative statistical interactions 
are underpowered). For any test that was statistically significant in the reduced model, it 
was also tested with the full and UNITE-HF clinical models described in Chapter IV for 
robustness. Also, for any variant that was statistically significant, baseline characteristics 
were compared between genotype sub-groups to determine possible differences in 
baseline characteristics that were not included as covariates in any of the above clinical 
adjustment models. Specific BBs (metoprolol and carvedilol) were assessed for 
significant genotype*BB interactions. Because UNITE-DNA is not a BB randomized 
clinical trial, any significant results for BB survival benefit were subjected to propensity 
matching (7). Patients treated and un-treated with BB were matched 1:1 using a greedy 
8→1 matching algorithm (8).  Because sample size is decreased with propensity 
matching, the propensity score was also used as a covariate in modeling the entire 
UNITE-DNA cohort. A sensitivity analysis was performed to evaluate the effect of a 
possible unknown or unmeasured confounder (9,10) on any significant results. HRs for 
BB versus no BB adjusted for an unknown binary confounder was derived assuming a 
HR = 2 for the unknown confounder.  There were very few patients with missing values 
for any covariate (~10%). But to ensure that including patients with missing data for the 
multivariable analysis did not significantly affect the conclusions, analyses were repeated 
with simple imputation for missing data and hence all patients were included in the 
analysis.  
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 Several exploratory analyses were performed in addition to the two primary 
hypotheses described above. To determine if the candidate genetic variants or haplotypes 
would replace any of the candidate clinical variables in the final multivariable model, the 
candidate genetic variants were subject to model building similar to Chapter IV. 
Specifically, a series of univariate proportional hazards regression models were fit, one 
model for each of 11 candidate variants, two haplotypes, and pre-defined clinical factors. 
A significance level of p < 0.10 was prospectively defined for inclusion in the 
multivariable analysis. Final inclusion in the multivariable model was determined using 
stepwise selection with a significance level of p < 0.05. Additional exploratory analysis 
tested the other inheritance models, recessive and additive (except for ADRA2C which 
can only be tested in the dominant inheritance model [see Chapter III]), for an 
independent association with survival or BB survival benefit. These analyses were also 
performed stratified by race, BB treatment, and etiology. A 5% false discovery rate (with 
modification for dependency) (11) was used to adjust the p-values for the many 
exploratory tests performed.  
 
Results 
 Survival. For the primary hypothesis (independent association of candidate 
genetic variants or diplotypes with survival in a dominant inheritance model), none of the 
candidate genetic variants or diplotypes met the criteria for statistical significance as 
shown in Table 21. The results were similar when simple imputation was used for 
missing data. In the exploratory analyses, none of the candidate genetic variants or 
diplotypes replaced the clinical variables in the multivariable model because none of the 
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genetic variants had a univariate association with p < 0.1. When the other inheritance 
models (recessive and additive) and strata (by race, etiology, or BB treatment) were 
explored, none of the candidate genetic variants or diplotypes were independently 
associated with survival after correction with a 5% false discovery rate modified for 
dependency (Table 22). 
 Beta-blocker response. For the primary hypothesis (independent association of 
candidate genetic variants or diplotypes with BB response in a dominant inheritance 
model), one candidate genetic variant met the criteria for a statistical significance, 
ADRB1 Ser49Gly, as shown in Table 23 (Appendix III) (12). The results were similar 
when simple imputation was used for missing data. The Ser49Gly*BB interaction term 
remained statistically significant in the full model (p = 0.0030) and UNITE-HF model (p 
= 0.0028). Race and history of hypertension were significantly different between 
genotype groups (Table 24), and these were included as covariates in the full clinical 
model which remained statistically significant.   In the propensity matched dataset (n = 
406; see Chapter IV), the Ser49Gly*BB interaction term p-value was p = 0.0206, and it 
was p = 0.0032 when the propensity score was used as a covariate for the entire UNITE-
DNA cohort. The propensity-matched and propensity-adjusted stratified results are 
shown in Table 25.  The adjusted stratified and contrast results for BB and BB dose 
response within the dominant inheritance genotype groups are shown in Table 26. BB 
dose response was only present in the Ser49-homozygotes and was approximately linear 
on the ln(HR) scale because polynomial terms in the model (e.g. BB*BB) were not 
statistically significant. The adjusted Ser49Gly*BB interaction was p = 0.0161 for 
metoprolol and p = 0.0046 for carvedilol specifically. Figure 7 shows the adjusted 
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survival curves stratified by BB and Ser49Gly genotype, and Figure 8 shows the adjusted 
BB dose-associated survival benefit by Ser49Gly genotype. An unknown binary 
confounder with a HR = 2 would have to be present in 70% more of the BB untreated 
patients than the BB treated patients to render the BB association in Ser49-homozygotes 
non-significant. In the exploratory analyses, the other inheritance models (recessive and 
additive) and strata (by race and etiology) did not have any statistically significant 
associations after adjustment for a 5% false discovery rate modified for dependency 
(Table 22).   
     
Discussion  
 Survival. In this chapter, none of the 11 individual genetic variants or 2 
diplotypes was independently and significantly associated with survival in UNITE-DNA.  
The negative results for survival are surprising, as each of the variants has established 
molecular effects which have been translated to HF relevant clinical outcomes (see 
Chapter II: Identification of Candidate Genetic Variants). The two most probable 
explanations for the negative survival results are selection bias and lack of power. The 
UNITE-DNA patient population comes from outpatient HF specialty clinics. Therefore it 
is possible that there is selection occurring before the patients even make it to the clinic. 
For example, if certain genetic variants were extreme risk factors for poor clinical 
outcome, patients may die or receive a heart transplant before they are even referred to 
the HF clinic. Also, UNITE-DNA was a heavily treated population. Therefore the 
patients may have been treated beyond any potential genetic effects. For example, the 
patients could have such extreme pharmacologic inhibition of the SNS and RAAS with a 
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combination of ACE inhibitor or ARB, BB, and aldosterone antagonist that any effects of 
genetic polymorphisms in the SNS and RAAS are neutralized. Indeed, this has been seen 
previously in the literature. The ACE indel was associated with clinical outcome in BB-
untreated HF patients, but there was no influence of the ACE indel in patients treated with 
BB and ACE inhibitor (13). However, the exploratory analysis of UNITE-DNA also did 
not reveal an association of any of the genetic variants in BB-untreated patients after 
correction for multiple comparisons. There may also be true underlying differences in the 
genetic association for the genetic variants in the patient populations initially studied and 
UNITE-DNA. Power may also be an explanation for the negative survival results. 
According to the common disease common variant hypothesis (1), common genetic 
variants such as those studied herein are expected to have a small effect on common 
diseases such as HF. The expected odds ratios are typically in the range of 1.2 to 1.5, and 
there was only 80% power to detect a HR = 1.19 in univariate analysis of UNITE-DNA. 
Publication bias may have falsely elevated the expected odds ratios for common variants 
studied herein (14).  Negative results, especially in smaller studies, may not be submitted 
for publication let alone accepted. Therefore any systematic review of published results 
would be misleading. Although the individual effects of the genetic variants may be 
small, the genetic variants come from the same physiologic systems (SNS and RAAS), 
and therefore may have additive effects when combined. This concept was explored in 
the next chapter.  
  
ADRB1 Ser49Gly and BB response. There is strong biologic plausibility and 
prior literature to support the pharmacogenetic interaction between BB and Ser49Gly in 
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ADRB1.  The beta-1 adrenergic receptor is the principal adrenergic receptor subtype 
expressed on human cardiomyocytes. It is the primary mediator of catecholamine-
mediated increases in cardiac inotropy and chronotropy, as well as the cardiomyopathic 
effects leading to HF (15). Stimulation of myocardial beta-1 adrenergic receptors with 
catecholamines results in the activation of the heterotrimeric Gs protein, which, in turn, 
activates adenylyl cyclase and promotes the production of cAMP. The gene encoding the 
beta-1 adrenergic receptor (ADRB1) is localized to chromosome 10q24-q26 (16). ADRB1 
is intronless, consists of 1,714 base pairs, and codes for a 51.3 kDa protein consisting of 
477 amino acid residues (17). The non-synonymous single nucleotide polymorphism, 145 
A->G or rs1801252, causes the substitution of glycine for serine at amino acid 49 
(Ser49Gly) in the N-terminal extracellular domain of the receptor (18,19). The Ser49 
allele is common in humans, having an allele frequency of approximately 75-87% in 
Caucasians, Chinese, and AAs (20). However the Gly49 allele is conserved across other 
mammalian species (21), indicating that Ser49Gly may have functional relevance. 
Indeed, Ser49Gly has been widely studied in vitro, ex vivo, and in vivo.  
 In transfected cell experiments, the influence of Ser49Gly on agonist binding and 
basal and agonist-stimulated adenylyl cyclase activity is unclear. Levin et al found that 
Gly49-expressing cells have a higher affinity for beta-1 agonists (22), but Rathz et al 
found identical agonist binding affinities (23). Levin et al found that Gly49-expressing 
cells have 4-fold and 2-fold higher basal and maximally-stimulated adenylyl cyclase 
activity compared to Ser49, respectively (22), but Rathz et al found identical basal and 
agonist-stimulated adenylyl cyclase activities (23).  However where the literature is 
consistent is with respect to antagonist binding and down-regulation. Ser49 and Gly49-
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cells bind metoprolol equally, and Gly49 receptors are down-regulated after sustained 
agonist stimulation whereas Ser49 receptors are not. In patients with chronic HF and 
persistent sympathetic stimulation that is toxic to the cardiomyocyte, down-regulation of 
beta-1 receptors is thought to be a protective adaptation. 
 In non-failing, human right atrial tissue experiments, Molenaar et al found that 
basal and norepinephrine-stimulated contractions were similar among Ser49- and Gly49-
containing tissues (24). This was also found by Sarsero et al using (-)-CGP 12177, a 
partial agonist BB which increases heart rate and force at high concentrations and is 
resistant to blockade with propranolol (25). Sarsero et al tested the potency (-)-CGP 
12177 in failing hearts, but did not test for the influence of Ser49Gly. The results were 
consistent among patients treated and not treated with BBs, supporting the in vitro 
findings of Rathz et al. It is important to note that the transfected cell experiments 
demonstrated changes in down-regulation between Ser49 and Gly49 only after sustained 
stimulation with agonist. Therefore the experiments by Molenaar et al and Sarsero et al 
may not have allowed sufficient time for beta-1 receptor down-regulation, and the results 
may have been different in tissues from patients with failing hearts or sustained 
experimental exposure to agonist.  
 Ser49Gly has been studied for an association with many in vivo cardiovascular 
parameters such as blood pressure, heart rate, and left ventricular remodeling and the 
changes in these parameters in response to beta-blockade. As would be expected by the 
lack of down-regulation of Ser49-containing receptors, patients with Ser49 tended to 
have a better blood pressure response to beta-blockade (26-29). Although there are 
several negative studies as well (30-35). Ser49 is associated with higher heart rate at rest 
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(36,37) and in response to exercise (30). Although no association (31,33,38,39) and the 
reverse association with heart rate have also been reported (40). In response to BB, there 
is a similar negative chronotropic response among genotypes (34,37). A single study 
showed improved left ventricular end diastolic diameter, but not LVEF, in response to 
metoprolol in Ser49 homozygous HF patients compared to Gly49 carriers (41). However 
many studies failed to find an association with left ventricular remodeling response 
(34,42-46). An important consideration in studies of cardiovascular parameters is the 
time dependency of beta-1 receptor down-regulation demonstrated in the in vitro 
experiments. Specifically, short-term measurements of cardiovascular parameters may 
fail to detect differences among Ser49Gly genotypes. Another consideration is that 
receptor down-regulation is in response to persistent agonist stimulation, like that seen in 
HF. Therefore studies in healthy volunteers or cardiovascular disease with non-failing 
hearts may also not translate the in vitro findings. Moreover, left ventricular remodeling 
response to beta-blockade is time dependent, in which it may take up to one year to see a 
complete response (47). 
 Ser49Gly has been studied for its association with the development of several 
cardiovascular diseases, albeit with inconsistent results. The seminal paper by Podlowski 
et al describes the striking association of Ser49Gly with the development of idiopathic 
dilated cardiomyopathy (IDCM), but the study was very small (21). Podlowski et al 
performed a case-control study of 37 German IDCM patients and 40 healthy volunteers, 
the Gly49 allele was only detected in the IDCM patients resulting in an estimated odds 
ratio for the development of IDCM of 14.7 with Gly49 (21). A similar association was 
found in larger case-control studies of Italian (48) and Chinese patients (49). However, a 
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recent meta-analysis of 2642 cases and 3136 controls revealed an association with IDCM 
only among Asian patients and not European (50). There are also mixed results for the 
association of Ser49Gly with the development of hypertension, with one large meta-
analysis showing no association (51) and another demonstrating an association (52). 
 Ser49Gly is not clearly involved with the development of cardiovascular disease, 
but it may alter the course of established cardiovascular disease. Indeed, this is supported 
by a retrospective study by Borjesson et al (19). In 184 patients with IDCM, the survival 
curve for Ser49-homozygous patients treated with BB was almost identical to Gly49-
carrying patients not receiving BB. This was confirmed in a study by Magnusson et al 
(53), in which they added a prospective IDCM cohort (n = 190) to the retrospective 
cohort studied by Borjesson et al (53), and a study of 171 Italian IDCM patients found 
similar results in univariate analysis (54). Magnusson et al found that patients carrying 
Gly49 had a similar survival rate regardless of high-dose (>50% of target dose) or low-
dose (≤ 50% of target dose) BB. However, in the group of patients treated with low-dose 
BB, patients carrying Gly49 had lower five-year mortality compared to patients 
homozygous for Ser49 (risk ratio = 0.24; p = .020). Like all genetic association literature, 
there are many things to consider when interpreting the association between Ser49Gly 
and survival such as study power, publication bias, phenotypic definition, and 
racial/ethnic stratification (55). Acknowledging these differences, the Magnusson et al, 
Borjesson et al, and the results described herein suggest that it is more critical that HF 
patients homozygous for Ser49 are treated with high dose BBs than Gly49-carriers.  
 ADRB1 Arg389Gly and BB response. Sympathetic stimulation of ADRB1 
results in activation of the Gs protein, which in turn activates adenylyl cyclase and the 
107 
 
production of cAMP (56). Arg389 of ADRB1 displays increased coupling to Gs 
compared to Gly389 (57); hence Arg389 has greater basal and agonist-stimulated activity 
(57). Therefore it has been hypothesized that HF patients possessing Arg389 would have 
a greater response to BB. With respect to ventricular remodeling responses, this has been 
studied in a series of small HF cohorts.  
Mialet-Perez et al retrospectively studied 224 patients with systolic dysfunction 
receiving carvedilol (58). They were the first to report that patients who were 
homozygous for Arg389 had a significantly greater improvement in LVEF after treatment 
with BB than patients who were homozygous for Gly389 (+8.7% ± 1.1% versus +0.93% 
± 1.7%, respectively; p < 0.02). Patients who were heterozygous at position 389 had a 
similar improvement in LVEF compared to Arg389 homozygotes (7.02% ± 1.5%). This 
association was confirmed in three prospective studies totaling 345 patients among a 
variety of etiologies (ischemic and non-ischemic), BB (metoprolol and bisoprolol), and 
ethnic groups (Caucasian, AA, and Chinese) (41,44,45). However there are also three 
studies totaling 416 patients that failed to find a significant association (34,59,60). Given 
that the series of studies investigating LVEF response were small, it is difficult to 
conclude if Arg389Gly is a good predictor of LVEF response to BB. Notably, the 
previous, positive LVEF studies are consistent for the beneficial variant (Arg389). If the 
previous positive findings were purely spurious, spurious findings for the Gly389 variant 
would be expected as well. The data on UNITE-DNA presented herein cannot weigh into 
this issue because UNITE-DNA only had baseline LVEF data available. However, LVEF 
was similar among Arg389Gly genotype groups in UNITE-DNA at baseline (data not 
shown). 
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 Liggett et al conducted a pharmacogenetic sub-study with a survival endpoint 
utilizing patients from the Beta-Blocker Evaluation of Survival Trial (BEST) (61). BEST 
was a randomized, placebo-controlled trial of the investigational beta antagonist 
bucindolol, which found that bucindolol did not significantly decrease mortality in HF 
patients overall (HR = 0.90; adjusted p = 0.13). However in the pharmacogenetic sub-
study of 1040 patients (62), these investigators found survival benefit from bucindolol 
varied by genotype.  Patients homozygous for Arg389 had a statistically significant 
improvement in survival compared to placebo (HR = 0.62; p = 0.03), whereas Gly389 
carriers did not (HR = 0.90; p = 0.57). Importantly, these results do not seem to apply to 
BB currently used to treat HF.  
White et al performed a pharmacogenetic sub-study (63) consisting of 600 
patients from MERIT-HF (64), a randomized, controlled trial for the effectiveness of 
metoprolol CR/XL in chronic HF. They did not find an association of Arg389Gly with 
the primary outcome of all-cause mortality or hospitalization in either the metoprolol 
CR/XL or placebo treated groups.  Cresci et al also found no association of Arg389Gly 
genotype with all-cause mortality in a prospective registry of two independently recruited 
U.S. HF populations where baseline BB therapy, if utilized, was predominantly 
metoprolol or carvediolol (65).  These findings are also consistent with the lack of 
association of Arg389Gly genotype with mortality described by Sehnert et al in a 
prospective registry study of 637 patients that were all treated with BB (66).  Consistent 
with these other studies, the UNITE-DNA data presented herein also does not support a 
pharmacogenetic interaction between Arg389Gly and currently used BB. Only a small 
study of 201 HF patients with a limited number of events reported by Biolo et al found 
109 
 
results consistent with Liggett et al, where metoprolol and carvedilol appeared to be more 
effective at high doses in decreasing HF-related mortality in patients carrying the Arg389 
allele (67).  
The discrepant pharmacogenetic results for bucindolol and the other currently 
used BB are most likely related to the unique pharmacological properties of bucindolol. 
Unlike currently used BB for HF, bucindolol has the additional pharmacologic property 
of marked sympatholysis, which contributed to the lack of mortality benefit in BEST 
(68). The marked sympatholysis with bucindolol is due to presynaptic beta-2 adrenergic 
receptor blockade unopposed by potent alpha adrenergic receptor blockade, which does 
not occur with carvedilol, metoprolol, or bisoprolol.  Further supporting a bucindolol-
specific Arg389Gly interaction, Liggett et al demonstrate in an ex vivo experimental 
model that the effects of the Arg389Gly variant differs by BB (62), and the ex vivo model 
is consistent with clinical findings. Specifically, bucindolol produced a significant, 
negative inotropic effect in Arg389-homozygous hearts, but not in Gly389-carrying 
hearts, which is consistent with the clinical finding that only Arg389-homozygous 
patients, and not Gly389-carriers, derive survival benefit from bucindolol. Accordingly, 
the ex vivo model demonstrated a similar negative inotropic response to carvedilol in 
Arg389-homozygous and Gly389-carrier hearts, which is consistent with the previous 
clinical findings and UNITE-DNA herein that Arg389-homozygotes and Gly389-carriers 
derive similar survival benefit from carvedilol. According to the MERIT-HF 
pharmacogenetic sub-study and UNITE-DNA herein, this may also be applicable to 
metoprolol (ex vivo experimental data for metoprolol not available).   
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ADRB2 Gly16Arg and BB response. In HF, chronic adrenergic stimulation 
causes down-regulation of the beta-1 adrenergic receptor but not the beta-2 adrenergic 
receptor. This causes a change in the ratio of beta-1:beta-2 from approximately 80:20 in 
healthy heart tissue to approximately 60:40 in the failing heart (69). Therefore the use of 
beta-1 selective versus non-selective BBs in HF remains a clinical issue. Although the 
density of the beta-2 adrenergic receptor in HF is unchanged compared to beta-1, the 
beta-2 receptor is subject to desensitization via functional uncoupling from the 
intracellular G protein, Gs (56). A glycine (Gly) at amino acid position 16 results in 
increased agonist-promoted desensitization compared to arginine (Arg) (70). The 
pharmacogenetic interaction between this variant and BB has not been studied in vitro. 
However it has been hypothesized that because Gly16 allows for greater desensitization 
of the beta-2 receptor, HF patients possessing Gly16 have “genetic beta-blockade.” 
“Genetic beta-blockade,” or the lack thereof, may interact with exogenously administered 
BB.  
Six clinical studies tested the Gly16Arg variant in 738 HF patients 
(34,43,44,60,71,72), and none found a significant association between Gly16Arg and BB 
response with respect to BB tolerability, LVEF, or LVFS. Importantly, in three of these 
studies, the patients received beta-1 selective BB, which could have limited the power to 
detect a pharmacogenetic interaction with Gly16Arg. Acknowledging this limitation, and 
the negative results in UNITE-DNA, it seems unlikely that this variant could have a 
clinically meaningful pharmacogenetic interaction with BB. 
ADRB2 Gln27Glu and BB response. A glutamine (Glu) at amino acid position 
27 in the beta-2 adrenergic receptor is resistant to agonist-promoted desensitization (70), 
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and in contrast to Gly16Arg, there is ventricular remodeling data to support a 
pharmacogenetic interaction with BB. Although the pharmacogenetic interaction has not 
been studied in vitro, it has been hypothesized that patients with Glu27 will be more 
responsive to BB because they have more sensitive beta-2 receptors. Indeed, this has 
been confirmed in three clinical studies evaluating LVEF changes. Kaye et al were the 
first to report this pharmacogenetic interaction in a retrospective study of 80 HF patients 
on at least 4 months of carvedilol (72). They defined good responders as having an 
increase in LVEF of at least 10%, or an increase in LVFS of at least 5%. Patients 
homozygous for Gln27 had a significantly lower proportion of good responders than 
patients who were carrying Glu27 (26% versus 63%, p = 0.003). These findings were 
confirmed in two prospective studies by Troncoso et al (73) and Metra et al (60), which 
totaled 216 patients with systolic dysfunction and receiving carvedilol. Troncoso et al and 
Metra et al also found that Glu27 was associated with a favorable BB response in other 
parameters such as heart rate (73), malondialdehyde levels (a marker of oxidative stress) 
(73), and pulmonary wedge pressure both at rest and peak exercise (60). However, there 
are four studies that did not find a significant association between Gln27Glu and 
ventricular remodeling response to BB (34,41,43,44), and there is no previous data on 
this variant and BB survival benefit. Ventricular remodeling is not a perfect surrogate for 
survival, and therefore according to the UNITE-DNA data herein, the Gln27Glu 
pharmacogenetic interaction may be limited to ventricular remodeling differences that do 
not translate into survival differences.  
ADRA2C indel and BB response. The function of the alpha-2C adrenergic 
receptor is pre-synaptic auto-inhibition of norepinephrine release. An indel variant in 
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ADRA2C results in a four amino acid loss at positions 322-325. The deletion results in the 
loss of normal auto-inhibitory receptor function and hence increased presynaptic release 
of norepinephrine (74). Although not studied in vitro, it is possible that the deletion is 
associated with BB response, especially when it is inherited with other genetic variants 
affecting sympathetic activity. For example, HF patients with ADRB1 Arg389 (with 
increased agonist-promoted activity) and the ADRA2C deletion (with increased 
presynaptic release of norepinephrine) could have enhanced beta-adrenergic receptor 
activity and hence greater response to beta-blockade.  
Lobmeyer et al investigated the possible interaction between ADRB1 Arg389, the 
ADRA2C indel, and BB response in 54 HF patients with systolic dysfunction (75). The 
deletion carriers had an increased improvement in LVEF compared to insertion 
homozygotes (+6% versus +1%; p = 0.045). Synergy between the ADRB1 and ADRA2C 
variants was supported by the magnitude of results, in that patients both homozygous for 
Arg389 and a deletion carrier exhibited the greatest LVEF response compared to all other 
genotypes (+12% versus +2% as the greatest change in all other genotypes; p < 0.05 for 
all comparisons). Nonen et al also investigated ventricular changes (LVFS) in response to 
BB and ADRA2C status in 80 IDC patients, but did not find a significant association (43). 
Therefore like the UNITE-DNA results, the Nonen et al data may indicate that the 
ADRA2C indel is not meaningful for BB response alone, but according to the Lobmeyer 
et al data, it may be important in combination with ADRB1 Arg389Gly. 
The complexity of adrenergic regulation through ADRA2C was highlighted in a 
pharmacogenetic sub-study consisting of 1040 patients from BEST (61) by Bristow et al 
(76). Although Lobmeyer et al found that deletion carriers experienced greater LVEF 
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improvement with BB, Bristow et al found that deletion carriers did not experience 
survival benefit from beta-blockade (HR = 1.09; p = 0.80) (76). However Bristow et al 
found that the insertion homozygous patients experienced survival benefit (HR = 0.70; p 
= 0.025). Importantly, the BB investigated by Bristow et al was bucindolol. Bristow et al 
previously showed that the marked sympatholysis caused by bucindolol results in 
increased mortality and HF hospitalizations compared to patients with little or no 
sympatholytic response (68). Indeed, this was the case in deletion-carriers. In bucindolol-
treated patients, a comparison of homozygous ADRA2C insertion and deletion carriers 
revealed that deletion carriers had a 3.1-fold greater reduction in norepinephrine (p = 
0.001). As described above, marked sympatholysis is unique to bucindolol; therefore the 
pharmacogenetic interaction between the ADRA2C indel and bucindolol survival benefit 
may not be applicable to other BB, and this idea is supported by the negative results for a 
pharmacogenetic interaction in UNITE-DNA. 
GRK5 Gln41Leu and BB response. The function of the G-protein receptor 
kinases is to desensitize ligand-occupied G-protein coupled receptors such as beta-
adrenergic receptors (77). The Leu41 allele more effectively desensitizes agonist-
stimulated responses (78). Because HF patients with Gln41 may have more sensitive 
beta-adrenergic receptors, it has been hypothesized that HF patients with Gln41 would 
have a greater response to beta-blockade. Although not studied in vitro, this potential 
pharmacogenetic interaction has been examined both retrospectively and prospectively in 
HF patients (78).  
In a case-control study, Liggett et al found a significant pharmacogenetic 
interaction, but only in the AA sub-group (n = 242) and not in European-Americans (n = 
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568). They then confirmed these findings in a prospective, observational study of a 
second cohort of 375 AAs with HF, where they found that only individuals who were 
homozygous for Gln41 had significantly improved transplant-free survival with BB 
treatment (HR = 0.22; p < 0.001). There was no difference in this outcome in patients 
carrying Leu41 with or without BB (HR = 0.78; p = 0.53). Cresci et al found similar 
results in a cohort of AA HF patients (65). In the overall cohort, there was a trend for a 
BB treatment effect (HR = 0.698; p = 0.1). However in a sub-group of ADRB1 Gly389 
homozygous/GRK5 Gln41 homozygous AAs, BB did provide mortality benefit (HR: 
0.385; p = 0.012). When these investigators matched AAs and Caucasians by ADRB1 
Gly389 homozygous/GRK5 Gln41 homozygous genotype and BB treatment, survival was 
similar in the two races. These findings must be considered with some caution due to the 
limited number of events in the first prospective cohort and the overlapping composition 
of the study populations in the Liggett et al and Cresci et al cohorts.  
The previous literature indicates that the GRK5 Gln41Leu pharmacogenetic 
interaction with BB is limited to AAs. The primary hypothesis in this chapter covered the 
entire UNITE-DNA cohort, but the exploratory analyses, which included race 
stratification, still did not replicate the previous findings in AAs. The Liggett et al, Cresci 
et al, and the UNITE-DNA data herein all come from well-executed pharmacogenetic 
studies; therefore it is difficult to determine the true pharmacogenetic interaction of 
GRK5 Gln41Leu with BB.  There are some important differences between the previous 
GRK5 literature and UNITE-DNA that may explain the discrepancy in results. There may 
be regional differences in the pharmacogenetic interaction. The Liggett et al and Cresci et 
al patients were predominantly from Cincinnati, whereas the UNITE-DNA patients are 
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predominantly from the southeastern U.S. Indeed global regional differences in BB 
response have been reported (79). The data supporting the GRK5 Gln41Leu and BB 
pharmacogenetic interaction is only significant in AAs. The genetic admixture of the 
AAs in Cincinnati may be different than in the southeastern U.S., but ancestry-
informative markers are not available in UNITE-DNA. The Liggett et al and Cresci et al 
studies only included HF patients with systolic dysfunction. If the pharmacogenetic 
interaction is only applicable to patients with systolic dysfunction, then the inclusion of 
HF patients with preserved ejection fraction in UNITE-DNA may limit the ability to 
detect the association.  
RAAS variants and BB response. Although BB are deemed adrenergic 
antagonists, biologic plausibility supports a pharmacogenetic interaction between BB 
response and RAAS variants as well as the SNS variants. The rate-limiting step in the 
cascade of enzymatic events leading to the formation of angiotensin II is the release of 
renin. The release of renin is increased with increased SNS activity (Figure 2), and 
treatment of HF patients with BB results in marked suppression of renin levels (80). The 
inhibition of the RAAS by BB is one of the potential mechanisms of BB survival benefit. 
Because BB inhibit the rate limiting step of the RAAS cascade and the RAAS plays a 
major role in the pathophysiology of HF, functional RAAS variants were also tested for a 
pharmacogenetic interaction with BB response in addition to SNS variants. However the 
largely negative results for the RAAS variants do not support this hypothesis. It is 
possible that BB inhibition of the RAAS does not play a large enough role in the 
mechanism of BB survival benefit in HF patients for a pharmacogenetic interaction to be 
detected or meaningful. Except for the ACE indel, previous studies testing a 
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pharmacogenetic interaction between RAAS variants and BB response have not been 
published. Therefore, the negative results for the other four RAAS variants (i.e. AGT G-
6A, AGTR1 A1166C, CYP11B2 T-344C, and the BDKRB2 indel) in UNITE-DNA are 
novel and cannot be placed in the context of any available literature. Although Chapter II 
summarizes the functional effects of these RAAS variants and their association with HF 
patient physiologic and clinical outcomes, which led to the general hypothesis for a BB 
pharmacogenetic interaction. 
The role of ACE in the RAAS is to convert angiotensin I to angiotensin II, 
resulting in downstream effects including sodium and water retention and 
vasoconstriction. Since its discovery, the 287 base pair indel in intron 16 of ACE has 
been the most studied cardiovascular-relevant variant. The ACE indel accounts for half of 
the variance in serum ACE levels (2), with the deletion allele conferring significantly 
higher levels. Because the ACE deletion results in higher RAAS activity and BBs 
decrease RAAS activity, this led to the specific hypothesis that HF patients with the ACE 
deletion would have a greater response to BB. The literature testing this hypothesis is 
mixed, in that two studies support this hypothesis (13,81), while a single study (82) and 
the UNITE-DNA data presented herein do not.  
 In 2001, McNamara et al were the first to publish the pharmacogenetic interaction 
between BB and the ACE indel in a cohort of 328 HF patients followed for a median 21 
months (13). In the overall cohort, there was a trend for increased transplant-free survival 
in patients receiving BB (p = 0.065). However when ACE indel sub-groups were 
analyzed individually, only patients homozygous for the deletion had a significant 
improvement in transplant-free survival from beta-blockade (deletion homozygous: p = 
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.007; insertion homozygous: p = 0.74; heterozygous: p = 0.59). These results were 
validated in another study published by McNamara et al in 2004 (81), when the size of 
the same cohort increased from 328 to 479. de Groote et al also tested this 
pharmacogenetic interaction in 199 HF patients, but the study did not yield a significant 
result with respect to LVEF, peak VO2, or cardiac survival (82).  
 In UNITE-DNA, there was no association between the ACE indel and BB 
survival benefit. The negative results in UNITE-DNA are surprising because this research 
is very similar to the studies by McNamara et al. For example, the study designs by 
McNamara et al are also prospective, observational cohorts recruited from a HF specialty 
clinic, and the enrollment period was similar to UNITE-DNA (1996-2001 in McNamara 
et al vs. 2000-2002 in UNITE-DNA). The patients in UNITE-DNA and the McNamara et 
al studies had similar anti-RAAS treatment rates (~90%) and minor allele frequency of 
the ACE indel (~44% for the insertion allele).  The BB treatment rate was much lower in 
the McNamara et al studies (~37% in McNamara et al vs. 67% in UNITE-DNA), but the 
distribution of specific BB was similar and also BB doses. The association between BB 
and mortality reduction overall was also similar between UNITE-DNA and the 
McNamara et al studies (~30% reduction).   
However, there are several important differences between the UNITE-DNA study 
herein and the studies by McNamara et al that could potentially explain the discrepant 
results. The studies by McNamara et al were from a single center, the University of 
Pittsburgh, and therefore their results may only be applicable to that particular patient 
population. Indeed, the ACE indel pharmacogenetic interaction was not replicated in the 
multicenter UNITE-DNA (predominantly from the southeastern U.S.) or by de Groote et 
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al (82) (a single center study in France). Notably, the de Groote et al study was smaller 
than both the UNITE-DNA and McNamara et al cohorts, and de Groote et al did not 
report a power calculation. McNamara et al only enrolled patients with systolic 
dysfunction, but the type of cardiac dysfunction is not available for UNITE-DNA. 
Therefore, including patients without systolic dysfunction in UNITE-DNA may limit the 
ability to detect the pharmacogenetic interaction if the interaction is driven by patients 
with systolic dysfunction only. This is plausible since the large BB clinical trials did not 
demonstrate survival benefit in HF patients with preserved ejection fraction. The 
McNamara et al cohorts also had a higher percentage of men (75% vs. 63%), less AAs 
(9% vs. 37%), and lower baseline LVEF (24% vs. 32%). Interestingly, the analyses in the 
McNamara et al studies were not adjusted for clinical covariates (only a log-rank test was 
used). Baseline differences existed between the BB treatment groups (e.g. LVEF and the 
number of women) in the McNamara et al studies, and therefore these differences should 
be adjusted for in the survival analysis. Whether the ACE indel and BB pharmacogenetic 
interaction found by McNamara et al would remain significant despite covariate 
adjustments is unknown. Notably, the univariate UNITE-DNA analysis did not reveal a 
signal for this pharmacogenetic interaction. The UNITE-DNA data presented herein is 
more definitive than the McNamara et al studies because it is multicenter, and there is 
substantially more power due to longer follow-up and sample size. Therefore according 
to the UNITE-DNA and de Groote et al data, it is unlikely that the ACE indel and BB 
pharmacogenetic interaction would be applicable to other HF patient populations than 
those studied by McNamara et al. 
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Table 21. Independent association of 11 candidate genetic variants and 2 haplotypes with  
 
survival.  
 
Risk allele HR 95% CI lower 95% CI upper *p-value 
ADRB1 Ser49 0.79 0.62 0.99 0.0461 
ADRB1 Arg389 0.88 0.71 1.11 0.2769 
ADRB2 Arg16 1.00 0.79 1.27 0.9797 
ADRB2 Glu27 1.08 0.86 1.36 0.4976 
GRK5 Gln41 0.92 0.67 1.26 0.6070 
ADRA2C Del 1.24 0.98 1.58 0.0782 
ACE Del 0.98 0.77 1.24 0.8542 
AGT -6A 1.31 1.03 1.65 0.0252 
AGTR1 1166C 0.89 0.71 1.12 0.3237 
CYP11B2 -344C 0.84 0.67 1.05 0.1224 
BDKRB2 Ins 1.16 0.91 1.48 0.2356 
ADRB1 diplotype Ser49/Arg389 0.69 0.53 0.90 0.0065 
ADRB2 diplotype Arg16/Glu27 0.76 0.45 1.29 0.3085 
 
*Bonferroni-adjusted alpha = 0.0038 
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Table 22. Ten lowest p-values in the exploratory analyses for an association with survival 
and beta-blocker survival benefit prior to and after correction for 5% FDR modified for 
dependency. 
Survival BB survival benefit 
Test *Raw 
p 
FDR 
corrected p 
Test *Raw 
p 
FDR 
corrected p 
Variant: ADRB1 
Ser49Gly  
Model: Dominant 
Stratum: BB-
treated 
0.0004 0.4989 Variant: ACE indel  
Model: Recessive 
Stratum: Ischemic 
etiology 
0.0002 0.193 
Variant: ADRB1 
Ser49Gly  
Model: Additive 
Stratum: BB-
treated  
0.0009 0.4989 Variant: ADRB1 
Ser49Gly  
Model: Dominant 
Stratum: Non-
ischemic 
0.0028 1 
Variant: ADRB1 
Ser49-Arg389  
Model: 2 copies vs. 
<2 copies 
Stratum: BB-
treated 
0.0010 0.4989 Variant: ADRB1 
Ser49Gly  
Model: Additive 
Stratum: All 
patients 
0.0044 1 
Variant: ADRB1 
Ser49-Arg389  
Model: 2 vs. 1 vs. 
0  
Stratum: BB-
treated 
0.0014 0.5089 Variant: ADRB1 
Ser49Gly  
Model: Additive 
Stratum: Non-
ischemic 
0.0053 1 
Variant: AGT G-
6A 
Model: Additive 
Stratum: Ischemic 
etiology 
0.0017 0.5089 Variant: ACE indel  
Model: Additive 
Stratum: Ischemic 
etiology 
0.0066 1 
Variant: AGT G-
6A 
Model: Dominant 
Stratum: Ischemic 
etiology 
0.0021 0.5132 Variant: ADRB1 
Ser49-Arg389  
Model: 2 vs. 1 vs. 
0 copies 
Stratum: Ischemic 
0.0168 1 
Variant: GRK5 
Gln41Leu 
Model: Recessive 
Stratum: Not BB-
treated 
0.0024 0.5132 Variant: BDKRB2 
indel  
Model: Recessive 
Stratum: Non-
ischemic 
0.0195 1 
121 
 
Variant: GRK5 
Gln41Leu 
Model: Recessive 
Stratum: Non-AA 
0.0076 1 Variant: ADRB1 
Ser49Gly  
Model: Dominant 
Stratum: AA 
0.0223 1 
Variant: AGTR1 
A1166C 
Model: Recessive 
Stratum: Not BB-
treated 
0.0099 1 Variant: AGTR1 
A1166C  
Model: Additive 
Stratum: Non-AA 
0.0279 1 
Variant: CYP11B2 
T-344C 
Model: Dominant 
Stratum: BB-
treated 
0.0128 1 Variant: ADRB1 
Ser49-Arg389  
Model: 2 vs. 1 vs. 
0 copies 
Stratum: All 
patients 
0.0312 1 
*Adjusted for reduced model covariates but not for multiple comparisons
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Table 23. Adjusted interaction between 11 candidate genetic variants and 2 haplotypes 
and BB survival benefit.  
 
Risk allele *p-value 
ADRB1 Ser49 
0.0018 
ADRB1 Arg389 
0.8542 
ADRB2 Arg16 
0.5318 
ADRB2 Glu27 
0.1427 
GRK5 Gln41 
0.2754 
ADRA2C Del 
0.6272 
ACE Del 
0.6959 
AGT -6A 
0.6823 
AGTR1 1166C 
0.6236 
CYP11B2 -344C 
0.0962 
BDKRB2 Ins 
0.9871 
ADRB1 diplotype Ser49/Arg389 
0.0309 
ADRB2 diplotype Arg16/Glu27 
0.8525 
 
*Bonferroni-adjusted alpha = 0.0077 
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Table 24. Baseline characteristics by Ser49Gly genotype 
 
 Pooled 
n = 722 
Ser49Ser 
n = 491 
Ser49Gly + Gly49Gly  
n = 228 
p-value  
 
Male gender n(%) 455 (63.1%) 312 (63.5%) 140 (61.7%) 0.6295 
Age mean(sd) 57.0 (13.2) 56.8 (13.5) 57.5 (12.6) 0.5073 
Race (AA) 270 (38%) 159 (33%) 111 (49%) <.0001 
NYHA functional class mean(sd) 2.50 (0.64) 2.50 (0.65) 2.51 (0.60) 0.8587 
Ischemic etiology n(%) 314 (44.5%) 212 (44.1%) 101 (45.5%) 0.7246 
Hx of hypertension n(%) 488 (68.0%) 317 (64.8%) 169 (74.8%) 0.0080 
Hx of diabetes n(%) 233 (32.5%) 162 (33.3%) 70 (30.8%) 0.5189 
SBP mean(sd) 119 (22) 119 (22) 121 (23) 0.3321 
DBP mean(sd) 70 (13) 70 (12) 71 (14) 0.4802 
HR mean(sd) 75 (14) 75 (14) 76 (14) 0.3386 
LVEF mean(sd) 32 (15) 32 (15) 32 (16) 0.7837 
Serum creatinine mean(sd) 1.47 (1.37) 1.43 (1.35) 1.58 (1.44) 0.1856 
Estimated GFR (ml/min) 66.3 (26.5) 67.1 (26.7) 64.7 (26.3) 0.2739 
BB n(%) 484 (67.4%) 331 (67.8%) 152 (67.0%) 0.8176 
ACE inhibitor n(%) 577 (80.8%) 401 (82.5%) 174 (77.3%) 0.1026 
ACE inhibitor and ARB n(%) 13 (1.9%) 9 (1.9%) 4 (1.8%) 1.0000 
ACE inhibitor or ARB n(%) 639 (89.5%) 440 (90.5%) 196 (87.1%) 0.1669 
Loop diuretic n (%) 603 (84.0%) 408 (83.6%) 193 (84.6%) 0.6303 
Any diuretic n (%) 635 (88.4%) 434 (88.9%) 199 (87.7%) 0.6200 
Digoxin n(%) 516 (72.0%) 353 (72.5%) 161 (70.9%) 0.6656 
Spironolactone n (%) 172 (24.1%) 118 (24.4%) 54 (23.8%) 0.8636 
Days of follow-up mean(sd) 2410 (1288) 2453 (1263) 2330 (1332) 0.2356 
Number of deaths (%) 336 (46.5%) 223 (45.4%) 111 (49.7%) 0.4138 
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Table 25. Propensity-matched and propensity-adjusted Ser49Gly-stratified BB response.  
 
Propensity-matched (n = 406) 
Genotype HR 95% CI lower 95% CI upper p-value 
Ser49-homozygotes (n = 279) 0.59 0.42 0.83 0.0025 
Gly49-carriers (n = 125) 1.45 0.85 2.48 0.1767 
Propensity-adjusted (n = 719) 
Genotype HR 95% CI lower 95% CI upper p-value 
Ser49-homozygotes (n = 491) 0.58 0.43 0.78 0.0003 
Gly49-carriers (n = 228) 1.20 0.75 1.93 0.4472 
  
125 
 
Table 26. Stratified and contrast-derived HR for BB in Ser49Gly genotypes adjusted with 
reduced clinical model. 
BB as dichotomous variable (on BB vs. off BB) 
Stratified 
Genotype HR 95% CI lower 95% CI upper p-value 
Ser49-homozygotes 0.54 0.41 0.72 <.0001 
Gly49-carriers 1.38 0.89 2.12 0.1462 
Contrast 
Genotype HR 95% CI lower 95% CI upper p-value 
Ser49-homozygotes 0.57 0.43 0.75 <.0001 
Gly49-carriers 1.26 0.83 1.91 0.2859 
BB dose as continuous variable (25mg metoprolol equivalent increase) 
Stratified 
Genotype HR 95% CI lower 95% CI upper p-value 
Ser49-homozygotes 0.92 0.87 0.97 0.0012 
Gly49-carriers 1.01 0.96 1.07 0.6990 
Contrast 
Genotype HR 95% CI lower 95% CI upper p-value 
Ser49-homozygotes 0.92 0.88 0.97 0.0010 
Gly49-carriers 1.01 0.96 1.06 0.6798 
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Figure legends 
Figure 7. Survival curves for UNITE-DNA derived from the Cox proportional hazards 
model adjusted for age, diabetes, systolic blood pressure, NYHA class, LVEF, and GFR 
are shown and were stratified by Ser49Gly genotype (Ser49-homozygous and Gly49-
carriers) and BB treatment (treated or not treated with BB at baseline). 
 
Figure 8. The linear association between BB dose and reduction in mortality derived 
from the Cox proportional hazards model adjusted for age, diabetes, SBP, NYHA class, 
LVEF, and GFR is shown by 25, 50, 100, 150, and 200mg of metoprolol dose equivalents 
and stratified by Ser49Gly genotype.   
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Figure 7. Adjusted survival curves stratified by Ser49Gly genotype and BB treatment. 
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Figure 8. Adjusted BB dose-associated survival benefit by Ser49Gly genotype. 
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CHAPTER VI: 
GENETIC RISK SCORES ASSOCIATED WITH  
HF PATIENT SURVIVAL AND BETA-BLOCKER RESPONSE 
 
Summary 
 The previous chapter covered the association of the individual genetic variants 
with HF survival and BB survival benefit. The goal of this chapter is to assess the 
additive association of genetic variant combinations, via genetic risk scores (GRS), with 
HF patient survival and BB survival benefit. Neither the simple nor internally-weighted 
genetic risk scores were associated with HF patient survival or BB survival benefit. The 
genetic risk scores also did not add to the predictability of clinical risk factors for 
mortality or reclassify HF patients to new mortality risk categories.  
 
Introduction 
 Common, complex diseases such as HF are influenced by multiple genetic and 
environmental factors. The importance of genetic factors in HF is exemplified by the 
heritability of HF risk factors (e.g. hypertension  [1], increased left ventricular mass [2], 
and coronary heart disease[3]), the increased risk of HF in children of parents with HF 
(4), and the individual associations of genetic variants with HF patient survival (5-9) and 
drug response (Appendices I & II) (10,11). However, as the number and prevalence of 
genetic risk factors increases, the contribution of each individual genetic variant 
decreases. For example, in another multifactorial disease such as diabetes, eight 
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statistically significant genetic variants in a GWAS only explained 0.04% to 0.5% of the 
total variance in diabetes risk (12). Moreover, common genetic variants (i.e. minor allele 
frequency greater than 5%) have modest associations with clinical outcomes in common, 
complex diseases; the odds ratios typically range from 1 to 2 (13).  An example specific 
to HF would be the 287-bp intron 16 deletion in ACE; in a study of 193 HF patients, 
homozygotes for the deletion had an adjusted odds ratio of 1.69 for death compared to all 
other patients (5). This example of the modest risk associated with individual common 
genetic variants limits their clinical application. However, common genetic variants can 
be aggregated into a genetic risk score (GRS), with the expectation that a high GRS 
would be sufficient to influence clinical decision-making.  
 GRS models are evolving, but currently there are four general GRS models in the 
literature (14): simple (15,16), internal weighted (17), external weighted (18), and 
polygenic (19).  The simple GRS model is the sum of all risk alleles (0, 1, or 2) for all 
variants, and only involves two parameters in the model:  
 
The simple GRS has the advantage of easier application in clinical practice because it 
does not involve complicated calculations. A disadvantage of the simple GRS is that it 
gives equal weight to each variant, which is unlikely to be biologically plausible and may 
not accurately capture the true genetic risk contribution from each variant. This can be 
overcome by weighting the variants, which is generally calculated by multiplying the 
number of risk alleles for each variant by the weight for that variant, and then taking the 
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sum across all variants. The weight for each variant can be derived from internal or 
external data. The internal weighted GRS uses the beta coefficients directly from the 
original dataset model: 
 
A disadvantage of this method is the number of parameters in the model is equal to the 
number of variants +1. The major disadvantage of using an internal weighted GRS is the 
bias inherent in using the same dataset to both create and test a GRS model. This bias can 
be overcome by using an external weighted GRS: 
 
The weight for each variant is usually the log odds ratio calculated from an independent 
GWAS or meta-analysis of the SNP. This model, like the simple GRS, only has two 
parameters. The disadvantage of the external weighted GRS is that GWAS or meta-
analysis data is not always available for the genetic variants, and the patient population 
from which the weight is derived may differ from the patient population in which it is 
tested. A disadvantage that is common to all three GRS methods discussed thus far 
(simple, internal weighted, and external weighted) is that they assume an additive 
association, in which heterozygotes have intermediate risk between low-risk 
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homozygotes and high-risk homozygotes. This disadvantage can be overcome using a 
polygenic GRS model:  
 
Briefly, two dummy variables are considered for each variant, so ultimately the three 
possible genotypes are coded as a three-level class variable (14). The polygenic GRS 
does not assume an additive risk model, and therefore it is more flexible if the underlying 
genetic model is unknown. The major disadvantage of the polygenic GRS is that the 
number of parameters is dramatically increased in the model (2 x number of variants + 1), 
which can lead to over-fitting and loss of power. Currently, the best GRS model is 
unknown, but the appropriate GRS model selection may depend on a number of factors: 
the number of variants in the panel, sample size, number of covariates, underlying 
inheritance models, variant effect sizes, etc (14). 
  These GRS models have been applied in a variety of common, complex diseases 
such as prostate cancer (20), coronary heart disease (21,22), type 2 diabetes (23), and 
primary cardiovascular events (15). These are successful examples in which the patients 
with a high GRS had significantly higher risk for clinical outcome compared to patients 
with a low GRS, and the association was stronger than with the individual variants alone. 
Notably, the study by Kathiresan et al (15) used genetic variants associated with an 
intermediate phenotype (i.e. LDL), which when aggregated were significantly associated 
with a clinical phenotype (i.e. primary cardiovascular events). This logic may also 
translate to HF, in which the aggregate of multiple genetic variants affecting intermediate 
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phenotype (i.e. SNS and RAAS activity), could be associated with clinical phenotype (i.e. 
mortality) (24). Mechanistically this is plausible, as data from separate HF studies 
demonstrate that genetic variants individually can affect SNS and RAAS activity in vitro 
and are associated with clinical outcome. For example, an Arg389Gly substitution in the 
beta-1 adrenergic receptor (ADRB1) results in decreased coupling to the intracellular 
stimulatory protein Gs (25). This Arg389Gly ADRB1 variant was associated with survival 
and beta-blocker response in HF patients (9). In another study, a Gln41Leu substitution in 
the G-protein coupled receptor kinase 5 (GRK5), which enhances beta-adrenergic 
receptor intracellular uncoupling, was also associated with HF patient survival and beta-
blocker response (8). Because both of these variants affect beta-adrenergic intracellular 
coupling, which is necessary for receptor function, they could have an additive 
association with clinical outcome.  
  One may argue how a GRS could be useful in HF when the intermediate 
phenotype, SNS and RAAS activity, can be measured directly such as with plasma 
norepinephrine and angiotensin II levels. However there are several reasons for 
measuring a GRS instead of, or in addition to, plasma norepinephrine and angiotensin II 
levels. In Katherisan et al (15), a GRS composed of SNPs associated with LDL was 
associated with primary cardiovascular events independent of actual LDL levels. A 
possible explanation is that genotype represents life-long exposure to LDL, or in the case 
of HF it would be life-long exposure to SNS and RAAS activity. Genotype also 
represents activity at the intracellular and receptor levels, which are not represented by 
plasma levels. For example, although a HF patient’s plasma norepinephrine levels could 
be elevated, it may not manifest adverse effects if the patient also possesses genetic 
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polymorphisms that decrease intracellular coupling to stimulatory G proteins (e.g. 
ADRB1 Arg389Gly and GRK5 Gln41Leu described above). In addition, plasma levels are 
dynamic, whereas genotype is stable from birth. Therefore the GRS can be measured 
early in life at stages where plasma norepinephrine and angiotensin II are normal. The 
GRS also has the advantage of only requiring a single measurement, and plasma levels of 
SNS and RAAS activity may require serial measurements, for example, before and after 
new therapies. Genotyping assays are easier and more accurate than bioanalytical assays 
because there are only a few possible discrete results, and genotyping also has the 
advantage of multiplexing. Most importantly, plasma levels are not an accurate reflection 
of SNS or RAAS activity because plasma levels are determined by both the rate of 
release and rate of clearance. The reduced blood flow to the kidneys that occurs in HF 
may falsely elevate plasma levels (26).    
 In addition to ADRB1 Arg389Gly and GRK5 Gln41Leu described above, several 
other common SNS and RAAS variants in the literature have functional effects and are 
associated with HF physiologic or clinical outcomes (see Chapter II: Identification of 
Candidate Genetic Variants). Because these variants are common, a given HF patient 
would be expected to possess multiple functional SNS and RAAS genetic variants. 
However, to date, no genetic association study in HF patients has integrated multiple 
genetic variants that affect SNS and RAAS activity into a clinical outcomes model. A HF 
GRS could have profound clinical implications. For example, a HF GRS could be used to 
identify patients who have increased genetic risk of mortality independent of clinical risk 
factors. It is also possible that HF patients with a high GRS may need additional 
pharmacotherapy compared to patients with low GRS. 
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 Because of the potential advantages and clinical implications of the GRS in HF, 
the objective of this chapter was to test the independent association, additive 
predictability, and discriminative capability of a simple GRS for HF patient survival and 
BB response. The simple GRS model was chosen because this is the first application of 
the GRS method to HF; the easy calculation would facilitate clinical application; and the 
small number of parameters required in the final model. The external weighted GRS 
model could not be performed because there is no GWAS or meta-analysis data available 
for genetic variants in HF. The internal weighted GRS model was not chosen because of 
the increased number of parameters in the model and the bias inherent in creating and 
testing the model in the same patient population. The polygenic GRS model was not 
chosen because of the dramatically increased number of parameters in the model, and 
currently there is not a replication patient population to rule out over-fitting of the 
polygenic GRS model. 
   
Methods 
 Genetic risk score calculation. The panel of 11 variants identified in Chapter II: 
Identification of Candidate Genetic Variants was used. Based on the molecular, 
physiologic, and clinical phenotypes in the previous literature, the assigned risk alleles 
have been summarized in Table 27. Only patients with complete genotypes for all 11 
variants had a GRS calculated and were included in the analysis (n = 701). The GRS for 
each UNITE-DNA patient was calculated by summing the number of risk alleles (0, 1, or 
2) for each variant, with the exception of the ADRA2C indel. The ADRA2C indel 
genotyping assay was unable to discriminate deletion homozygotes from heterozygotes 
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(see Chapter III: Characterization of Candidate Genetic Variants), and therefore insertion 
homozygotes had 0 added to their GRS and deletion-carriers had 1 added to their GRS. 
Therefore the range of possible GRS was 0 to 21. 
 Statistical analysis. Descriptive statistics for the GRS included mean, standard 
deviation, median, minimum, maximum, and quintiles. Baseline characteristics and 
cumulative incidence of death among GRS quintiles were tested using the Cochran-
Armitage test for trend. The distributions of GRS in UNITE-DNA patients that died and 
did not die during the 10-year follow-up were plotted and mean GRS compared using 
Student’s t-test. The GRS was analyzed as a continuous variable in a Cox proportional 
hazards model unadjusted and adjusted with the reduced model of clinical covariates (see 
Chapter IV: Characterization of Patient Population) for association with time to all-cause 
mortality. Cumulative incidence curves and the hazard ratio with 95% confidence 
intervals for GRS quintiles (with the lowest GRS quintile as the reference) were also 
derived from the Cox model. Receiver-operating-characteristic (ROC) curves were 
plotted for the clinical covariates with and without the GRS, with incidence of all-cause 
mortality at 10 year follow-up as the outcome. The C statistic, a measure of the area 
under the ROC curve, was calculated with and without the GRS, and was compared using 
a nonparametric approach (27). Net reclassification index and integrated discrimination 
improvement were also calculated with incidence of all-cause mortality at 10 year follow-
up as the outcome (28).   Secondary subgroup analyses included stratification by age 
(using median), race (AA and non-AA), etiology (ischemic and non-ischemic), and beta-
blocker treatment (on BB at baseline and not).  
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 To assess the association between GRS and BB response, multiplicative 
interaction terms (GRS*BB and GRS*BB dose) were incorporated into the Cox 
proportional hazards model unadjusted and adjusted with the reduced model of clinical 
covariates (see Chapter IV: Characterization of Patient Population). BB response in the 
highest GRS quintile was compared to the lowest GRS quintile. The alpha level of 
statistical significance for all tests was defined as 0.05, except where multiple 
comparisons were made and alpha was adjusted using a Bonferroni correction. All 
statistical analyses were performed using SAS v.9.2 (Cary, NC, USA). 
   
 
Results 
 The number of patients with complete genotypes for all 11 variants was 701 out 
of 722.  The mean ± sd, median, minimum, and maximum GRS were 11.2 ± 1.72, 11, 6, 
and 17, respectively, which were similar among all sub-groups (age [above and below 
median = 58 years], race [self-reported AA and non-AA], etiology [ischemic and non-
ischemic HF], and beta-blocker treatment) (Table 28). Clinical characteristics, drug 
utilization, and vital status were similar among GRS quintiles (Table 29), except the 
percentage of AAs decreased as the GRS quintile increased.  The distribution of GRS in 
alive (mean ± sd = 11.2 ± 1.70) and deceased patients (mean ± sd = 11.1 ± 1.75) were 
similar in the entire cohort (p = 0.5393; Figure 9) and all sub-groups (data not shown).  
The GRS was not associated with time to all-cause mortality in univariate models (data 
not shown) or multivariable models as a continuous variable (Figure 10) or in quintiles 
(Table 30), and this was similar among all clinical sub-groups.  The area under the ROC 
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curves were similar for the clinical risk factors alone (area = 0.7489) versus the clinical 
risk factors plus GRS (area = 0.7487; p = 0.6550; Figure 11). The net reclassification 
index and integrated discrimination improvement were both equal to zero because none 
of the patients were reclassified by the addition of GRS to the clinical model.   
An exploratory post-hoc analysis of an internal-weighted GRS using all 11 
variants and a J48 decision tree-pruned (29) variant panel was performed. The HR for the 
internal-weighted GRS’s was tested for external generalizability using 10-fold cross-
validation and the 95% CI estimated using a bootstrap technique with 10,000 samples 
(30,31). The 10-fold cross-validated HR and bootstrapped 95% CI for an internal-
weighted GRS using all 11 variants was HR = 0.74 and 95% CI = 0.28-1.35. The J48 
decision tree did not prune any of the 11 variants, and hence a reduced internal-weighted 
GRS could not be carried out. 
 The BB*GRS adjusted interaction using GRS as a continuous variable was not 
statistically significant in all of the UNITE-DNA patients or any of the sub-groups (Table 
31). However, when comparing BB response in the highest GRS quintile to the lowest, 
patients in the highest GRS quintile seemed to have a greater response to BB (n = 62; 
adjusted HR = 0.29; 95% CI = 0.12-0.71; p = 0.0070) compared to the patients in the 
lowest GRS quintile (n = 242; adjusted HR = 0.85; 95% CI = 0.56-1.30; p = 0.4618). 
There was not a statistically significant interaction between BB dose and GRS in all 
patients, but there was a statistically significant interaction between BB dose and GRS in 
the non-ischemic sub-group of patients (p = 0.0011) (Table 31). In the non-ischemic 
etiology patients, BB dose response improved as the GRS increased. In the highest GRS 
quintile non-ischemic patients (n = 30), every 25mg metoprolol equivalent increase in 
147 
 
dose yielded an adjusted HR = 0.64, 95% CI = 0.38-1.07, and p = 0.0885. However in the 
lowest GRS quintile non-ischemic patients (n = 130), every 25mg metoprolol equivalent 
increase in dose yielded an adjusted HR = 1.13, 95% CI = 1.03-1.24, and p = 0.0098.  
 
Discussion 
 This is the first report to incorporate multiple genetic variants known to affect the 
SNS or RAAS into a clinical outcomes model for HF. The simple GRS was not 
independently associated with time-to-mortality. The simple GRS did not add to the 
predictability of clinical risk factors for mortality, nor did it reclassify HF patients into 
new mortality risk categories. Even when the internal-weighted GRS method was 
explored it was non-significant, and 10-fold cross-validation revealed that the internal-
weighted GRS would not be generalizable to other patient populations. There are several 
possible explanations for these negative GRS results. Only a few variants within the 
complex physiologic systems such as the SNS and RAAS were included in the panel. 
There are many variants in the genes included in this panel that were not genotyped, and 
there are entire genes that were not represented in the panel (e.g. ADRB3, SLC6A2, REN, 
NOS). Many more variants may be required to adequately capture the genetic effects on 
the activity of these systems. Simulated studies of GRS demonstrate that the addition of 
much more common variants with small effect sizes or a few rare variants with large 
effect sizes may improve discrimination (32,33). Indeed, as many as 500 genetic loci may 
underlie the risk for another common complex disease, type 2 diabetes mellitus (34). It is 
also possible that system-level counter-regulatory mechanisms may neutralize adverse 
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genetic effects in the SNS and RAAS, such as arginine vasopressin, endothelin, 
natriuretic peptides, which were not included in this study.  
 A major limitation of this study is the lack of the direct measurement of the 
intermediate phenotype, e.g. plasma norepinephrine and angiotensin II levels. Therefore 
the individual variant associations with SNS and RAAS activity were not validated. Also, 
the individual associations between the variants and survival (see Chapter V: Assessment 
of Candidate Genetic Variants and Survival) were not validated. However the rationale 
for the GRS is that common variants will only have a modest (and perhaps undetectable) 
association with outcomes in common diseases, but in aggregate the association may be 
detectable. Indeed this is the case for examples in the literature: studies did not validate 
the individual association of the variants in the GRS, but when combined there was a 
significant association (24,35,36). Another possible limitation is that the risk allele 
designation was incorrect. The risk allele designations were based solely on previous 
literature and not associations determined in UNITE-DNA to prevent bias. However it is 
possible that the previous literature was false positives or exaggerated due to publication 
bias, but even the internal-weighted GRS was negative. Using the simple GRS model 
also has limitations. Specifically, each variant was given equal weight, which is not 
biologically plausible. However this limitation would be more important when using 
variants with highly variable effect sizes. For example, we only tested common variants, 
in which the expected associations in common diseases are usually odds ratios of 1 to 2 
(13). This is exemplified in other common diseases where weighting the score did not 
substantially improve predictive value (36). The simple GRS model also assumes 
additive risk per allele. Notably, the additive genetic model performs well even when the 
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true genetic model is unknown or wrongly specified (37). There are also the limitations 
inherent to the registry study design (see Chapter IV: Characterization of Patient 
Population), and we were not able to discriminate ADRA2C deletion homozygotes from 
heterozygotes. Hence, only 1 was added for deletion-carriers. However due to the largely 
negative results, this is unlikely to have a large effect. 
 Given the sacrifice of power, the lack of association within all of the sub-groups 
was somewhat surprising. The sub-groups were chosen based on an increased theoretical 
likelihood for an association and on previous literature. Because the GRS represents 
possible long-term exposure to high SNS and RAAS activity, adverse effects of a high 
GRS, if present, would be expected to manifest in younger patients (35). Racial sub-
groups were also considered because the frequency of the risk alleles varies by race. 
Because patients with an ischemic HF etiology may have irreversible damage to their 
myocardium, it is possible that the GRS would more likely have an association in patients 
with a non-ischemic etiology. Beta-blocker treatment sub-groups were analyzed because 
pharmacogenetic studies demonstrate that, in general, individual SNS and RAAS variants 
conferring higher activity are associated with increased beta-blocker response (Appendix 
I) (10).            
 Interestingly, BB response differed between the highest and lowest GRS, but the 
sample sizes are very small and thus must be considered exploratory. Although it is 
biologically plausible because the patients with the highest GRS would be expected to 
have the highest SNS and RAAS activation, and hence would derive the most benefit 
from SNS and RAAS inhibition with BB. This was statistically significant when looking 
at BB dose in non-ischemic patients. Given the very small sample size again, this is 
150 
 
biologically plausible as patients with ischemic etiology may have irreversible damage to 
the myocardium, and the beneficial ventricular remodeling response may not be as 
profound in patients with ischemic etiology compared to patients with non-ischemic. Of 
course this would need to be replicated in a prospective cohort. 
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Table 27. Designation of risk alleles for 11 variant panel used in GRS calculation 
Gene Variant Literature-defined  
risk allele 
References 
ADRB1 Ser49Gly 
 
Ser 
 
 
(6,38-40) 
 Arg389Gly Arg (9,25) 
ADRB2 Gly16Arg Arg (41,42) 
Gln27Glu Glu (41,42) 
ACE Ins/Del Del (43,44) 
ADRA2C Ins/Del Del (45,46) 
GRK5 Gln41Leu Gln (8) 
AGT G-6A A (47,48) 
AGTR1 A1166C C (49-51) 
CYP11B2 T-344C C (52,53) 
BDKRB2 Ins/Del Ins (54-56) 
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Table 28. Mean ± sd, median, minimum, and maximum GRS in all patients and sub-
groups 
Group Mean ± sd Median Minimum Maximum 
All patients 11.2 ± 1.7  11 6 17 
Age < 58 11.3 ± 1.6 11 7 17 
Age > 58 11.1 ± 1.8 11 6 17 
Non-AA 11.4 ± 1.8 11 6 17 
AA 10.8 ± 1.6 11 6 16 
Ischemic etiology 11.3 ± 1.8 11 6 17 
Non-ischemic etiology 11.1 ± 1.6 11 6 16 
BB treated 11.2 ± 1.7 11 7 16 
No BB 11.2 ± 1.7 11 6 15 
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Table 29. Baseline clinical characteristics, drug utilization, and vital status by GRS 
quintiles 
Variable 1st quintile 
GRS = 0-10 
(n=242;35%) 
2nd quintile 
GRS = 11 
(n=157;22%) 
3rd quintile 
GRS = 12 
(n=156;22%) 
4th quintile 
GRS = 13 
(n=84;12%) 
5th quintile 
GRS = 14-17 
(n=62;9%)  
p-value 
Male  168 (64%) 97 (62%) 96 (62%) 58 (69%) 36 (58%) 0.8188 
Age  58 (13) 56 (13) 55 (14) 60 (12) 55 (13) 0.2225 
African-Am 111 (42%) 66 (42%) 57 (37%) 27 (32%) 9 (15%) 0.0001 
NYHA class 2.5 (0.6) 2.5 (0.7) 2.5 (0.6) 2.5 (0.6) 2.6 (0.7) 0.3397 
Ischemic  115 (45%) 66 (43%) 59 (39%) 42 (51%) 32 (52%) 0.4137 
Hx of HTN  180 (69%) 110 (71%) 104 (68%) 56 (67%) 38 (61%) 0.2925 
Hx of DM 87 (34%) 41 (26%) 49 (31%) 34 (40%) 22 (35%) 0.3883 
SBP (mmHg) 120 (22) 119 (23) 119 (21) 119 (19) 117 (24) 0.4019 
DBP (mmHg) 70 (13) 71 (14) 71 (11) 69 (13) 68 (11) 0.1285 
Heart rate (bpm) 76 (15)  74 (12) 77 (14) 74 (14) 72 (14) 0.0922 
LVEF (%) 33 (14) 31 (16) 32 (17) 32 (16) 31 (15) 0.6481 
GFR (ml/min) 65 (26) 68 (27) 68 (26) 65 (31) 65 (22) 0.9463 
ACE inhibitor 210 (81%) 130 (83%) 122 (79%) 63 (77%) 52 (85%) 0.8623 
ACE inhibitor or 
ARB 
233 (90%) 140 (89%) 138 (89%) 72 (88%) 56 (92%) 0.9645 
BB 177 (68%) 109 (69%) 102 (66%) 54 (64%) 42 (69%) 0.7690 
BB dose (mg 
metop equiv)  
105 (82) 119 (84) 106 (89) 115 (77) 105 (103) 0.7869 
Loop diuretic  221 (84%) 133 (85%) 127 (82%) 71 (85%) 51 (85%) 0.9127 
Digoxin  183 (70%) 114 (73%) 111 (73%) 62 (74%) 46 (75%) 0.3123 
Spironolactone 61 (24%) 41 (26%) 35 (23%) 20 (24%) 15 (25%) 0.9881 
Length of 
follow-up (days) 
2393 (1307) 2345 (1339) 2477 (1262) 2486 (1299) 2471 (1090) 0.3257 
Deaths n(%) 125 (48%) 70 (45%) 73 (47%) 42 (50%) 26 (42%) 0.7772 
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Table 30. Adjusted survival by GRS quintiles. 
GRS quintile HR 95% CI p-value 
1 (GRS = 0-10) reference 
2 (GRS = 11) 1.20 0.87-1.65 0.2660 
3 (GRS = 12) 1.20 0.87-1.64 0.2658 
4 (GRS = 13) 1.01 0.69-1.47 0.9697 
5 (GRS = 14-17) 0.82 0.51-1.32 0.4257 
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Table 31. Adjusted interaction between the GRS and BB in all patients and sub-groups. 
BB yes or no 
Group *p-value 
All patients 0.2433 
Age < 58 0.0239 
Age > 58 0.7198 
Non-AAs 0.7580 
African Americans 0.0831 
Ischemic etiology 0.7687 
Non-ischemic etiology 0.0249 
BB dose 
Group *p-value 
All patients 0.1334 
Age < 58 0.2808 
Age > 58 0.5321 
Non-AAs 0.9833 
African Americans 0.0170 
Ischemic etiology 0.3083 
Non-ischemic etiology 0.0011 
 
*Bonferroni-adjusted alpha = 0.1/7 = 0.0143 
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Figure legends 
Figure 9. The normal approximation for the distribution of GRS in UNITE-DNA patients 
that were still alive at 10-year follow-up and those that have died during follow-up is 
shown. 
 
Figure 10. The HR for GRS in the Cox proportional hazards model adjusted for age, 
diabetes, systolic blood pressure, NYHA class, LVEF, and GFR where necessary and 
stratified by age (at median), race (AA and Non-AA), etiology (ischemic and non-
ischemic), and BB treatment (treated or not treated with BB at baseline). 
 
Figure 11. Receiver-operation characteristic (ROC) curves for clinical risk factors alone 
and clinical risk factors plus the GRS are shown. The area under the ROC curve for the 
clinical risk factors alone was 0.7489 and with the GRS was 0.7487 (p = 0.6550). 
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Figure 9. Distribution of GRS in alive and deceased patients. 
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Figure 10. Adjusted HR for GRS in all UNITE-DNA patients and sub-groups.  
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Figure 11. ROC curves for clinical risk factors ± GRS. 
 
 
 
 
  
p = 0.6550 
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CHAPTER VII:  
GENE-GENE INTERACTIONS ASSOCIATED WITH  
HF PATIENT SURVIVAL AND BETA-BLOCKER RESPONSE 
 
Summary 
 The previous chapter covered the additive association of the candidate genetic 
variants with survival and BB survival benefit, and this chapter covers the association of 
gene-gene interactions (epistasis) with HF patient survival and BB survival benefit. The 
classification and regression tree (CART) algorithm, a recursive partitioning data mining 
method, was used with 15 clinical and 13 genetic input variables to detect gene-gene 
interactions associated with the binary endpoint of 10-year all-cause mortality in UNITE-
DNA. There were no epistatic interactions associated with HF patient survival or BB 
survival benefit in UNITE-DNA overall or in the AA patients, but in the non-AA patients 
there was a pharmacogenetic gene-gene interaction between ADRB1 Ser49-Arg389 
diplotype and AGTR1 A1166C. In the non-AA patients aged less than 60 and treated with 
BBs, the mortality rate was approximately 3-fold higher (24% vs. 73%) if patients had 
the ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype and carried AGTR1 1166C. Although 
the CART algorithm was 10-fold cross-validated, these results need to be validated in an 
independent cohort. 
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Introduction 
 Common genetic variants, individually, explain very little variability in polygenic 
traits (such as survival and BB response) in complex diseases (such as HF), leading to the 
failure of many genetic association studies (1-6). One of the potential explanations for 
this phenomenon is epistasis, or gene-gene interactions. The association of an individual 
genetic variant with a complex phenotype will be missed if it is tested individually but 
involved in epistasis. Epistasis has long been recognized to be fundamentally important 
in complex, non-Mendelian traits such as HF (7), but detecting epistasis is statistically 
challenging.  Traditional, parametric statistical methods can be used to detect epistasis by 
incorporating multiplicative interaction terms (e.g. SNP1*SNP2) into the model (e.g. 
multiple linear, logistic, or Cox proportional hazards regression). However there are 
many limitations in using traditional statistical methods for detecting epistasis; the 
following parametric regression assumptions must be met: data are normally distributed, 
equal variances, independent observations, independent variables are not correlated, 
linear association between variables and outcome, and the sample is random. Traditional 
regression models also cannot handle the highly dimensional nature of genetic data 
because the power of the model is dramatically decreased with an increasing number of 
parameters. Traditional regression models are typically only used to test pairwise 
interactions because testing higher order interactions (i.e. 3-way, 4-way, etc.) 
dramatically increases the number of models, and hence, multiple testing becomes a 
major issue. Testing more than one genetic inheritance model (e.g. dominant, recessive, 
or additive) also contributes to the multiple comparisons issue. Statistically significant 
marginal effects are necessary to detect interactions; therefore purely epistatic 
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interactions or those variants with slight marginal effects will be missed when using 
traditional statistics. Observations with missing values are typically excluded or the 
missing values need to be imputed. Although traditional statistical methods are widely 
accepted, the clinical application of a gene-gene interaction traditional statistical model to 
an individual patient is difficult and requires calculations. 
Because of the many limitations of traditional statistical methods for detecting 
epistasis, novel data-mining techniques have been developed (8) and are preferred (9).  
Data mining is a burgeoning new technology which takes advantage of recent 
technological advances in computational power, using computer algorithms that 
automatically sift through databases seeking regularities or patterns. Data mining and 
traditional statistical analysis are not mutually exclusive, but rather they are closely 
related. Data mining utilizes traditional statistics, for example, in algorithm definitions or 
correction for over-fitting. The major difference between data mining and traditional 
statistical analysis is that statistics are typically used to test formal hypotheses, but data 
mining recognizes patterns in data that leads to formal hypotheses. Data mining has 
several advantages over traditional statistical methods for detecting epistasis; data mining 
is non-parametric and essentially hypothesis, assumption, and model free. Data mining 
also inherently handles observations with missing values. There are no multiple 
comparisons issues because data mining methods inherently test for higher-order 
interactions and all genetic inheritance models. Data mining methods also have output 
models that are easily interpreted and clinically applicable without calculation. 
Data mining methods for epistasis can be defined into three categories: recursive 
partitioning, combinatorial, or neural network (9). The recursive partitioning methods, or 
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tree-based methods, split the data using logical if-then conditions to best classify the 
observations according to a binary outcome. The recursive partitioning methods have 
several advantages: 1) handle a large number of input variables, 2) fast computation times 
(even for very large datasets), 3) suited to deal with different types of genetic 
heterogeneity, 4) the results are presented in an easily interpretable final model, and 5) 
they can detect interactions without strong marginal effects. The major limitation of the 
recursive partitioning methods is dependence on slight marginal effects because the splits 
are based on a single variable. The combinatorial approaches are not dependent on 
marginal effects, and therefore they are ideal for detecting purely epistatic interactions 
(9). Combinatorial methods exhaustively search over all possible variable combinations 
to find the combinations that best predict the outcome (9). Due to this exhaustive search, 
the major disadvantage of the combinatorial approaches is extremely long computational 
time. Long computational time is also a major disadvantage of neural networks. Neural 
networks “learn” to make predictions for new datasets from a training dataset based on 
the hypothesized processes of the brain (9). Neural networks consist of inter-connected 
nodes arranged in layers through which the input signal is processed. The major 
disadvantage of the combinatorial and neural network approaches is output that is 
complex and thus difficult to interpret and apply clinically.   
 For this dissertation research, a data mining method was chosen to test the general 
hypothesis that gene-gene interactions between and within functional genetic variants in 
the SNS and RAAS will be associated with HF patient survival and BB response. 
Because data mining was chosen, a specific hypothesis on which genetic variants and 
how many genetic variants would interact and the nature of the interaction is not 
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necessary. The disadvantage when using a data mining method to test a general 
hypothesis is that any positive gene-gene interactions would be considered hypothesis-
generating, and therefore it would need to be prospectively validated in an adequately 
powered study. A data mining method was chosen over traditional statistical methods 
because the data mining methods do not rely on parametric assumptions or statistically 
significant marginal effects, they can handle highly dimensional data, can test for higher 
order interactions, handles observations with missing values, and avoid multiple 
comparisons issues. Of the three data mining methods described above (i.e. recursive 
partitioning, combinatorial, and neural network), recursive partitioning was chosen 
because the output is easily interpreted and the epistatic interactions are placed in a 
clinical context. Recursive partitioning also has the advantage fast computation time 
compared to the combinatorial and neural network methods. There are several different 
types of recursive partitioning algorithms, such as CART, J48, or C4.5 (8), but the CART 
algorithm was specifically chosen because it has previously been applied to HF for 
clinical input variables (10),  allowing a comparison of this CART model accuracy to an 
independent CART model in HF patients. Also, other recursive partitioning algorithms 
(e.g. J48 and C4.5) are prone to over-fitting, limiting the generalizability of the results to 
HF patient populations other than UNITE-DNA. 
 
Methods 
 Recursive partitioning. The open source Waikato Environment for Knowledge 
Analysis (WEKA) version 3.6.7 (8) implementation of the classification and regression 
tree (CART) algorithm (11) was used to detect epistasis in UNITE-DNA. The binary 
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outcome variable was 10-year all-cause mortality. Fifteen clinical and 13 genetic input 
variables were included in the analysis (Table 32). The ADRB1 and ADRB2 diplotypes 
were estimated using PHASE is version 2.1.1. The CART algorithm segregates different 
values of the input variables through a decision tree composed of progressive binary 
splits (11). Each parent node in the decision tree produces two child nodes, which in turn 
can become parent nodes producing additional child nodes. Every value of each input 
variable is considered as a potential split, and the split is made to maximize the purity of 
the resultant leaf nodes (e.g. 100% deceased and 0% alive or 0% deceased and 100% 
alive).  If variables have missing values, a surrogate value is imputed based on all of the 
other variables with non-missing values in the patient. This procedure is analogous to 
replacing a missing value in a linear model by regressing on the non-missing value most 
highly correlated with it, but it is more robust (11). The partitioning process continues 
until all of the patients in UNITE-DNA are classified, and then the tree is pruned using 
minimal cost-complexity pruning (11) to optimally balance tree complexity with tree 
generalizability. Because there is not a validation cohort, internal validation using 10-fold 
cross validation was used during the tree building process. Tree accuracy was assessed 
using area under the receiver operating characteristic curve (AUC ROC) and 
misclassification rate. Because allele frequencies and the heart failure phenotype are 
dramatically different between the AA and non-AA patients, decision trees were also 
derived in racial strata. 
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Results 
 When recursive partitioning all of the UNITE-DNA patients, the variables that 
stayed in the model for predicting 10-year all-cause mortality (in order of importance) 
were age (less than or greater than 62 years), GFR (less than or greater than 43 mL/min), 
heart failure etiology (ischemic or non-ischemic), and systolic blood pressure (less than 
or greater than 107 mmHg) (Figure 12). There were no gene-gene interactions, or even 
single genetic variants, that were predictive of mortality in all of the UNITE-DNA 
patients. The ROC AUC was 0.663 and the misclassification rate was 35%. Notably, the 
accuracy of the UNITE-DNA model is similar to a much larger study of hospitalized HF 
patients in the ADHERE registry (n = 33,046), in which the ROC AUC was 0.687 (10). 
Specifically in the non-AA patients, the tree is much larger (Figure 13). Ten variables 
were important for predicting 10-year all-cause mortality, including a pharmacogenetic 
gene-gene interaction between ADRB1 and AGTR1 in the non-AA patients aged less than 
60 treated with BB (Figure 14). If the non-AA patients did not have the ADRB1 Ser49-
Arg389/Gly49-Arg389 diplotype, were treated with BB, and aged less than 60, then their 
10-year all-cause mortality rate was only 19% (n = 147). However, if the non-AA 
patients did have the ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype, carried AGTR1 
1166C, were treated with BB, and aged less than 60, then their mortality rate was 73% (n 
= 12). If the non-AA patients did have the ADRB1 Ser49-Arg389/Gly49-Arg389 
diplotype, were homozygous for AGTR1 1166A, treated with BB, and aged less than 60, 
then their mortality rate was only 24% (n = 9). The ROC AUC was 0.645 and the 
misclassification rate was 36% for the non-AA model. In the AA patients, there were no 
pharmacogenetic gene-gene interactions, but a single genetic variant was important for 
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predicting mortality: ADRB2 Arg16Gly (Figure 15).  If the AA patients had a GFR 
greater than 54 mL/min, age less than 73, LVEF less than 23, diastolic blood pressure 
greater than 67, and were homozygous for ADRB2 Gly16, then their mortality rate was 
82% (n = 10), but if they carried ADRB2 Arg16 then their mortality rate was only 29% (n 
= 29). The ROC AUC was 0.616 and the misclassification rate was 37% for the AA 
model. 
 
Discussion 
This is the first report using data mining to detect gene-gene interactions 
associated with HF clinical outcome. When considering all of the UNITE-DNA patients, 
there were no gene-gene interactions. Because the allele frequencies and HF phenotypes 
are dramatically different between non-AA and AA HF patients, decision trees were also 
derived separately in racial strata, and a pharmacogenetic gene-gene interaction between 
ADRB1 and AGTR1 was identified in the non-AA. Only one previously published study 
has evaluated the association between gene-gene interactions and clinical outcome in HF 
patients (12). This study by Kardia et al tested a novel hypothesis, but the methodology is 
fraught with limitations. In Kardia et al, 655 Caucasian patients were genotyped for 16 
variants in ADRA2C and 17 variants in ADRB1. The patients were followed for a mean 
3.16 years to the endpoint of death or heart transplant. Kardia et al used traditional 
statistical methods, despite the numerous limitations of this approach as described in the 
introduction, to detect intra- and inter-genic epistasis. Kardia et al only tested for 
pairwise interactions, and they used a 30% FDR to control for multiple comparisons and 
leave-one-out cross validation due to the lack of a validation cohort. Covariates used to 
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adjust the Cox proportional hazards model were age at initial diagnosis, BB usage, 
hypertension status, and sex. Kardia et al found two genetic variants with statistically 
significant main effects, but these same two genetic variants were also involved in gene-
gene interactions, making the interpretation of the main effects impossible. Three variants 
in ADRA2C and five variants in ADRB1 were involved in eight cross-validated epistatic 
interactions, resulting in two-locus genotype classes with significant relative risks 
ranging from 3.02 to 9.23. The clinical interpretation of this data is difficult because 
Kardia et al only tested pairwise interactions, and it is unknown whether higher-order 
interactions are associated with outcome. Higher-order interactions are highly likely, 
given that the eight cross-validated epistatic interactions stem from within and between 
two highly related genes. It is impossible to determine a given HF patient’s mortality risk 
from this data because there may be synergy between the risk-increasing epistatic pairs. 
Alternatively, a HF patient’s risk cannot be estimated if they possessed a combination of 
protective and harmful epistatic pairs. In addition, because multiple tests were performed, 
the probability of these associations being falsely positive is very high. The FDR method 
they used to control for false discoveries allowed 30% to be false, meaning at least two of 
the eight epistatic interactions they discovered are probably false.  
 The recursive partitioning data mining method used herein addresses many of the 
limitations encountered by Kardia et al for detecting gene-gene interactions associated 
with HF clinical outcome. Because all of the input variables are added to the model 
simultaneously, there are no multiple comparisons issues. Also, the Kardia et al study did 
not study AAs, whereas UNITE-DNA includes both AA and non-AA patients analyzed 
together and separately. The output for the CART algorithm is easily interpreted and in a 
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clinical context. Known functional variants were studied herein, whereas Kardia et al 
studied variants with unknown functional consequences. In addition, nine genes were 
tested in UNITE-DNA whereas Kardia et al only tested two genes. The recursive 
partitioning data mining method also does not depend on the assumptions necessary for 
the parametric regression approach used by Kardia et al i.e. data is normally distributed, 
equal variances, independent observations, independent variables are not correlated, 
linearity, or a random sample. As evident in the Kardia et al study, statistically significant 
marginal effects are necessary to detect epistatic interactions. Whereas recursive 
partitioning only depends on slight marginal effects of each single variant. Kardia et al 
also only tested a dominant genetic inheritance model. Recursive partitioning can handle 
a large number of input variables (no loss of degrees of freedom with increasing number 
of parameters like regression models). Importantly, recursive partitioning has its own 
limitations. Although it is not dependent on strong marginal effects, recursive 
partitioning is dependent on slight marginal effects since the splits are made on a single 
variable. To overcome this limitation, data mining methods that could potentially be used 
in future work are the combinatorial and neural network methods (9), which are capable 
of detecting purely epistatic interactions. Another limitation of recursive partitioning is 
the very small sample sizes in the leaf nodes, which limits the generalizability of the 
results to large patient populations and makes recruitment of subjects for adequately 
powered prospective studies difficult.  
It should be emphasized that data mining methods are not hypothesis-testing, but 
rather hypothesis-generating. For instance, the general hypothesis for this study was that 
gene-gene interactions between functional variants within the SNS and RAAS will be 
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associated with survival in patients with HF. A specific hypothesis on which and how 
many of the genetic variants will interact was not made. Because of the small sample 
sizes in the leaf nodes, the pharmacogenetic gene-gene interaction between ADRB1 and 
AGTR1 can now lead to a prospective, adequately-powered study tested with traditional 
statistical methods.  The gene-gene interaction needs to be validated both statistically and 
biologically, but the statistical interaction needs to be validated prior to the biological 
interaction. Although this finding was 10-fold cross-validated, it was only found in a 
single cohort. Figure 16 shows a proposed research pathway for implementation of the 
pharmacogenetic gene-gene interaction identified in the non-AA into clinical practice. 
The next step for this gene-gene interaction would be retrospective validation in another 
HF patient population. One such cohort could be from the study by Cresci et al (13). 
Cresci et al studied 2,460 HF patients, of which 1,392 were Caucasian and treated with 
BBs. Also estimating the number of those patients under the age of 60 and considering 
the frequencies of the AGTR1 1166C allele and the ADRB1 Ser49-Arg389/Gly49-Arg389 
diplotype, about 20 of the patients from the Cresci et al study would fall into the high risk 
category (i.e. ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype and AGTR1 1166AA) and 
425 patients into the low risk category (i.e. not ADRB1 Ser49-Arg389/Gly49-Arg389 
diplotype or with the diplotype but carrying AGTR1 1166C) for the gene-gene 
interaction.  Assuming the survival rates are 3-fold different between the high and low 
risk group, the Cresci et al cohort would have 77% power to detect this difference. 
Although this may be underpowered considering the “winner’s curse (Appendix IV) 
(14),” where the initial report of a genetic association is exaggerated due to sampling 
bias. If retrospectively validated in an independent cohort (or cohort backwards; 
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“trohoc”) such as Cresci et al, the next step would be to initiate a new prospective cohort. 
Assuming the difference in mortality rates between the high-risk and low-risk groups is 
2-fold at 5 years of follow-up, 312 patients (156 per high risk and low risk genotype 
group) would be necessary for 80% power at alpha = 0.05. Alternatively, because the 
high risk group would be only be approximately one or two out of every 100 patients in 
an outpatient HF specialty clinic (making recruitment difficult), 80% power at alpha = 
0.05 for 5 years of follow-up and 2-fold difference in mortality rate could also be 
achieved by enrolling 96 high risk patients and 1150 low risk patients. The advantage 
being lower enrollment of the high risk patients, but the disadvantage is that total 
enrollment would be much greater (n = 1246). However if there is still a significant 
difference in mortality due to the pharmacogenetic gene-gene interaction after 
retrospective and prospective cohort validation, then the next step would be to determine 
effective interventions for the high-risk patients. Although effective interventions could 
not be tested until the biological interaction is characterized.  
As described in detail in Chapter II, there is clear functional, physiologic, and 
clinical plausibility for an association of each the 11 candidate genetic variants with 
survival and BB response in patients with HF. However the biologic plausibility 
specifically for this pharmacogenetic gene-gene interaction found in the following select 
group of patients is difficult to describe: non-AA, aged less than 60, treated with BBs, 
with the ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype, and carrying AGTR1 1166C.  It 
is possible that a gene-gene interaction involving the SNS and RAAS was able to be 
detected in non-AA and not the AA because the SNS and RAAS play a smaller role in 
AA patients compared to non-AA (15). For example, despite more severe LV 
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dysfunction, AA patients have either similar or lower norepinephrine levels and they do 
not respond to pharmacologic neurohormonal inhibition as well as Caucasians (16). It is 
also possible that a genetic association would be detected in younger patients (aged less 
than 60 years) compare to older (aged greater than 60 years) because genetic variation 
represents long-term exposure to high SNS and RAAS activity. Therefore adverse effects 
of a genetic variant, if present, would be expected to manifest in younger patients (17). If 
the genetic variant has weak or no association with survival, then as patients age they 
would be more likely to succumb to comorbidities. However, a limitation of the UNITE-
DNA registry design is that we cannot determine the cause of death.  
As described in detail in Chapter II, the ADRB1 Ser49 allele is relatively resistant 
to down-regulation compared to the Gly49 allele (18,19), and Arg389 couples to the 
stimulatory intracellular G-protein more than the Gly389 allele (20). Hence, the Ser49-
Arg389 diplotype would be considered the most active form of the beta-1 adrenergic 
receptor, and it would also be the most responsive to BB inhibition. Therefore it would be 
expected that with an increasing number of Ser49-Arg389 haplotypes (0, 1, or 2) there 
would be increasing BB responsiveness. Because the Ser49-Arg489/Gly49-Arg389 
diplotype only has one copy of the most active Ser49-Arg389 haplotype, patients with 
this diplotype would be expected to have an intermediate BB response compared to other 
diplotypes. Therefore it is not clear why patients with the least responsive diplotype (i.e. 
Gly49-Arg389/Gly49-Arg389) is low risk and grouped with the presumably most 
responsive diplotype (i.e. Ser49-Arg389/Ser49-Arg389). AGTR1 1166C has increased 
sensitivity to AII (21,22), is associated with left ventricular dysfunction in coronary 
artery disease patients (23), diastolic HF (24), and decreased survival in patients with HF 
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(25). It is not surprising that a variant from the RAAS is important in BB treated patients 
since there are beta-1 receptors in the kidney that mediate the release of renin (26). The 
CART results are the opposite of what would be expected based on the previous literature 
because UNITE-DNA patients carrying AGTR1 1166C had lower mortality than those 
homozygous for 1166A. Further research defining the potential biological interaction 
between AGTR1 A1166C and the ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype is 
necessary. 
The biological interaction between ADRB1 and AGTR1 has not been directly 
tested in experimental models, and it is difficult to determine from a statistical interaction 
at what level the interaction is occurring. For example, the biological interaction could be 
occurring at the transcriptional, translational, functional, or physiological level, each of 
which could be tested with a variety of experimental models. The best course of action 
would be studying the interaction at the most basic level, and then to gradually increase 
study complexity to the system level. For example, initial studies at the basic level could 
evaluate the protein-protein interaction in transcriptional regulation using the yeast two-
hybrid system (27). A wide variety of animal models of HF exist to test more complex, 
system level gene-gene interactions (28). For example, rodent models are relatively 
inexpensive (compared with large-animal models), and manipulation of mouse genetics 
allows gain or loss of function of specific genes in specific cell types at specific times. 
Limitations of animal models of HF include: 1) difficulty in mimicking the variety of 
causes of HF (e.g. hypertension, ischemia, genetics, valvular disorders, etc.) and 2) 
animal models are often developed on a defined genetic background that does not reflect 
the genetic diversity of human HF populations (28). Fly and fish HF models are also 
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available, and these models are particularly well-suited to study specific genes due to the 
ease in which their genes can be modified. The limitations of fly and fish models are that 
they are far removed from the complexity of the adult mammalian heart (28).  
The difficulty in deriving a biological explanation for this gene-gene interaction 
highlights the inherent difficulty in defining biological epistasis from statistical epistasis 
(29). Biological epistasis is the result of physical interactions among biomolecules within 
and between biochemical pathways or physiologic systems in an individual. In contrast, 
statistical epistasis is usually defined as deviation from linearity in a mathematical model 
or simply the relationship between multiple genotypes with phenotype in a population is 
not predictable from the individual genetic variants alone (29). The extent to which 
statistical evidence of epistasis from population studies, such as UNITE-DNA, is 
predictive of biological epistasis from experimental studies remains elusive (29). 
Currently, it is not possible to connect biological and statistical epistasis in humans, but 
with the promise of systems biology it may be possible in the future (30).  
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Table 32. Clinical and genetic variables input into the CART algorithm. 
Clinical input variables Genetic input variables 
1. History of diabetes 1. ADRB1 Ser49Gly 
2. Age (years) 2. ADRB1 Arg389Gly 
3. Gender 3. ADRB1 diplotype 
4. HF etiology (ischemic vs. non-ischemic) 4. ADRB2 Arg16Gly 
5. History of hypertension 5. ADRB2 Gln27Glu 
6. Systolic blood pressure (mmHg) 6. ADRB2 diplotype 
7. Diastolic blood pressure (mmHg) 7. ACE 287bp deletion 
8. Heart rate (beats per minute) 8. ADRA2C 12bp 
deletion 
9. Left ventricular ejection fraction (%) 9. GRK5 Gln41Leu 
10. NYHA functional class 10. AGT G-6A 
11. Race (self-identified Caucasian, AA, or other) 11. AGTR1 A1166C 
12. BB treatment status 12. CYP11B2 T-344C 
13. Specific BB (atenolol, metoprolol XL, metoprolol IR, 
carvedilol, bisoprolol, other) 
13. BDKRB2 9bp 
deletion 
14. BB dose (in mg metoprolol equivalents) 
15. Glomerular filtration rate (mL/min) 
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Figure legends 
Figure 12. Decision tree output from recursive partitioning all UNITE-DNA patients 
using the CART algorithm in WEKA version 3.6.7 is shown. Progressive binary splits of 
the UNITE-DNA data are made, considering all input variables and their values, to best 
classify UNITE-DNA patients according to the binary outcome variable of 10-year all-
cause mortality. Red highlighted arrows are the split values associated with increased risk 
of 10-year all-cause mortality, and green highlighted arrows are the split values 
associated with decreased risk of 10-year all-cause mortality. N = number of patients that 
have died out of the total number of patients remaining after the preceding splits/total 
number of patients remaining after the preceding splits. 
 
Figure 13. Complete decision tree output from recursive partitioning non-AA UNITE-
DNA patients using the CART algorithm in WEKA version 3.6.7 is shown. Progressive 
binary splits of the UNITE-DNA data are made, considering all input variables and their 
values, to best classify UNITE-DNA patients according to the binary outcome variable of 
10-year all-cause mortality. Red highlighted arrows are the split values associated with 
increased risk of 10-year all-cause mortality, and green highlighted arrows are the split 
values associated with decreased risk of 10-year all-cause mortality. N = number of 
patients that have died out of the total number of patients remaining after the preceding 
splits/total number of patients remaining after the preceding splits. 
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Figure 14. The branches of the decision tree derived from the non-AA UNITE-DNA 
patients using the CART algorithm leading to the gene-gene interaction is shown. N = 
number of patients that have died out of the total number of patients remaining after the 
preceding splits/total number of patients remaining after the preceding splits. 
 
Figure 15. Complete decision tree output from recursive partitioning AA UNITE-DNA 
patients using the CART algorithm in WEKA version 3.6.7 is shown. Progressive binary 
splits of the UNITE-DNA data are made, considering all input variables and their values, 
to best classify UNITE-DNA patients according to the binary outcome variable of 10-
year all-cause mortality. Red highlighted arrows are the split values associated with 
increased risk of 10-year all-cause mortality, and green highlighted arrows are the split 
values associated with decreased risk of 10-year all-cause mortality. N = number of 
patients that have died out of the total number of patients remaining after the preceding 
splits/total number of patients remaining after the preceding splits. 
 
Figure 16. A research pathway to the clinical implementation of the pharmacogenetic 
gene-gene interaction identified in the non-AA UNITE-DNA patients is proposed. 
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Figure 12. Decision tree for all UNITE-DNA patients. 
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Figure 13. Complete decision tree for Non-AA UNITE-DNA patients. 
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Figure 14. Branches of Non-AA decision tree leading to gene-gene interaction. 
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Figure 15. Complete decision tree for AA UNITE-DNA patients. 
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Figure 16. Research pathway to clinical implementation of the pharmacogenetic gene-
gene interaction in non-AA. 
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CHAPTER VIII:  
DISCUSSION AND PERSPECTIVE 
 
Summary 
This chapter has several goals: 1) address the gaps in and limitations of the 
previous HF genetic association literature, 2) describe how this dissertation research fills 
the gaps in or overcomes the limitations of the previous HF genetic association literature, 
3) summarize the findings of this dissertation research, 4) discuss these research findings 
within the context of the broader body of literature, 5) evaluate the potential clinical 
impact of these findings, and 6) propose areas for future investigation.  
 
Discussion 
HF is an enormous public health problem, with immense cost, incidence, 
prevalence, morbidity, and mortality.  Hyperactivity of the SNS and RAAS is the primary 
contributor to HF pathophysiology, and, in patients with HF, it is associated with 
hemodynamic abnormalities (1), symptoms (2), and survival (3-6). The survival rates in 
patients with HF are highly variable, ranging from 93% (7) to 25% (8) per year, and 
individual patient responses to SNS and RAAS pharmacologic inhibition in HF are also 
highly variable.  Pharmacologic inhibition of the SNS and RAAS with BB significantly 
decreases morbidity and mortality, on average, in large HF clinical trials (9,10), but long-
term optimal dosing of BB fails to improve LVEF greater than 5% in as many as 43% of 
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HF patients (11).  Unfortunately, clinical characteristics do not entirely explain the 
variability in HF patient survival rates and BB response. However genetic variation 
affects SNS and RAAS activity, and thus genetic variation may be associated with HF 
patient survival and BB response. Therefore the collective objective of this dissertation 
research was to determine the association of genetic variation in the SNS and RAAS with 
HF patient survival and BB response.  
Several common, functional genetic variants in the SNS and RAAS are 
individually associated with HF physiologic (e.g. ventricular remodeling) or clinical 
outcomes (e.g. survival or BB response) in the literature. For example, an 
insertion/deletion variant in the gene that encodes for angiotensin-converting enzyme 
(ACE) accounts for half of the variance in plasma ACE levels (12). The ACE deletion 
allele is found in approximately one-half of HF patients, and it is associated with 
significantly higher plasma ACE levels (12), higher risk of mortality (13), and increased 
BB response (14). Like the ACE genetic variant, 11 total common variants supported by 
prior functional and clinical literature were chosen for this dissertation research: ADRB1 
Ser49Gly and Arg389Gly, ADRB2 Gly16Arg and Gln27Glu, ACE 287 bp Ins/Del, 
ADRA2C 12 bp Ins/Del, GRK5 Gln41Leu, AGT G-6A, AGTR1 A1166C, CYP11B2 T-
344C, and BDKRB2 9bp Ins/Del.  
The literature on these 11 genetic variants dates back 15 years. To date, no genetic 
test has been applied in HF clinical practice, and limitations of the previously published 
studies may have led to the lack of clinical application.  Early genetic association studies 
with HF patient survival were conducted prior to the widespread use of BB (13,15). 
Therefore the confounding effect of BB on the genetic association with survival could not 
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be determined nor could BB pharmacogenetic associations. There has also been 
conflicting and non-replicated results in the HF genetic association literature. For 
example, two genetic variants in the beta-2 adrenergic receptor (ADRB2 Gly16Arg and 
Gln27Glu) were associated with lower risk of worsening HF (16). However the same two 
variants have also been associated with higher risk of adverse outcome (17), or no 
association at all (15). Additionally, the majority of previous studies tested only one to 
three genetic variants, and therefore the independence of each genetic association, or the 
relative contribution of each variant, cannot be verified. For example, each of the 
following genes have been associated with HF patient survival in separate studies: ACE 
(13), CYP11B2 (18), and AGT (19). All three of these genes are part of the RAAS, and 
therefore they may not have independent effects. And finally, many of the initial, positive 
genetic associations in HF have yet to be validated (20,21).  
Validation of independent genetic associations needs to be performed in an 
adequately powered, well-characterized, and extensively genotyped patient cohort, which 
was accomplished in aim #1 (Chapter V). None of the eleven variants were significantly 
associated with HF patient survival, but a single genetic variant, ADRB1 Ser49Gly, was 
significantly associated with BB response despite rigorous adjustment for clinical 
covariates and multiple comparisons. BB treatment was associated with a statistically 
significant 46% reduction in mortality in Ser49-homozygotes but a non-significant 38% 
increase in Gly49-carriers. This finding is consistent with two European studies of 
patients with IDCM (22,23) and also the hypertension literature, in that patients with 
Ser49 have a better blood pressure response to BB (24-27).  Notably, there are other BB 
HF pharmacogenetic studies of Ser49Gly with a survival endpoint that were negative 
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(28,29), and the studies with intermediate endpoints (e.g. ventricular remodeling response 
to BB) are not supportive of this pharmacogenetic interaction (11,28,30-33). Therefore, 
acknowledging that these studies have many limitations, the weight of the evidence for 
this pharmacogenetic interaction between Ser49Gly and BB still needs to be increased 
prior to any prospective studies. Future research should focus on validating this 
pharmacogenetic association in another adequately-powered patient cohort with a large 
proportion of patients not treated with BB. The clinical implications for this finding, if 
validated, are profound because Ser49Gly could be used to identify genetic non-
responders to BB therapy. HF patients could be screened for the Ser49Gly genetic variant 
in the clinic, and Gly49-carriers could be targeted for closer clinical monitoring and/or 
titration of other life-saving HF medications (e.g. RAAS inhibitors).     
Another important limitation of the previous HF genetic association literature is 
that several different SNS and RAAS genetic variants had positive associations but in 
separate studies. Because these genetic variants are part of the same physiologic systems, 
it is reasonable to think that they could have additive effects. Indeed, these genetic 
variants are common, so a given HF patient would possess multiple, functional, SNS and 
RAAS genetic variants. In common, complex diseases such as HF, common genetic 
variants typically have weak associations with clinical outcomes (34), which could 
explain the largely negative results in Chapter V. The additive association of multiple 
SNS and RAAS genetic variants has not been previously studied, which was 
accomplished in aim #2 (Chapter VI) via simple and internally-weighted GRS’s (35).  
Neither the simple nor internally-weighted genetic risk scores were associated with 
survival. The GRS’s also did not add to the predictability of clinical risk factors for 
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mortality or reclassify HF patients to new mortality risk categories. There are several 
possible explanations for these negative results: only a few variants from the vastly 
complex SNS and RAAS physiologic systems were included, the literature reported 
associations upon which candidate selection was made were falsely positive, or there 
simply is not an additive association of the genetic variants. The second reason, that the 
literature reported associations upon which the candidate selection was made, is 
supported by the failed validation in aim #1. Unfortunately, these findings in aim #2 are 
consistent with several other negative GRS studies for cardiovascular disease in the 
literature (36-38), but this may still be a viable methodology in HF due to the successful 
GRS application in a variety of other common, complex diseases such as prostate cancer 
(39), coronary heart disease (40,41), type 2 diabetes (42), and primary cardiovascular 
events (43).  As more genetic variants are discovered and validated in HF, future research 
could focus on using more advanced GRS methods such as the polygenic score (35) or 
the incorporation of rare genetic variants with larger effect sizes. A successful GRS in HF 
is clinically important because it could be used to accurately estimate the risk of mortality 
in HF, which enables informed decisions by providers, patients, and patients’ families on 
HF medications, devices, heart transplantation, and end-of-life care. 
Although additive associations of the genetic variants were not found, it is 
possible that there are synergistic associations or gene-gene interactions. For example, 
Liggett et al reported an Arg389Gly substitution in the beta-1 adrenergic receptor 
(ADRB1) which results in decreased coupling to the intracellular stimulatory protein Gs 
(44). The Arg389Gly ADRB1 variant was associated with survival and beta-blocker 
response in HF patients (45). In another study by Liggett et al, a Gln41Leu substitution in 
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the G-protein coupled receptor kinase 5 (GRK5), which enhances beta-adrenergic 
receptor intracellular uncoupling, was also associated with HF patient survival and beta-
blocker response (46). Because both of these variants affect beta-adrenergic intracellular 
coupling, which is necessary for receptor function, they could have a synergistic 
association with clinical outcome. Synergy, or other forms of gene-gene interactions, 
would not be detected in an additive model such as a GRS.  Epistasis, or gene-gene 
interactions, is another possible explanation for the failure of other genetic association 
studies (28,47-51) and aims #1 and #2 because the association of an individual genetic 
variant with a complex phenotype will be missed if it is tested individually but involved 
in epistasis. A single gene-gene interaction study in patients with HF has been published 
(52), but they used traditional statistical methods fraught with limitations. Traditional 
statistical methods depend on parametric assumptions, a pre-specified genetic inheritance 
model, and cannot handle high dimensional data. Therefore the objective of aim #3 
(Chapter VII) was to determine if gene-gene interactions within and between the SNS 
and RAAS were associated with survival in patients with HF.  
A recursive partitioning data mining method, CART, was chosen to test the gene-
gene interaction hypothesis in aim #3. Data mining methods have several advantages 
over traditional statistical methods for detecting epistasis because they are essentially 
assumption and model free and they can handle high dimensional data. There were no 
epistatic interactions associated with HF survival or BB response in UNITE-DNA overall 
or in the AA patients, but in the non-AA patients there was an interaction between the 
ADRB1 Ser49-Arg389 diplotype and AGTR1 A1166C. In the non-AA patients aged less 
than 60 and treated with BB, the mortality rate was approximately 3-fold higher (24% vs. 
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73%) if patients had the ADRB1 Ser49-Arg389/Gly49-Arg389 diplotype and carried 
AGTR1 1166C. This is a novel association, and it is difficult to explain in the context of 
the available literature. The biological interaction between ADRB1 and AGTR1 has not 
been directly tested in experimental models, and it is difficult to determine from a 
statistical interaction at what level the interaction is occurring (e.g. transcriptional, 
translational, functional, or physiological level). Although the CART algorithm was 10-
fold cross-validated, future research should focus on validating this association in an 
independent HF patient cohort. If validated, this finding has important clinical 
implications. Like the GRS, screening for this gene-gene interaction could potentially 
enable informed decisions by providers, patients, and patients’ families on HF 
medications, devices, heart transplantation, and end-of-life care. 
 
Perspective 
 This dissertation research has the potential to make an impact on both HF clinical 
practice and HF genetic association research. The ADRB1 Ser49Gly pharmacogenetic 
interaction is the major finding in this dissertation research, and it is the closest to 
potential clinical application. If validated, the Ser49Gly variant could be used to tailor 
pharmacotherapy in HF patients. In a syndrome that is as fatal and prevalent as HF, and 
with the widespread use of beta-blockers, screening for this single genetic variant could 
have a profound public health impact. This research also makes an impact on the field of 
HF genetic association research, by using one of the largest community HF patient 
cohorts with the longest follow-up to date, testing multiple genetic variants, and the novel 
application of advanced analytical methods such as GRS’s and data mining.   
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 Besides the potential for an impact, this dissertation research also highlights the 
need for shifts in the current HF clinical practice and research paradigms.  The current 
HF clinical practice paradigm more resembles generalized medicine instead of 
personalized medicine. (Personalized medicine as defined by the implementation of 
advanced “omic” technologies). For example, beta-blockers are recommended in all HF 
patients with an LVEF < 40%.  However the results of this dissertation research 
challenge that recommendation because beta-blockers may not be effective in HF patients 
carrying the ADRB1 Gly49 allele. Of course, the guideline recommendation for beta-
blockers in HF is based on large clinical trials demonstrating an average benefit in large 
HF patient populations. Such large clinical trials are designed to evaluate average 
population benefit and not individual patient benefit. Therefore the current HF clinical 
research paradigm is bolstering the practice of generalized medicine and not personalized 
medicine.  
In order to achieve personalized HF medicine, the HF clinical research paradigm 
must change. Given the size of the human genome, 1) a randomized clinical trial for 
every potential personalized intervention is not possible, 2) traditional statistical methods 
can no longer handle the amount of data available, and 3) current sample sizes do not 
meet the demands for statistical distinction.  Randomized clinical trials yield gold-
standard evidence, but, in the future, other levels of evidence must also be accepted if 
personalized HF medicine is to become a reality. For example, drug dosage is empirically 
adjusted according to the renal function of a patient if the drug is known to be renally 
cleared, and this practice was adopted without a randomized clinical trial for every 
renally cleared drug. Traditional statistical methods developed in the 1960’s and 70’s, 
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such as the Bonferroni correction and Cox regression, were developed for pencil and 
paper calculation out of necessity. Now that computers are widely available, more 
advanced statistical methods, such as data mining, should be used. And finally, the 
current methods for recruitment of HF patients for clinical research are not meeting the 
demands for the large sample sizes needed to carry out genetic association research. 
However this could change in the future with the aid of electronic medical records and 
opt-out instead of opt-in research participation.  In conclusion, HF clinical practice and 
research has come a long way, but it still has a long way to go. 
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Genetic Tailoring of Pharmacotherapy in Heart Failure: Optimize the old, while we 
wait for something new 
 
Talameh JA, McLeod HL, Adams KF Jr, Patterson JH. Genetic tailoring of 
pharmacotherapy in heart failure: optimize the old, while we wait for something new. J 
Card Fail. 2012 Apr;18(4):338-49. 
 
 
Abstract  
 
Background: The combination of angiotensin-converting enzyme (ACE) inhibitors and 
beta-adrenergic receptor blockers remains the essential component of heart failure (HF) 
pharmacotherapy. However the individual patient responses to these pharmacotherapies 
widely vary. The variability in response cannot be entirely explained by clinical 
characteristics, but genetic variation may play a role. Therefore the purpose of this review 
is to examine our current state of understanding for beta-blocker and ACE inhibitor 
pharmacogenetic literature in HF. 
 
Methods: Beta-blocker and ACE inhibitor pharmacogenetic studies performed in 
patients with HF were identified from the PubMed database from 1966 to July 2011.  
 
Results: Thirty beta-blocker and ten ACE inhibitor pharmacogenetic studies in patients 
with HF were identified. The ACE deletion variant was associated with greater survival 
benefit from ACE inhibitors and beta-blockers compared to the ACE insertion.  Ser49 in 
the beta-1 adrenergic receptor, the insertion in the alpha-2C adrenergic receptor, and 
Gln41 in G-protein coupled receptor kinase 5 are associated with greater survival benefit 
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from beta-blockers, compared to Gly49, the deletion, and Leu41, respectively. However 
many of these associations have not been validated. 
 
Conclusions: The HF pharmacogenetic literature is still in its very early stages, but there 
are promising candidate genetic variants that may identify which HF patients are most 
likely to benefit from beta-blockers and ACE inhibitors and patients that may require 
additional therapies.  
 
Key Words  
 
Heart failure; beta blocker; ACE inhibitor; pharmacogenetic; pharmacogenomic; 
polymorphism; variant 
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Introduction 
 Advances in pharmacotherapy over the past two decades have significantly 
improved heart failure (HF) morbidity and enhanced survival. The combination of 
angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic receptor blockers 
remains the essential component of HF pharmacotherapy.(1) Both drugs significantly 
improve survival; particularly beta-blockers, which result in a 35% reduction in mortality 
when added to ACE inhibitors and have been firmly entrenched in HF evidence-based 
guidelines since the late 1990's.(2,3)  However, physiological actions, side effects, and 
efficacy vary substantially on a patient to patient basis.  For example, ACE inhibition 
may fail to suppress angiotensin II in HF patients and aldosterone escape is common. (4) 
The prevalence and severity of ACE inhibitor-induced cough varies significantly and 
angioedema, a rare but potentially serious side effect, remains unpredictable. (5) 
Treatment with beta-blockers results in widely variable effects on left ventricular ejection 
fraction (LVEF). A distinct minority of patients (approximately 25%) experience a 
marked and sustained improvement in ventricular function, while others have no change 
or rarely may experience a decline.(6) HF patients may experience worsening of their 
symptoms during beta-blocker titration, requiring increased diuretic doses and rarely 
discontinuation of beta-blocker therapy.(7) Unfortunately, variability in ACE inhibitor 
and beta-blocker clinical response is typically not predictable based on clinical 
characteristics. Clearly, a better understanding of the basis of variable therapeutic 
response to ACE inhibitors and beta-blockers would be clinically useful. 
Genetic variation is expected to account for a significant part of the individual 
patient response to cardiovascular medication.  Differences in genetic coding have been 
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shown to influence pharmacokinetics and pharmacodynamics, which may translate into 
clinical outcomes such as therapeutic efficacy and adverse events. Whether genetic 
tailoring of ACE inhibitors and beta-blockers will improve the response to these agents in 
HF is unknown. Therefore it is important to understand the current state of 
pharmacogenetic literature for HF. The purpose of this review is to specifically examine 
genetic variants influencing the response to the mainstay of HF pharmacotherapy: ACE 
inhibitors and beta-blockers. For papers examining the association between genetic 
variants and HF predisposition or survival the reader is directed elsewhere.(8-11) We will 
discuss 1) the in vitro data supporting the mechanisms for pharmacogenetic interactions 
in HF, 2) the translation of mechanistic data to clinical pharmacogenetic studies in 
patients with HF, and 3) if the current state of the literature is sufficient for routine 
genetic tailoring of ACE inhibitor and beta-blocker pharmacotherapy in patients with HF.  
 
Methods 
 Beta-blocker and ACE inhibitor pharmacogenetic studies were identified in the 
PubMed database from 1966 to July 2011 by combining the following search terms: heart 
failure, variant, polymorphism, pharmacogenetics, pharmacogenomics, beta blocker, 
ACE inhibitor, and each individual drug name. Studies were also identified from the 
reference lists of articles. Studies were limited to those performed in patients with heart 
failure and those published in English.  
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Results 
Beta-blockers  
 Thirty beta-blocker pharmacogenetic studies in patients with HF have been 
published from 2000 to 2011, and the genetic variants studied for an association with 
(FDA-approved) beta-blocker response in HF patients are summarized in Table 1. These 
studies are heterogeneous in many aspects: design, sample size, endpoint, HF patient 
population, specific beta-blockers, and genetic variants tested. The study designs include 
retrospective, prospective non-randomized cohorts, pharmacogenetic sub-studies of 
randomized clinical trials, and a meta-analysis. The smallest study investigated 33 HF 
patients,(12) whereas the largest study included 2,460.(13) The endpoints ranged from 
intermediate phenotypes such as heart rate and LVEF to clinical outcomes such as 
survival. Some studies only included HF patients with idiopathic dilated cardiomyopathy 
(IDC), but the majority studied HF patients with systolic dysfunction from ischemic and 
non-ischemic etiologies. Most studies investigated FDA-approved beta-blockers for HF 
such as carvedilol and metoprolol succinate. Some report findings for the investigational 
agent bucindolol.(14-16) The majority of studies tested genetic variants related to the 
sympathetic adrenergic system, but there were some that investigated genetic variants 
related to the renin-angiotensin-aldosterone system. (17-19) The following sections will 
review the most commonly studied genetic variants in the HF beta-blocker 
pharmacogenetic literature. 
Beta-1 adrenergic receptor  
 The largest amount of pharmacogenetic data for beta-blockers is for the primary 
drug target, the beta-1 adrenergic receptor (ADRB1). ADRB1 is the principal beta-
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adrenergic subtype expressed on the cardiac myocyte, and it mediates cardiac 
contractility. The gene for ADRB1 is localized to chromosome 10q24-q26.(20) The gene 
is intronless, consists of 1,714 base pairs, and codes for a 51.3 kDa protein consisting of 
477 amino acid residues. There are two variants in ADRB1 that have been studied: an 
amino acid substitution of glycine for serine at position 49 (Ser49Gly) and a glycine 
substituted for arginine at position 389 (Arg389Gly) in the receptor. These variants are 
common in the general population, and there are racial differences in their frequencies. 
The frequency of these variants and other variants that will be discussed in this review 
are presented in Table 2.  
Beta-1 adrenergic receptor variant: Ser49Gly 
 Functionally, Gly49 results in greater agonist-promoted down-regulation of 
ADRB1 compared to Ser49.(21,22) Down-regulation of the beta-adrenergic receptors is 
thought to be a protective adaptation in HF, where chronic sympathetic activity is toxic to 
the cardiac myocyte.(23) This concept suggests that the Gly49 variant may be protective 
in patients with heart failure and patients with this variant may be less responsive to beta 
block.  In contrast, in vitro experiments also demonstrate that cells expressing Gly49 are 
more sensitive to the inhibitory effects of metoprolol.(21) But whether HF patients 
possessing Gly49 treated with metoprolol would respond favorably despite down 
regulation of this receptor has not been determined. A number of clinical studies have 
examined the association of the Ser49Gly genotype with ventricular remodeling 
parameters such as LVEF, left ventricular end diastolic diameter (LVEDD), and left 
ventricular fractional shortening (LVFS) and outcomes during beta blockade, with 
complex and somewhat inconsistent results that will discussed in detail below.  
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Terra et al studied 54 patients with systolic dysfunction receiving at least three 
months of the target or highest tolerated dose of metoprolol CR/XL.(24) Patients carrying 
Gly49 had a significant decrease in LVEDD compared to Ser49 homozygous patients in 
response to metoprolol CR/XL (-2 mm vs. +2 mm; p = 0.003). However changes in 
LVEF were not significantly different between Ser49Gly sub-groups. de Groote et al 
studied 199 patients with systolic dysfunction and at least three months of the maximum 
tolerated dose of bisoprolol or carvedilol.(25) They found no difference in LVEF or 
RVEF among Ser49Gly sub-groups, but de Groote et al did not compare LVEDD 
responses. Nonen et al studied LVFS response in 80 patients with IDC on at least six 
months of a variety of beta-blockers, in which they did not find an influence of 
Ser49Gly.(26)  
There are limitations to the Terra et al,(24) de Groote et al,(25) and Nonen et 
al(26) studies. It is possible that the duration of beta-blocker therapy was too short, and it 
may take at least one year to see a complete LVEF response.(27) HF etiology is also an 
important consideration when using ventricular remodeling endpoints. Patients with an 
ischemic etiology may have irreversible damage to the myocardium. These limitations 
were addressed by Chen et al in a study of 135 non-ischemic cardiomyopathy patients 
after 1.5 years of treatment with carvedilol, and there was still no significant impact of 
Ser49Gly on LVEF.(28) 
 Although there is little data supporting an interaction between Ser49Gly and 
ventricular remodeling response after beta-blocker treatment, Ser49Gly may have an 
impact on long-term response to beta-blockers. Because Gly49 is protective against 
chronic sympathetic stimulation, it has been hypothesized that long-term exogenous beta-
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blockade is more critical for HF patients with Ser49. Indeed, this is supported by a 
retrospective study by Borjesson et al.(29) In 184 patients with IDC, the survival curve 
for Ser49 homozygous patients treated with beta-blockers was almost identical to Gly49 
carrying patients not receiving beta-blockers. This was confirmed in a study by 
Magnusson et al,(30) in which they added a prospective IDC cohort (n = 190) to the 
retrospective cohort studied by Borjesson et al.(30) Magnusson et al found that patients 
carrying Gly49 had a similar survival rate regardless of high-dose (>50% of target dose) 
or low-dose (≤ 50% of target dose) beta-blocker. However, in the group of patients 
treated with low-dose beta-blocker, patients carrying Gly49 had lower five-year mortality 
compared to patients homozygous for Ser49 (risk ratio = 0.24; p = .020).  
 The Borjesson et al and Magnusson et al studies need to be interpreted cautiously. 
These studies consisted of entirely Swedish patients, and Biolo et al did not confirm these 
findings prospectively in a Brazilian population (n = 201) that included ischemic 
etiology.(31) Racial and ethnic stratification is especially a concern for genetic 
association studies due to differences in allele frequencies, haplotype structure, and the 
genetic admixture of populations.(32) Acknowledging these differences, the Magnusson 
et al and Borjesson et al studies suggest that it is more critical that patients homozygous 
for Ser49 are treated with high dose beta-blockers, and that Gly49 carrying patients 
receive equal benefit regardless of high- or low-dose beta-blocker.  
Beta-1 adrenergic receptor variant: Arg389Gly 
Sympathetic stimulation of ADRB1 results in activation of the Gs protein, which 
in turn activates adenylyl cyclase and the production of cAMP.(33) Arg389 of ADRB1 
displays increased coupling to Gs compared to Gly389;(34) hence Arg389 has greater 
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basal and agonist-stimulated activity.(34) Therefore it has been hypothesized that HF 
patients possessing Arg389 would have a greater response to beta-blockers. With respect 
to ventricular remodeling responses, this has been studied in a series of small HF cohorts.  
Mialet-Perez et al retrospectively studied 224 patients with systolic dysfunction 
receiving carvedilol.(35) They were the first to report that patients who were 
homozygous for Arg389 had a significantly greater improvement in LVEF after treatment 
with beta-blocker than patients who were homozygous for Gly389 (+8.7% ± 1.1% versus 
+0.93% ± 1.7%, respectively; p < 0.02). Patients who were heterozygous at position 389 
had a similar improvement in LVEF compared to Arg389 homozygotes (7.02% ± 1.5%). 
This association was confirmed in three prospective studies totaling 345 patients among a 
variety of etiologies (ischemic and non-ischemic), beta-blockers (metoprolol and 
bisoprolol), and ethnic groups (Caucasian, African-American, and Chinese).(24,28,36) 
However there are also three studies totaling 416 patients that failed to find a significant 
association.(25,37,38) Given that the series of studies investigating LVEF response were 
small, it is difficult to conclude if Arg389Gly is a good predictor of LVEF response to 
beta-blocker. However the positive studies are promising because they are consistent for 
the beneficial variant (Arg389). If the positive findings were purely spurious, one would 
expect spurious findings for the Gly389 variant as well.  
 Liggett, Bristow and colleagues conducted a ground-breaking prospective 
pharmacogenetic sub-study utilizing patients from the Beta-Blocker Evaluation of 
Survival Trial (BEST) study.(39) BEST was a randomized, placebo-controlled trial of the 
investigational novel beta antagonist bucindolol, which found that bucindolol did not 
significantly decrease mortality in HF patients (HR = 0.90; adjusted p = 0.13). However 
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in the pharmacogenetic sub-study of 1040 patients,(14) these investigators found 
response to bucindolol varied by genotype.  Patients homozygous for Arg389 had a 
statistically significant improvement in survival compared to placebo (HR = 0.62; p = 
0.03), whereas Gly389 carriers did not (HR = 0.90; p = 0.57). In contrast, these results do 
not seem to apply to beta-blockers currently used to treat HF. White et al performed a 
pharmacogenetic sub-study (40) consisting of 600 patients from MERIT-HF,(41) a 
randomized, controlled trial for the effectiveness of metoprolol CR/XL in chronic HF. 
They did not find an association of Arg389Gly with the primary outcome of all-cause 
mortality or hospitalization in either the metoprolol CR/XL or placebo treated groups.  
Cresci et al also found no association of Arg389Gly genotype with all-cause mortality in 
a prospective registry of two independently recruited US heart failure populations where 
baseline beta blocker therapy, if utilized, was predominantly metoprolol or carvediolol. 
(13)  These findings are also consistent with the lack of association of Arg389Gly 
genotype with mortality described by Sehnert et al in a prospective registry study of 637 
patients that were all treated with beta-blockers.(42)  Only a small study of 201 HF 
patients with a limited number of events reported by Biolo et al found results consistent 
with Liggett et al, where metoprolol and carvedilol appeared to be more effective at high 
doses in decreasing HF-related mortality in patients carrying the Arg389 allele.(31) 
Although additional study is needed, these discrepant results are most likely related to the 
unique pharmacological properties of bucindolol which include marked suppression of 
the beta-1 receptor activity in patients homozygous for Arg389.  
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Beta-2 adrenergic receptor 
 In HF, chronic adrenergic stimulation causes down-regulation of ADRB1, but not 
the beta-2 adrenergic receptor (ADRB2). This causes a change in the ratio of 
ADRB1:ADRB2 from approximately 80:20 in healthy heart tissue to approximately 
60:40 in the failing heart.(43) Therefore the use of beta-1 selective versus non-selective 
beta-blockers in HF remains a clinical issue. The gene for ADRB2 is localized to 
chromosome 5q31-q32.(44) ADRB2 consists of a single exon of 2015 nucleotides which 
encodes a 413 amino acid protein. There are three variants in ADRB2 that have been 
studied: Gly16Arg, Gln27Glu, and Thr164Ile.  
Beta-2 adrenergic receptor variant: Gly16Arg 
 Although the density of ADRB2 in HF is unchanged compared to ADRB1, 
ADRB2 is subject to desensitization via functional uncoupling from the intracellular G 
protein, Gs.(33) A glycine (Gly) at amino acid position 16 results in increased agonist-
promoted desensitization compared to arginine (Arg).(45) The pharmacogenetic 
interaction between this variant and beta-blockers has not been studied in vitro. However 
it has been hypothesized that because Gly16 allows for greater desensitization of 
ADRB2, HF patients possessing Gly16 have “genetic beta-blockade.” “Genetic beta-
blockade,” or the lack thereof, may interact with exogenously administered beta-blocker.  
Six clinical studies tested the Gly16Arg variant in 738 HF 
patients,(25,26,28,38,46,47) and none found a significant association between Gly16Arg 
and beta-blocker response with respect to beta-blocker tolerability, LVEF, or LVFS. 
Importantly, in three of these studies the patients received beta-1 selective beta-blockers, 
which could have limited the power to detect a pharmacogenetic interaction with 
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ADRB2. Acknowledging this limitation, it seems unlikely that this variant could have a 
clinically meaningful pharmacogenetic interaction with beta-blockers. 
Beta-2 adrenergic receptor variant: Gln27Glu 
 A glutamine (Glu) at amino acid position 27 in ADRB2 is resistant to agonist-
promoted desensitization,(45) and in contrast to Gly16Arg, there is clinical literature to 
support a pharmacogenetic interaction with beta-blockers. Although the pharmacogenetic 
interaction has not been studied in vitro, it has been hypothesized that patients with 
Glu27 will be more responsive to beta-blockers because they have more sensitive 
ADRB2. Indeed, this has been confirmed in three clinical studies evaluating LVEF 
changes. Kaye et al were the first to report this pharmacogenetic interaction in a 
retrospective study of 80 HF patients on at least 4 months of carvedilol.(47) They defined 
good responders as having an increase in LVEF of at least 10%, or an increase in LVFS 
of at least 5%. Patients homozygous for Gln27 had a significantly lower proportion of 
good responders than patients who were carrying Glu27 (26% versus 63%, p = 0.003). 
These findings were confirmed in two prospective studies by Troncoso et al(12) and 
Metra et al,(38) which totaled 216 patients with systolic dysfunction and receiving 
carvedilol. Troncoso et al and Metra et al also found that Glu27 was associated with a 
favorable beta-blocker response in other parameters such as heart rate,(12) 
malondialdehyde levels (a marker of oxidative stress),(12) and pulmonary wedge 
pressure both at rest and peak exercise.(38) There are four studies that did not find a 
significant association between Gln27Glu and ventricular remodeling response to beta-
blockers.(24-26,28) Although the majority of the data still support the pharmacogenetic 
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interaction because the negative studies are small (n < 200) and most included beta-1 
selective beta-blockers. 
Beta-2 adrenergic receptor variant: Thr164Ile 
 An isoleucine (Ile) substitution for threonine (Thr) at amino acid position 164 in 
ADRB2 has profound effects on receptor function in vitro. Ile164 demonstrates a 
substantial decrease in basal and agonist-stimulated activity due to defective coupling of 
the receptor to the stimulatory G protein, Gs.(48) Ile164 also has a lower affinity for beta-
blockers.(48) This is a rare allele (Table 2) so definitive studies are lacking, but Liggett et 
al found suggestive evidence of a counterintuitive adverse association between the 
presence of the Ile164 genotype and poor outcome in HF.(9) This finding, coupled with 
the observation that Ile164 also has a lower affinity for beta-blockers, led to the 
hypothesis that HF patients with Ile164 would be less responsive to beta-blockade.
 
However an exploratory clinical pharmacogenetic study by Littlejohn et al had an even 
more surprising finding.(49) These investigators retrospectively studied the association of 
survival with Ile164 genotype in 443 patients with HF. The Thr164 homozygotes 
demonstrated the expected mortality benefit from an average 3.09 years of beta-blockade 
(55.2% mortality rate without beta-blocker and 39.5% mortality rate with beta-blocker; p 
= 0.004). Only 14 patients were heterozygous for Ile164, and no homozygotes were 
found. Surprisingly, the beta-blocker effect was reversed in patients carrying Ile164. 
There was a 2-fold higher mortality rate in the seven Ile164 heterozygous patients treated 
with beta-blocker (57.1%), compared to the seven Ile164 heterozygous patients not 
treated with beta-blocker (28.6%). This could be due to the excessive impairment of 
cardiac function via the combination of dysfunctional ADRB2 and pharmacologic 
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blockade. The difference in mortality between beta-blocker treated and untreated Ile164 
heterozygous patients was not statistically significant (p = 0.247), but the sample size was 
small. Three other studies failed to find a significant association.(25,26,28)  
Alpha-2C adrenergic receptor  
 The function of the alpha-2C adrenergic receptor (ADRA2C) is pre-synaptic auto-
inhibition of norepinephrine release. The gene is localized to chromosome 4p16.3 - 
p16.3. An insertion/deletion variant in ADRA2C results in a four amino acid loss at 
positions 322-325. The deletion results in the loss of normal auto-inhibitory receptor 
function and hence increased presynaptic release of norepinephrine.(50) Although not 
studied in vitro, it is possible that the deletion is associated with beta-blocker response, 
especially when it is inherited with other genetic variants affecting sympathetic activity. 
For example, HF patients with ADRB1 Arg389 (with increased agonist-promoted 
activity) and the ADRA2C deletion (with increased presynaptic release of 
norepinephrine) could have enhanced beta-adrenergic receptor activity and hence greater 
response to beta-blockade.  
Alpha-2C adrenergic receptor variant: deletion 322-325  
Lobmeyer et al investigated the possible interaction between ADRB1 Arg389, the 
ADRA2C insertion/deletion, and beta-blocker response in 54 HF patients with systolic 
dysfunction.(51) The deletion carriers had an increased improvement in LVEF compared 
to insertion homozygotes (+6% versus +1%; p = 0.045). Synergy between the ADRB1 
and ADRA2C variants was supported by the magnitude of results, in that patients both 
homozygous for Arg389 and a deletion carrier exhibited the greatest LVEF response 
compared to all other genotypes (+12% versus +2% as the greatest change in all other 
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genotypes; p < 0.05 for all comparisons). Nonen et al also investigated ventricular 
changes (LVFS) in response to beta-blocker and ADRA2C status in 80 IDC patients, but 
did not find a significant association.(26) However Nonen et al did not test for synergy 
between ADRB1 Arg389 and the ADRA2C deletion. The discrepancy in results between 
the Lobmeyer et al and Nonen et al studies could be due to population differences. 
Lobmeyer et al studied Caucasians and African-Americans with systolic dysfunction due 
to ischemic and non-ischemic etiologies. Nonen et al studied Japanese patients solely 
with IDC. Whether the influence of ADRA2C on LVEF is population- specific or only 
important when inherited in combination with Arg389Gly variants remains unknown.    
 The complexity of adrenergic regulation through ADRA2C was highlighted in a 
pharmacogenetic sub-study consisting of 1040 patients from BEST(39) by Bristow et 
al.(16) Although Lobmeyer et al found that deletion carriers experienced greater LVEF 
improvement with beta-blocker, Bristow et al found that deletion carriers did not 
experience survival benefit from beta-blockade (HR = 1.09; p = 0.80).(16) However 
Bristow et al found that the insertion homozygous patients experienced survival benefit 
(HR = 0.70; p = 0.025). Importantly, the beta-blocker investigated by Bristow et al was 
bucindolol. Bristow et al previously showed that the marked sympatholysis caused by 
bucindolol results in increased mortality and HF hospitalizations compared to patients 
with little or no sympatholytic response.(52) Indeed, this was the case in deletion-
carriers. In bucindolol-treated patients, a comparison of homozygous ADRA2C insertion 
and deletion carriers revealed that deletion carriers had a 3.1-fold greater reduction in 
norepinephrine (p = 0.001). Marked sympatholysis is unique to bucindolol; therefore it is 
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unclear if the results from Bristow et al can be applied to other beta-blockers, and further 
study is needed. 
G-protein coupled receptor kinase 5 
The function of the G-protein receptor kinases is to desensitize ligand-occupied 
G-protein coupled receptors such as beta-adrenergic receptors.(53) GRK5 is localized to 
chromosome 10q26.11 - q26.11. Liggett and co-workers studied a variant in G-protein 
coupled receptor kinase 5 (GRK5) that changes amino acid 41 from glutamine (Gln) to 
leucine (Leu) both in vitro and in association with outcomes in HF patients. The Leu41 
allele more effectively desensitizes agonist-stimulated responses.(54) Because patients 
with Gln41 have more sensitive beta-adrenergic receptors, Liggett et al hypothesized that 
HF patients with Gln41 would have a greater response to beta-blockade.  
G-protein coupled receptor kinase 5 variant: Gln41Leu 
Liggett et al examined this potential pharmacogenetic interaction both 
retrospectively and prospectively in HF patients.(54) In a case-control study, Liggett et al 
found a significant pharmacogenetic interaction, but only in the African-American sub-
group (n = 242), not in European-Americans (n = 568). They then confirmed these 
findings in a prospective, observational study of a second cohort of 375 African-
Americans with HF, where Liggett et al found that only individuals who were 
homozygous for Gln41 had significantly improved transplant-free survival with beta-
blocker treatment (HR = 0.22; p < 0.001). There was no difference in this outcome in 
patients carrying Leu41 with or without beta-blocker (HR = 0.78; p = 0.53). Cresci et al 
found similar results in a combined cohort of African-American HF patients. (13) In the 
overall cohort, there was a trend for a beta-blocker treatment effect (HR = 0.698; p = 
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0.1). However in a sub-group of ADRB1 Gly389 homozygous/GRK5 Gln41 homozygous 
African-Americans, beta-blockers did provide mortality benefit (HR: 0.385; p = 0.012). 
When these investigators  matched African-Americans and Caucasians by GRK5 
genotype and beta-blocker treatment, survival was similar in the two races. These 
findings must be considered with some caution due to the limited number of events in the 
first prospective cohort, overlapping composition of the study populations, and the 
registry design used in these studies. Whether there are differences in beta-blocker 
treatment effect between Caucasians and African-Americans, has been a subject of 
controversy.(55)  Additional prospective studies are needed, but the work of Liggett and 
co-workers suggests that genetic variation among African-Americans with heart failure 
could help explain the heterogeneous efficacy of beta blockade observed in this racial 
group.  
Angiotensin-converting enzyme 
 The genetic variants discussed to this point are related to the sympathetic 
adrenergic system, but the renin-angiotensin-aldosterone system (RAAS) also contributes 
to worsening of the HF syndrome. ACE plays a critical role in the RAAS, where it 
converts angiotensin I to angiotensin II resulting in downstream effects including sodium 
and water retention and vasoconstriction. The ACE gene is localized to chromosome 
17q23.3 - q23.3, and it comprises 26 exons that are alternately spliced to give two 
isoforms. The predominant isoform contains exons 1-12 and 14-26 and when translated 
results in a 1306 amino acid protein. Since its discovery, a 287 base pair 
insertion/deletion in intron 16 of ACE has been the most studied cardiovascular-relevant 
variant. The ACE insertion/deletion accounts for half of the variance in serum ACE 
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levels,(56) with the deletion allele conferring significantly higher levels. Beta-blockers 
have been shown to decrease RAAS activity in HF,(57) probably via inhibition of 
ADRB1 present in the kidney, where activation leads to release of renin and ultimately 
aldosterone.(58) Because the ACE deletion results in higher RAAS activity, it has been 
hypothesized that HF patients with the ACE deletion would have a greater response to 
beta-blockers.  
Angiotensin-converting enzyme variant: intron 16 insertion/deletion  
 In 2001, McNamara et al were the first to publish this pharmacogenetic 
interaction in a cohort of 328 HF patients followed for a median 21 months.(17) In the 
overall cohort, there was a trend for increased transplant-free survival in patients 
receiving beta-blockers (p = 0.065). However when the ACE insertion/deletion sub-
groups were analyzed individually, only patients homozygous for the deletion had a 
significant improvement in transplant-free survival from beta-blockade (deletion 
homozygous: p = .007; insertion homozygous: p = 0.74; heterozygous: p = 0.59). These 
results were validated in another study published by McNamara et al in 2004,(18) when 
the size of the cohort increased from 328 to 479. de Groote et al also tested this 
pharmacogenetic interaction in 199 HF patients, but did not yield a significant result with 
respect to LVEF, peak VO2, or cardiac survival.(19) However the de Groote et al study 
was smaller (n = 199) than McNamara et al. Therefore based on the results from 
McNamara et al and the profound functional effects of the ACE insertion/deletion, 
further study is needed.  
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ACE inhibitors 
 The majority of pharmacogenetic literature in HF patients has focused on beta-
blockers. Although there have been ten studies from 1998-2010 evaluating 
pharmacogenetic interactions with ACE inhibitors. A summary of the genetic variants 
studied for an association with ACE inhibitor response is presented in Table 3. Like the 
beta-blocker pharmacogenetic literature, the study designs and HF patient populations are 
diverse. The sample sizes were small, with the majority having less than 200 patients, and 
the largest study having 479 patients. Not surprisingly, along with a few other genes in 
the RAAS, ACE was the most commonly studied gene. 
Angiotensin-converting enzyme variant: intron 16 insertion/deletion  
 Because the deletion allele results in significantly higher ACE levels,(56) it has 
been hypothesized that HF patients possessing the deletion will require a higher dose of 
ACE inhibitor to achieve the same response as a patient without a deletion allele. Most of 
the studies investigating intermediate phenotypes such as mean arterial pressure, 
aldosterone escape, and serum ACE activity support this hypothesis.  
 In a small (n = 34), double-blind crossover study of captopril and lisinopril, 
O’Toole et al found that the insertion allele was associated with a greater decrease in 
mean arterial pressure in patients with HF.(59) However this was only found with 
captopril and not lisinopril. It is possible that short- and long-acting ACE inhibitors 
interact with ACE in different ways, with more complete suppression of ACE activity 
with the longer-acting lisinopril. Cicoira et al(60) addressed the clinical issue of 
“aldosterone escape,” in which up to 38% of patients with HF have elevated plasma 
levels of aldosterone despite long-term ACE inhibitor therapy.(4) In a study of 132 
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patients with HF, Cicoira et al prospectively defined aldosterone escape as the presence 
of aldosterone plasma concentrations above the upper limit of the reference range (>42 
nmol/L) after at least 6 months of ACE inhibitor. Thirteen patients had aldosterone 
escape, and there was a significantly higher frequency of the deletion allele in these 
patients compared to those who did not experience aldosterone escape (62% vs. 24%; p = 
0.005). Of those that experienced aldosterone escape, none were homozygous for the 
insertion allele. Tang et al also investigated aldosterone escape in a smaller HF cohort (n 
= 74), but aldosterone escape was not affected by ACE genotype.(61) However Tang et al 
did find that pre-dose and post-dose ACE activity remained consistently higher in 
deletion homozygotes.  
 The relationship between the ACE genotype and the intermediate phenotype of 
LVEF improvement after ACE inhibitor is not clear. Tiago et al tested this interaction in 
107 IDC patients.(62) After 2.5 years of ACE inhibitor therapy, the LVEF improvement 
was similar among ACE genotypes, but there was a high amount of variability in LVEF 
changes (deletion homozygotes LVEF change = 9% ± 13%; insertion carriers = 8% ± 
13%). Cuoco et al prospectively studied 168 patients with systolic dysfuction.(63) 
Deletion carriers responded better to ACE inhibitor with respect to LVEF than insertion 
homozygotes (change in LVEF for deletion carriers = +8.8 %; insertion homozygotes -
1.73%; p = 0.01). Perhaps there are population-specific effects of the ACE 
insertion/deletion on LVEF response. Tiago et al studied IDC patients of African ancestry 
and Cuoco et al studied Brazilian patients with systolic dysfunction due to ischemic and 
non-ischemic etiologies.  
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 The relationship between the ACE variant and survival benefit from ACE 
inhibitors is more clear than the intermediate phenotypes. McNamara et al investigated 
this pharmacogenetic interaction with the clinical endpoint of death or cardiac 
transplantation.(18) This was the largest ACE inhibitor pharmacogenetic study in HF 
patients (n = 479), and investigated the interaction with beta-blockers as well. McNamara 
et al found a dose-dependent relationship between the ACE insertion/deletion and 
transplant-free survival. After a median follow-up of 33 months, patients on low-dose 
ACE inhibitors (≤ 50% of target dose) had poorer transplant-free survival associated with 
the deletion allele, with a relative risk for deletion homozygotes of 2.07 (p = 0.03). This 
was exaggerated in patients who were also not receiving a beta-blocker, with a relative 
risk for deletion homozygotes of 2.75 (p = 0.012). However high-dose ACE inhibitor 
(>50% of target dose), with or without concomitant beta-blocker, eliminated the adverse 
effect of the ACE deletion. Although the deletion allele was associated with poorer 
transplant-free survival, it seemed that deletion homozygotes benefitted the most from 
ACE inhibitor and beta-blocker therapy. For example, beta-blockers only reduced the 
event rate in deletion homozygotes (53%; p = 0.004), but not for patients who were 
heterozygotes (15%; p = 0.46) or insertion homozygotes (3%; p = 0.94).  
 Wu et al investigated this pharmacogenetic interaction to the endpoint of death 
from any cause,(64) and this is the only pharmacogenetic study published exclusively 
analyzing patients with preserved ejection fraction. There was a long follow-up to the 
primary endpoint, in which the median was 8.7 years for the ACE inhibitor-treated group, 
and 6.4 years in the non-ACE inhibitor treated group. Similar to the findings by 
McNamara et al, the deletion allele was associated with all-cause mortality in patients not 
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receiving an ACE inhibitor (HR = 2.23; p = 0.008), but not for patients receiving an ACE 
inhibitor (HR = 1.64; p = 0.20). Acknowledging that the McNamara et al and Wu et al 
studies were performed in observational cohorts in which the patients were not 
randomized to ACE inhibitor treatment, the ACE data seem to indicate that HF patients 
with the deletion allele need to be treated with ACE inhibitors to compensate for the 
increased ACE activity associated with the deletion and also to demonstrate similar 
outcomes compared to patients with the insertion.  
 
Discussion 
The first report of a pharmacogenetic interaction in HF patients was published 13 
years ago.(59) Since then, the work of Liggett, Bristow and colleagues concerning the 
investigational drug bucindolol provides the best evidence yet to support that genetic 
variation can be associated with differential response to HF pharmacotherapy which can 
in turn impact the risk of adverse outcomes.  Unfortunately, the literature as a whole does 
not provide sufficient evidence to guide application of available HF drug therapy based 
on genetic testing.  
There are numerous possible explanations for why initial pharmacogenetic 
associations have failed to be replicated in subsequent studies. Outcome studies are 
particularly problematic in this field as they almost uniformly lack statistical power due 
to insufficient event rates (from small sample size and/or short follow-up). The choice of 
endpoint is also important because studies noted differences in clinical outcome 
endpoints without detecting differences in surrogates like LVEF or heart rate.(14,16) 
Publication bias is a common problem in genetic association literature, in which initial 
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reports of pharmacogenetic associations are false positives due to chance alone or 
exaggerated due to sampling bias.(32) There are still many gaps in investigation in the 
HF pharmacogenetic literature. Many of the genetic candidates described to date are 
common in the population; therefore any given HF patient is likely to possess multiple 
genetic variants, and the consequences of that have not yet been studied. There is some 
evidence, such as in the study by Lobmeyer et al(51), that inheriting two genetic variants 
within the sympathetic adrenergic system has synergistic effects. The literature for ACE 
inhibitors is not nearly as developed for beta-blockers, and the influence of genetic 
variants in patients receiving combination anti-neurohormonal therapy is not clear. In an 
era where the vast majority of HF patients are being treated with combination anti-
neurohormonal therapy, teasing out the complex interplay between dual pharmacologic 
inhibition of the sympathetic adrenergic and renin-angiotensin-aldosterone systems and 
multiple genetic variants within these systems is difficult. To move the field of HF 
pharmacogenetics forward, adequately-powered, prospective HF patient cohorts with 
extensive genotyping and association analyses are needed.  
 Despite the shortcomings of the current state of HF pharmacogenetic literature, 
hypothesis-generating studies suggest a number of promising candidates (ADRB1 
Ser49Gly, the ADRA2C insertion/deletion, and GRK5 Gln41Leu in African-Americans) 
for future genetic tailoring of HF pharmacotherapy, and a potential explanation for 
variable beta-blocker response in African-Americans. The next steps for the potential 
candidate variants are validation in large, independent HF patient cohorts and then 
prospective evaluation of interventions based on genotype. In a syndrome that is as fatal 
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and prevalent as HF, any information that could improve pharmacotherapy decision-
making would have profound patient and public health benefit.    
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Table 1. Genetic variants studied in relation to beta-blocker response in HF patients. 
GENE NAME GENE 
SYMBOL 
VARIANT *rsID MOLECULAR 
PHENOTYPE 
(Reference) 
CLINICAL  
PHENOTYPE  
(Reference) 
Angiotensin-converting 
enzyme 
ACE Ins/Del **rs1799752 Higher serum 
ACE levels with 
Del(56) 
Decreased survival with Del in 
patients without beta-blocker, but no 
influence in patients with beta-
blocker.(17,18) One study found no 
association.(19) 
Adrenergic receptor 
alpha-1D 
ADRA1D T1848A rs2236554 Unknown Greater improvement in LVFS and 
LVDD with 1848A.(26) 
A1905G rs709024 Unknown Greater improvement in LVFS with 
1905G.(26) 
Adrenergic receptor 
alpha-2C 
ADRA2C Ins/Del rs61767072 Enhanced release 
of norepinephrine 
with Del(50) 
Greater LVEF improvement with 
Del.(51) 
Studies found no association with 
LVEF (16,26) and survival.(42) 
Survival benefit in Ins homozygotes 
but not Del carriers.(16)  
Adrenergic receptor 
beta-1 
ADRB1 Ser49Gly rs1801252 Greater agonist-
promoted down-
regulation with 
Gly49(21,22) 
Greater LVEF,(24,36) titration,(46) 
and survival(29,30) response with 
Gly49, but there are several negative 
studies. (14,25,26,28,31,37,42) 
Arg389Gly rs1801253 Greater basal and 
agonist-simulated 
activity with 
Arg389(34) 
Greater 
LVEF,(24,28,35,36,38,51,65) 
titration,(24) and survival 
response(31)(30) with Arg389. 
There are also negative 
(13,25,26,37,40,42,66) and 
conflicting studies(67).  
Adrenergic receptor 
beta-2 
ADRB2 Arg16Gly rs1042713 Increased agonist-
promoted 
desensitization 
with Gly16(45) 
Several negative studies 
(25,26,28,38,42,46,47) 
Gln27Glu rs1042714 Resistance to 
agonist-promoted 
desensitization 
with Glu27(45) 
Greater LVEF,(12,38,47) heart 
rate,(12) and survival response(67) 
with Glu27. There are also negative 
studies.(25,26,28,42,46) 
Thr164Ile rs1800888 Decreased basal 
and agonist-
stimulated activity 
with Ile164(48) 
Decreased survival with Ile164 in 
patients with beta-blocker.(49) There 
are also negative studies.(25,26,28) 
Cytochrome P450 2D6 CYP2D6 EM/IM/PM n/a Extensive, 
intermediate, or 
poor 
metabolism.(68) 
CYP2D6 phenotype was 
significantly associated with dose of 
carvedilol, but not metoprolol.(66) 
There is also a negative study.(46) 
G-protein coupled 
receptor kinase 5 
GRK5 Gln41Leu rs17098707 Increased agonist-
promoted 
desensitization 
with Leu41(54) 
Greater survival response with 
Gln41(13,54) 
Norepinephrine 
transporter 
NET T-182C rs2242446 Potentially affects 
transcription(69) 
Greater improvement in LVFS with  
-182T(26) 
UDP 
glucuronosyltransferase 
1 family polypeptide A1 
UGT1A1 EM/IM/PM n/a Extensive, 
intermediate, or 
poor 
metabolism(70) 
No association with dose of 
carvedilol or metoprolol.(66) 
*The rsID, or reference single nucleotide polymorphisms (SNP) identifier, is a unique 
number for each genetic variant assigned by the National Center for Biotechnology 
Information SNP database.   
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**The ACE insertion/deletion variant has also been assigned the following rsIDs: rs4340, 
rs13447447, and rs4646994. 
 
Arg = arginine, EM/IM/PM = extensive/intermediate/poor metabolizer, Gln = glutamine, 
Glu = glutamic acid, Gly = glycine, Ile = isoleucine, Ins/Del = insertion/deletion, LVEF = 
left ventricular ejection fraction, LVFS = left ventricular fractional shortening, LVDD = 
left ventricular diastolic diameter, Ser = serine, Thr = threonine  
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Table 2. Minor allele frequencies of the most commonly studied genetic variants in the 
beta-blocker and ACE inhibitor HF pharmacogenetic literature  
Gene name Gene 
symbol 
*rsID Variant  Minor 
Allele 
Caucasian 
(Reference) 
African-
American 
(Reference)  
Angiotensin-
converting 
enzyme 
ACE **rs1799752 
 
Ins/Del Ins 
 
44% (71) 43% (71) 
Adrenergic 
receptor alpha-
2C 
ADRA2C rs61767072 Ins/Del 
 
Del 
 
4% (16) 43% (16) 
Adrenergic 
receptor beta-1 
ADRB1 rs1801252 Ser49Gly 
 
Gly 
 
17% (30) 25% (72) 
rs1801253 Arg389Gly 
 
Gly 
 
27% (14) 38% (14) 
Adrenergic 
receptor beta-2 
ADRB2 rs1042713 Gly16Arg 
 
Arg 
 
40% (73) 50% (73) 
(Africans) 
rs1042714 Gln27Glu 
 
Glu 
 
42% (25) 20% (71) 
rs1800888 Thr164Ile  Ile 2% (25) <2% (73) 
(Africans) 
G-protein 
coupled 
receptor kinase 
5 
GRK5 rs17098707 Gln41Leu 
 
Leu 
 
2% (54) 24% (54) 
  
*The rsID, or reference single nucleotide variant (SNP) identifier, is a unique number for 
each genetic variant assigned by the National Center for Biotechnology Information SNP 
database.   
 
**The ACE insertion/deletion variant has also been assigned the following rsIDs: rs4340,  
rs13447447, and rs4646994. 
 
Arg = arginine, Gln = glutamine, Glu = glutamic acid, Gly = glycine, Ile = isoleucine, 
Ins/Del = insertion/deletion, Leu = leucine, Ser = serine, Thr = threonine  
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Table 3. Genetic variants studied in relation to ACE inhibitor response in HF patients.  
variants studied in relation to beta-blocker response in HF patients. 
GENE NAME GENE 
SYMBOL 
VARIANT *rsID MOLECULAR 
PHENOTYPE 
(References) 
CLINICAL  
PHENOTYPE  
(References) 
Angiotensin-
converting 
enzyme 
ACE Ins/Del **rs1799752 Higher serum ACE 
levels with Del(56)  
Greater reduction in 
mean arterial 
pressure with 
Ins,(59) higher 
frequency of 
aldosterone escape 
with Del,(60) higher 
serum ACE activity 
pre- and post-dose 
with Del (61), 
greater improvement 
in LVEF with 
Del,(63) poorer 
survival with Del in 
low-dose or non-
ACE inhibitor 
treated 
patients.(18,64) 
Also a negative 
LVEF study.(62)  
Adrenergic 
receptor beta-1 
ADRB1 Arg389Gly rs1801253 Greater basal and 
agonist-simulated 
activity with 
Arg389(34) 
No association with 
LVEF.(74) 
Adrenergic 
receptor beta-2 
ADRB2 Arg16Gly rs1042713 Increased agonist-
promoted 
desensitization with 
Gly16(45) 
No association with 
LVEF.(75) 
Gln27Glu rs1042714 Resistance to 
agonist-promoted 
desensitization with 
Glu27(45) 
No association with 
LVEF.(75) 
Angiotensinogen AGT M235T rs699 Higher plasma 
angiotensinogen 
levels with 
235T(76,77)  
No association with 
LVEF(62) or 
survival.(64)  
Angiotensin II 
receptor type 1 
AGTR1 A1166C rs5186 Greater 
responsiveness(78) 
and sensitivity(79) 
to angiotensin II 
with 1166C 
Increased all-cause 
mortality regardless 
of ACE inhibitor 
treatment with 
1166C.(64)  
Cytochrome 
P450 family 11 
subfamily B 
polypeptide 2 
CYP11B2 C-344T rs1799998 Increased 
aldosterone 
production with 
 -344C(80) 
Greater 
improvement in 
LVEF with -344C. 
(62) 
Tumor necrosis 
factor alpha 
TNF-α G-308A n/a Increased 
transcription with -
308A(81) 
No association with 
LVEF.(82) 
233 
 
 
*The rsID, or reference single nucleotide variant (SNP) identifier, is a unique number for 
each genetic variant assigned by the National Center for Biotechnology Information SNP 
database.   
 
**The ACE insertion/deletion variant has also been assigned the following rsIDs: rs4340,  
rs13447447, and rs4646994. 
 
Arg = arginine, Gln = glutamine, Glu = glutamic acid, Gly = glycine, Ins/Del = 
insertion/deletion, LVEF = left ventricular ejection fraction 
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Abstract 
 
The individual patient responses to chronic heart failure (HF) pharmacotherapies are 
highly variable. This variability cannot be entirely explained by clinical characteristics, 
and genetic variation may play a role. Therefore, this review will summarize the 
background pharmacogenetic literature for major HF pharmacotherapy classes (ie, β-
blockers, angiotensin-converting enzyme inhibitors, digoxin, and loop diuretics), evaluate 
recent advances in the HF pharmacogenetic literature in the context of previous findings, 
and discuss the challenges and conclusions for HF pharmacogenetic data and its clinical 
application.  
 
Keywords Pharmacogenetics; Pharmacogenomics; Personalized medicine; Heart failure; 
Polymorphism; Beta-blocker; Angiotensin-converting enzyme inhibitor; Angiotensin 
receptor blocker; Aldosterone antagonist; Loop diuretic; Digoxin; Hydralazine isosorbide 
dinitrate  
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Introduction 
 
Large clinical trials demonstrate, on average, that pharmacotherapy significantly 
decreases morbidity and/or mortality due to heart failure (HF). However, the individual 
patient responses to HF pharmacotherapies are highly variable. For example, long-term 
treatment with angiotensin-converting enzyme (ACE) inhibitors fails to suppress 
angiotensin II in as many as 15% of HF patients, and aldosterone in 38% (1). Long-term 
optimal dosing of β-blockers fails to improve left ventricular ejection fraction (LVEF) 
over 5% in as many as 43% of HF patients (2). The maintenance dose of loop diuretics 
can range from no diuretic at all to over 400–mg furosemide equivalents (3). Even when 
dosed according to age, sex, weight, renal function, and concomitant pharmacotherapy, 
the serum concentration of digoxin can range from 0.5 ng/mL to over 2.0 ng/mL (4). 
This wide variability in response to HF pharmacotherapies is not entirely 
explained by clinical characteristics, which is evident in large clinical trials where there is 
a similar response among most clinical subgroups (5, 6). Genetic variation may 
additionally contribute to differences in drug response, the study of which is referred to 
as “pharmacogenetics” or “pharmacogenomics” (7). Pharmacogenetics has proven 
successful in other therapeutic areas (8), but whether it can be used to improve the 
application of pharmacotherapies for HF remains unproven. Therefore, this review will 
summarize the background pharmacogenetic literature for major classes of HF 
pharmacotherapy, critically evaluate the most current HF pharmacogenetic literature in 
this context, and discuss the conclusions and remaining challenges to clinical application 
of pharmacogenetics in HF. 
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 β-Blocker Pharmacogenetics: Background (Literature Before 2010) 
 
HF pharmacogenetic studies have focused on β-blockers (BBs) much more than any other 
class of HF pharmacotherapy. Between 2000 and 2009, 25 studies were published. Much 
BB pharmacogenetic data comes from small (n < 400) observational cohorts of HF 
patients with systolic dysfunction. These studies are heterogeneous in many aspects (eg, 
design, size, end point, patient population, specific BB, and the genetic variants tested), 
making definitive conclusions difficult. A list of genetic variants associated with BB (and 
other HF pharmacotherapies) response is displayed in Table 1, and the major findings are 
discussed herein.  
 
Type 1 β-Adrenergic Receptor  
 
Stimulation of the cardiac β-adrenergic receptors results in increased heart rate and 
contractility. The type 1 β-adrenergic receptor (protein ADRB1; gene ADRB1) is the 
primary target of cardiac BBs and has been the focus of most BB pharmacogenetic 
literature. A nonsynonymous variant in this gene, Arg389Gly, has been the most-studied 
(Table 1). This variant is common in the general population, with differences in its 
frequency among the races (Table 2). Functionally, Arg389 has greater basal and agonist-
stimulated activity compared to Gly389 (9). Because Gly389 generally results in less 
ADRB1 sympathetic stimulation, it raises the question of whether this variant is 
protective in BB-naïve HF patients, and whether patients with Arg389 would receive 
greater benefit from BBs.  
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Consistent in the literature, patients possessing the Arg allele have greater LVEF 
improvement in response to BBs than those possessing Gly389. This comes from several 
prospective and retrospective studies totaling 569 patients with a variety of HF etiologies, 
ethnicities, and BBs (10–13). There is also evidence to support the influence of 
Arg389Gly on the survival benefit from BBs. The most convincing is a large (n = 1040) 
pharmacogenetic substudy (14) of the Beta-Blocker Evaluation of Survival Trial (BEST) 
(15). Patients homozygous for Arg389 had a statistically significant improvement in 
survival with bucindolol compared to placebo (HR 0.62; P = 0.03), whereas Gly389 
carriers did not (HR 0.90; P = 0.57). It is argued whether the results for bucindolol can be 
applied to other BBs because of its unique pharmacologic properties (16). While these 
results were replicated in a prospective observational study of 201 HF patients treated 
with metoprolol or carvedilol (17), other larger cohort studies have not found this 
association (18). A pharmacogenetic substudy of the Metoprolol CR/XL Randomized 
Intervention Trial in Congestive Heart Failure (MERIT-HF) (5) also did not find an 
association of Arg389Gly with survival benefit regardless of treatment (metoprolol 
CR/XL or placebo) (19). However, this last study did not test BB effect within genotype 
groups (as was done in BEST), which may help explain the discordant results.   
  
Type 2 β-Adrenergic Receptor 
 
Although not the primary target of BBs, the type 2 β-adrenergic receptor (protein 
ADRB2; gene ADRB2) is present in myocardium, can mediate inotropic response, and 
while ADRB1 is downregulated, the expression of ADRB2 is unchanged in the failing 
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heart (20). The most-studied variant in ADRB2 is Gln27Glu. Functionally, Glu27-
containing ADRB2 is resistant to agonist-promoted desensitization compared to Gln27 
(21, 22). This suggests that Gln27 genotype is associated with less sympathetic output 
relative to Glu27, but the clinical pharmacogenetic literature is inconsistent. Several 
small studies showed a favorable LVEF response for patients carrying Glu27 compared 
to patients homozygous for Gln27 (23–25). However, four other small studies failed to 
show a significant association (11, 12, 26, 27), although these included β1-selective BBs, 
which may limit the ability to detect an interaction with ADRB2 variants. In terms of 
survival benefit, one study showed a survival difference by genotype among BB-treated 
HF patients (28), but several large cohort studies have not demonstrated an association 
(18, 26, 29). Notably, most patients in these studies were treated with BBs, limiting the 
ability to examine true pharmacogenetic interactions. 
 
Adrenergic Receptor α-2C   
 
The α-2C adrenergic receptor is presynaptic (protein ADRA2C; gene ADRA2C), auto-
inhibiting norepinephrine release. A deletion variant in ADRA2C, causing a loss of amino 
acids 322 to 325, results in the loss of normal auto-inhibitory function and increased 
norepinephrine (30). A potential interaction between ADRB1 Arg389, the ADRA2C 
deletion, and BB response was prospectively studied in 54 HF patients with systolic 
dysfunction (31). The deletion carriers had a greater improvement in LVEF compared to 
insertion homozygotes (+6% vs +1%; P = 0.045). Synergy between the ADRB1 and 
ADRA2C variants was supported by the magnitude of results. No association was found 
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in 80 patients with idiopathic dilated cardiomyopathy (27), but synergy with ADRB1 
Arg389 was not tested.  
 
G Protein–Coupled Receptor Kinase 5  
 
The function of the G-protein receptor kinases (GRK) is to desensitize ligand-occupied G 
protein–coupled receptors such as β-adrenergic receptors (32). GRK5 is abundant in the 
heart and a Gln41Leu variant in this gene has been studied in vitro, with the Leu41 
version more effectively desensitizing agonist-stimulated responses compared to Gln41 
(33). Because the Gln41 subtype should have more active β-adrenergic receptors, it has 
been proposed that Leu41 is protective in BB-naïve HF patients, but these patients may 
be less responsive to BB. 
 In an observational study of 375 African-Americans with HF, only patients 
homozygous for Gln41 had significantly improved transplant-free survival with BB (HR 
0.22; P < 0.001) (33). There was no difference in outcome for patients carrying Leu41 
with or without BB (HR 0.78; P = 0.53). Similar results were found in another study 
featuring 711 African-American HF patients (34). Among all of the African-American 
patients, the BB treatment effect did not reach statistical significance (HR 0.698; P = 
0.1). However in a genetic subgroup of ADRB1 Gly389 homozygous/GRK5 Gln41 
homozygous African-Americans, BBs were associated with marked mortality benefit 
(HR 0.385; P = 0.012). Interestingly, when the African-Americans and Caucasians were 
matched by ADRB1 and GRK5 genotypes and BB treatment, their survival times were 
similar. This suggests that genetic variants, rather than race, are the major factor 
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contributing to the apparent differences in BB treatment effect between Caucasians and 
African-Americans.  
 
Β-Blocker Pharmacogenetics: Recent Advances (Publication Year 2010 or Later) 
 
As evidenced by the heterogeneous and observational nature of the background HF BB 
pharmacogenetic literature, this field is still in an early stage. The four most recent HF 
BB pharmacogenetic studies support previous insights, but they also demonstrate some 
unexpected results. 
 A small but intriguing study in 93 HF patients (35) studied a panel of both 
pharmacokinetic and pharmacodynamic genetic variants relevant to BBs (ADRB1 
[Arg389Gly], CYP2D6, and UGT1A1) and assessed them using a multidimensional BB 
response criteria. CYP2D6 and UGT1A1 are highly polymorphic metabolic enzymes for 
which carvedilol is a substrate, and metoprolol is mainly metabolized by CYP2D6. They 
defined BB response as meeting at least three out of five criteria: 1) duration and 2) 
tolerability of dose titration, 3) an increase in New York Heart Association functional 
class, 4) LVEF, or 5) 6-minute walk distance. There was no association between the 
panel of genetic variants and their BB response criterion, but there was a weak 
relationship between carvedilol dose and Arg389Gly status (P = 0.012). Gly389 patients 
reached higher doses, perhaps indicating greater BB responsiveness in those with 
Arg389. 
A recent prospective study of 183 patients with HF and three previously studied 
genetic variants (ADRB1 [Arg389Gly] and ADRB2 [Arg16Gly and Gln27Glu]) (25) had 
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findings consistent with the background BB pharmacogenetic literature. The increase in 
LVEF after carvedilol tended to be greater in ADRB1 Arg389 homozygous (+7.8 ± 7.6%) 
and heterozygous patients (+9.0 ± 11.4%) compared to those homozygous for Gly389 
(+4.1 ± 7.6%; P = 0.0847). Patients homozygous for ADRB2 Glu27 showed a greater 
increase in the LVEF (+13.0 ± 12.2%), compared to both heterozygous (+7.1 ± 8.1%) 
and Gln27 homozygous patients (+8.3 ± 11.4%; P = 0.022). In multivariable analysis, 
cause of HF, systolic blood pressure, dose of carvedilol, and Gln27Glu genotype were 
significant correlates of LVEF improvement after carvedilol treatment. Notably, the 
ADRB1 Arg389Gly genotype was not independently informative in this dataset. 
The ADRA2C insertion/deletion was tested in the genetic substudy of BEST (n = 
1040) (36•). In contrast to previous data, which indicated that the ADRA2C deletion was 
associated with improved LVEF response after BB, this large and adequately powered 
study found no differential effect on LVEF by ADRA2C genotype. Interestingly, 
interaction with ADRB1 Arg389Gly was not tested. Even more surprising was that this 
study found that the insertion allele, and not the deletion, was associated with enhanced 
survival benefit from BB. For the all-cause mortality end point, bucindolol produced a 
strong tendency toward significance (P = 0.025) for a reduction in mortality by 30% in 
the insertion homozygotes, while there was a nonsignificant (P = 0.79) 9% increase in 
mortality in the bucindolol-treated deletion carriers. There are several possible 
explanations for the discrepancy in results; the previous small studies could be false-
positive associations, or this could be a bucindolol-specific interaction. 
A recent retrospective study of 586 HF patients examined differential 
pharmacogenetic interactions between carvedilol and metoprolol (37). The investigators 
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combined two genotypes, ADRB1 Arg389-homozygous and ADRB2 Gln27-carrier, and 
compared these patients to all others in terms of time-to-death from any cause. They 
found a significant interaction between genotype group and carvedilol treatment (P = 
0.003), but no interaction with metoprolol (P = 0.61). In patients treated with carvedilol, 
survival was lower for Arg389/Gln27 group than the remaining patients (HR 2.30). 
Because two different variants defined these groups and the fact that one is associated 
with favorable BB response while the other is not, these results are difficult to put in 
context of the existing literature. Another concern is that there may have been negative 
results for metoprolol because the genotype groups were partly defined by an ADRB2 
genotype, and metoprolol is β1-specific.  
Overall these more recent results, like the preexisting BB pharmacogenetic 
literature, are provocative but require validation in large, prospective clinical trials of 
genetic-guided BB therapy. There is sufficient evidence to support this approach for 
bucindolol, as well as the currently approved agents such as metoprolol and carvedilol, 
and this represents the most pressing challenge for BB pharmacogenetics in HF. Other 
areas that remain unclear are whether additional yet unidentified genes should be the 
focus of future research, whether other genes are relevant to BB effectiveness, and the 
interaction of race with genetics. The current candidate gene list revolves strictly around 
the receptor, and whether other genetic loci may directly modify response or interact with 
the current candidates is unknown. As pointed out above, all of the current candidate 
variants have frequencies that differ significantly by ancestry (Table 2), which raises the 
issue of both genetic and nongenetic confounding factors. Therefore, additional 
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investigation is required for confidence in these associations and the potential application 
to non-Caucasian populations. 
 
Angiotensin-converting Enzyme Inhibitor Pharmacogenetics: Background 
(Literature before 2010) 
 
Our extensive searches reveal only six pharmacogenetic studies of ACE inhibitors in HF 
patients from 1998 to 2008. Like the BB literature, most of the ACE inhibitor 
pharmacogenetic literature in HF patients comes from small observational studies (n < 
200) that are heterogeneous in design. Not surprisingly, the literature has focused on the 
gene encoding the target of these agents, ACE. A 287–base pair insertion/deletion in 
intron 16 of ACE accounts for half of the variance in serum ACE levels (38). The 
deletion results in significantly higher ACE levels (38); therefore, it was postulated that 
HF patients possessing the deletion would require a higher dose of ACE inhibitor to 
achieve the same inhibition. Most of the clinical pharmacogenetic studies are consistent 
with the functional effects, with respect to mean arterial pressure (39), aldosterone escape 
(40), serum ACE activity (41), and survival (42), but the association with LVEF is less 
clear (43, 44). 
In 107 patients with idiopathic dilated cardiomyopathy receiving 2.5 years of 
ACE inhibitor therapy (43), the LVEF improvement was similar among ACE genotypes, 
but another study of 168 HF patients with systolic dysfunction (44) found that deletion 
carriers had a greater LVEF improvement after ACE inhibitor (deletion carriers: LVEF 
+8.8 %; insertion homozygotes: −1.73%; P = 0.01). The discordance in results may be 
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due to population-specific effects. In contrast, the relationship between the ACE variant 
and survival benefit from ACE inhibitors appears more clear based on the largest ACE 
inhibitor pharmacogenetic study in HF patients (n = 479) (42). There was a dose-
dependent relationship between the ACE insertion/deletion and transplant-free survival. 
After a median follow-up of 33 months, patients on low-dose ACE inhibitors (≤ 50% of 
target dose) had poorer transplant-free survival associated with the deletion allele (RR for 
deletion homozygotes: 2.07; P = 0.03), and this was exaggerated in patients who were 
also not receiving a BB. However high-dose ACE inhibitor (> 50% of target dose), with 
or without concomitant BB, eliminated the adverse effect of the ACE deletion. Although 
the deletion was associated with poorer transplant-free survival, it seemed that deletion 
homozygotes benefitted the most from ACE inhibitor and BB therapy.  
 
Angiotensin-converting Enzyme Inhibitor Pharmacogenetics: Recent Advances 
(Publication Year 2010 or Later) 
 
There is little ACE inhibitor pharmacogenetic literature recently, with only one study 
published (45) within the past 2 years. This study is consistent with the previous findings 
on survival, and extends this to HF patients with preserved LVEF. This study enrolled 
285 HF patients followed for about 7 years for all-cause mortality (45). The deletion 
allele was associated with higher mortality in patients not receiving an ACE inhibitor 
(HR 2.23; P = 0.008), but this impact was reduced among patients receiving an ACE 
inhibitor (HR 1.64; P = 0.20). Acknowledging the limitation that the ACE 
pharmacogenetic literature comes entirely from observational cohorts, the sum of these 
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data suggest that HF patients that are deletion carriers may need higher dose ACE 
inhibition to achieve similar outcomes compared to insertion homozygotes. While at this 
point it seems unlikely that renewed interest will come to ACE inhibitor 
pharmacogenetics, a variety of intriguing points remain, such as whether other genes are 
important, whether adverse events (eg, angioedema and hyperkalemia) can be predicted 
based on genetics, or whether genetics can help guide combinations of therapies (eg, BB 
+ ACE inhibition vs BB alone vs ACE inhibition alone). 
 
Pharmacogenetics of Loop Diuretics: Background (Literature before 2010)  
 
There have been six studies investigating the association between genetic variation and 
loop diuretic response published from 2004 to 2008. Five of the studies were performed 
in healthy volunteers (HV), and one small study included patients with HF. Collectively, 
these studies demonstrated that genetic variants involved in the metabolism (CYP2C9), 
uptake (SLC22A11 and SLCO1B1), and action (SLC12A3, SCNN1B, and SCNN1G) of the 
loop diuretics can influence their pharmacokinetics and pharmacodynamics. 
 In 10-mg torsemide single-dose HV studies, the decreased function CYP2C9*3 
allele had significant effects on torsemide pharmacokinetics and modest effects on 
pharmacodynamics (46). The total oral clearance of torsemide was about threefold lower 
in CYP2C9 *3/*3 patients compared to *1/*1 patients. Sodium and chloride excretion 
were about 25% higher in carriers of one CYP2C9*3 allele after torsemide administration 
(46). HVs homozygous for the two most frequent haplotypes of SLC22A11 (gene 
encoding the organic anion transporter 4 [OAT4]) had an 80% difference in the renal 
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clearance of torsemide (47), and HVs homozygous for 521T, and heterozygous and 
homozygous for 521C in SLCO1B1 (gene encoding the organic anion transporting 
polypeptide 1B1 [OATP1B1]) had torsemide oral clearances estimated as 62, 46, and 41 
mL/min, respectively (P < 0.001) (48). Taken together, variants in CYP2C9 and the genes 
forOATP1B1, OAT1, and OAT4 explain nearly 50% of torsemide pharmacokinetic 
variation (49).  
Three renal sodium reuptake transporters are the primary targets of the loop 
diuretics: NKCC2 (gene SLC12A1), NCC (gene SLC12A3), and ENaC (genes SCNN1A, 
SCNN1B, and SCNN1G) (50). A three-period crossover study was performed in 97 HVs 
using single oral doses of bumetanide (2 mg), furosemide (80 mg), and torsemide (10 
mg) to evaluate the influence of variation in these on diuretic response (50). There were 
three significant associations with the 24-hour excretion, and this was consistent among 
the three loop diuretics: 1) patients  homozygous for Ala264 in SLC12A3 excreted an 
average 32% more chloride and 42% more potassium compared to those homozygous for 
Gly264; 2) patients homozygous for the most frequent haplotype in SCNN1B excreted 
24% more volume, 13% more sodium, and 13% more chloride compared to patients 
without the most frequent haplotype; and 3) patients homozygous for G4 at a 
synonymous C4G substitution in SCNN1G excreted 23% less volume and 24% less 
calcium compared to patients homozygous for the C4 allele. 
The loop diuretic pharmacogenetic data discussed to this point involve single-
dose studies performed in HVs, but the data in HF patients receiving steady-state dosing 
appear consistent with the HVs. In a small, open-label, pharmacokinetic study of 24 
patients receiving stable doses of 10-mg daily torsemide (n = 18 with arterial 
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hypertension and n = 6 with HF) (51), the primary end point was area under the plasma 
concentration-time curve during the 24-hour dosing interval at steady state (AUC24,ss). 
CYP2C9 genotype, SLCO1B1 genotype, and sex independently predicted AUC24,ss. 
Similar to HVs, HF patients with the CYP2C9 *1/*3 genotype had a mean AUC24,ss 46% 
greater than those with the *1/*1. Patients heterozygous for T521C in SLCO1B1 had a 
38% increase in AUC24,ss compared to patients homozygous for 521T (no 521C 
homozygotes found).  
  
Pharmacogenetics of Loop Diuretics: Recent Advances (Publication Year 2010 or 
Later) 
 
Despite the interesting associations above, whether these differences in pharmacokinetic 
parameters across genotypes translate into clinically meaningful differences in drug 
effectiveness in patients with HF remains unknown. One recent study attempted to 
answer this question. This was a randomized, single-blind, three-arm, triple-crossover 
study in 95 HVs (52) who received a single oral dose of bumetanide (2 mg), furosemide 
(80 mg), and torsemide (10 mg) at 2-week intervals. Together, eight genetic variants had 
an impact of 20%, 15%, 10%, and 23% on the variation in the urinary excretion of 
sodium, volume, potassium, and calcium. Thus, genetic variation seems to importantly 
impact not only pharmacokinetics of loop diuretics but also their clinical effect. The 
incorporation of genetic data may help in determining diuretic dosing, though the clinical 
situation where this would be necessary is not obvious. Important questions that remain 
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to be addressed are whether genetic variation can predict worsening renal function 
associated with chronic diuretic therapy, or even the risk of recurrent hospitalization. 
 
Digoxin Pharmacogenetics: Background (Literature before 2010)  
 
Digoxin is a narrow therapeutic index drug, with recommended serum digoxin 
concentration (SDC) being 0.7 to 0.9 ng/mL (53). The pharmacokinetics, and therefore 
SDC, may be affected by genetic variation. Indeed, a study in monozygotic and dizygotic 
twins estimated the genetic component contributing to digoxin AUC0-12 to be 89% (54). 
The seminal paper investigating the influence of genetic variation on digoxin 
pharmacokinetics was published in 2000 (55), and it has been followed by 12 more 
studies with inconsistent results. 
Most of the digoxin pharmacogenetic literature has focused on a common 
C3435T variant in ABCB1 (Table 2). ABCB1 encodes for P-glycoprotein (P-gp), an efflux 
protein for which digoxin is a substrate. In the seminal paper, patients homozygous for 
3435T (n = 5) had over twofold lower expression of P-gp in the duodenum compared to 
patients homozygous for 3435C (n = 6; P = 0.056). As would be expected, patients 
homozygous for 3435T had 38% higher SDC than patients homozygous for 3435C (P = 
0.006). Acknowledging this small sample size, these results have been consistent with six 
subsequent studies in HVs (56–61), as well as a population-based study of 195 “digoxin-
users” (HF status not reported) (62). Despite this seemingly consistent line of evidence, 
some contrasting data has arisen. Another study of 39 HF patients found no difference in 
steady-state SDC among C3435T genotypes, which was consistent with another study in 
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50 HVs (63) as well as a meta-analysis (64). Unfortunately, this small HF study did not 
control for differences in renal function, which can vary widely among patients with HF.   
Overall, the preponderance of evidence favors an impact of genetic variation on 
digoxin pharmacokinetics. Despite this, whether the difference in digoxin 
pharmacokinetics by C3435T genotypes is clinically meaningful in patients with HF is 
not established. Adding to this complexity is that the association of the C3435T genotype 
with digoxin pharmacokinetics may depend on ethnicity. Two studies in Japanese 
patients found a reverse association, in which the 3435C genotype had higher SDC (65, 
66). 
 
Digoxin Pharmacogenetics: Recent Advances (Publication Year 2010 or Later)  
 
Only a single study, with a unique postmortem SDC design (n = 112), was identified in 
our searches regarding digoxin pharmacogenetics in the past 2 years. This study’s results 
are consistent with the notion that ABCB1 3435T confers higher SDC (67), but adds to 
the existing data by suggesting that the interactions with C3435T may be sex-specific. 
There was a relationship between the frequency of 3435T allele and postmortem SDC, 
but surprisingly, the results were driven by females. If true, this relationship could help 
explain previous data demonstrating higher mortality in women treated with digoxin 
versus placebo due to differences in SDC between women and men (68). Validation of 
this finding in adequately sized, prospective, sex-specific cohorts is needed. If validated, 
one could envision using genotype to identify patients at higher risk of toxicity who 
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should not receive digoxin, receive reduced dosing, or receive more intense drug-level 
monitoring.  
 
Conclusions 
 
While there are many gaps in the HF pharmacogenetic knowledge base, limiting its 
current clinical application, we have already learned a great deal from the relatively 
modest body of HF pharmacogenetic literature. For example, while genetic variant 
functional/mechanistic effects need to be demonstrated to truly establish causation, this is 
not sufficient as these associations do not always translate into clinical effects. Another 
important insight is that there can be synergy or interaction between multiple genetic 
variants, as is the case for ADRB1 Arg389Gly and ADRA2C insertion/deletion with 
LVEF response to BBs. Even more daunting is the complexity and specificity of some 
pharmacogenetic associations. HF pharmacogenetic associations may be race-specific 
(eg, GRK5 Gln41Leu and BB response in African-Americans), dose-specific (eg, ACE 
insertion/deletion and low- and high-dose ACE inhibitors), sex-specific (eg, ABCB1 
C3435T and SDC in women), and drug-specific (eg, ADRB1/ADRB2 and response to 
carvedilol but not metoprolol).  
Despite the fact that pharmacogenetics has been in existence for decades, the 
number of studies on HF therapies are still relatively small and we are yet in the early 
stages of this part of the field. This foundation has yielded the important insights above 
and also provided numerous improvements in approach both in terms of genotyping and 
analysis. This has set the stage for accelerated advances moving forward. At this point, 
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some of the key knowledge gaps include 1) lack of foundational pharmacogenetic data 
regarding angiotensin-receptor blockers, aldosterone antagonists, and 
hydralazine/isosorbide dinitrate; 2) investigation into acute or intravenous HF 
pharmacotherapies; and 3) better understanding of multi-variant/multi-drug combinations 
on pharmacogenetics. Most importantly, what are broadly needed to make real progress 
are prospective intervention clinical trials where a genetic-guided approach is compared 
to empiric therapy. These are required to validate proposed associations and establish that 
a specific response to the genetic information can improve treatment outcomes. Because 
HF is a fatal and common disease requiring polypharmacy, any information (even 
genetic) that could improve HF pharmacotherapies would give profound patient and 
public health benefit. 
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Table 1 Genetic variants associated with HF pharmacotherapy response  
Gene Variant rsID Beneficial allele Study 
β-Blockers 
ACE Ins/Del rs1799752 Del (42, 69) 
ADRA1D T1848A rs2236554 A (27)  
A1905G rs709024 G (27) 
ADRA2C Ins/Del rs61767072 Ins (36) 
Del (31) 
ADRB1 Ser49Gly rs1801252 Gly (11, 13, 70–72) 
Arg389Gly rs1801253 Arg (2, 10, 11, 13, 14, 
17, 25, 31, 35, 37, 
71–73)  
Gly (37) 
ADRB2 Gln27Glu rs1042714 Glu (23–25, 37) 
Thr164Ile rs1800888 Thr (74) 
EDN1 G/A (IVS)-4 rs2071942 G (75) 
Lys198Asn rs5370 Lys (75) 
GRK5 Gln41Leu rs17098707 Gln (33, 34) 
NET T-182C rs2242446 T (27) 
ACE inhibitors 
ACE Ins/Del rs1799752 Ins (39–42, 45) 
AGTR1 A1166C rs5186 A (45) 
CYP11B2 T-344C rs1799998 C (43) 
Aldosterone antagonists 
ACE Ins/Del rs1799752 Ins (76) 
Angiotensin-receptor blockers 
AGTR1 A1166C rs5186 C (77) 
Hydralazine/isosorbide dinitrate 
CYP11B2 T-344C rs1799998 C (78) 
NOS3 Glu298Asp rs1799983 Glu (79) 
Loop diuretics
a
 
ACE Ins/Del rs1799752 Del (52) 
ADD1 Gly460Trp rs4961 Trp (52) 
ANP Val32Met rs5063 Val (52) 
Ter152Arg rs5065 Arg (52) 
CYP2C9 CYP2C9*1/*2/*3 n/a *3 (46) 
GNB3 C825T rs5443 C (52) 
SCNN1B Most frequent 
haplotype vs others 
N/A Most frequent 
haplotype 
(50) 
SCNN1G C4G rs5723 C (50) 
SLC12A3 Gly264Ala rs1529927 Ala (50) 
a. Data from healthy volunteers 
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ACE/ACE—angiotensin-converting enzyme; ADD1—α-adducin 1; ADRA1D—α-1d 
adrenergic receptor; ADRA2C—α-2c adrenergic receptor; ADRB1—β-1 adrenergic 
receptor; ADRB2—β-2 adrenergic receptor; AGTR1—angiotensin II receptor type 1; 
Arg—arginine; ANP—atrial natriuretic peptide precursor; Asn— asparagine; 
CYP11B2— cytochrome P450, family 11, subfamily B, polypeptide 2; CYP2C9—
cytochrome P450, family 2, subfamily C, polypeptide 9; Del—deletion; EDN1—
endothelin-1; Gln—glutamine; Glu—glutamic acid; Gly—glycine; GNB3—guanine 
nucleotide binding protein-β polypeptide 3; GRK5—G-protein coupled receptor kinase 5; 
HF—heart failure; Ile— isoleucine; Ins—insertion; IVS—intervening sequence; Leu—
leucine; Lys—lysine; Met—methionine; N/A—not available; NET—norepinephrine 
transporter; NOS3—nitric oxide synthase 3; rsID—Reference Sequence Identification; 
SCNN1B—sodium channel non–voltage-gated 1-β; SCNN1G—sodium channel non–
voltage-gated 1-γ; Ser—serine; SLC12A3—solute carrier, family 12, member 3; Ter—
termination; Thr— threonine; Trp—tryptophan; Val—valine   
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Table 2 Frequencies of genetic variants associated with heart failure pharmacotherapy 
response 
 
Gene Variant rsID Minor 
allele 
Caucasian African-
Americans 
ABCB1 C3435T rs1045642 C 45% 87% (Africans) 
ACE Ins/Del 
Intron 16 
rs1799752 Ins 44% 43% 
ADD1 Gly460Trp rs4961 Trp 17% 11% 
ADRA1D T1848A rs2236554 A 46% 12% (Africans) 
A1905G rs709024 A 38% 70% (Africans) 
ADRA2C Ins/Del 
322-325 
rs61767072 Del 4% 43% 
ADRB1 Ser49Gly rs1801252 Gly 17% 25% 
Arg389Gly rs1801253 Gly 27% 38% 
ADRB2 Gly16Arg rs1042713 Arg 40% 50% (Africans) 
Gln27Glu rs1042714 Glu 42% 20% 
Thr164Ile rs1800888 Ile 2% < 2% (Africans) 
AGTR1 A1166C rs5186 C 25% 5% 
ANP Val32Met rs5063 Met 4% 2% 
Ter152Arg rs5065 Ter 14% 43% (Africans) 
CYP11B2 T-344C rs1799998 C 43% 30% 
CYP2C9 *2 N/A N/A 14% < 1% 
*3 N/A N/A 11% < 1% 
EDN1 G/A (IVS)-
4 
rs2071942 A 29% 17% (Africans) 
Lys198Asn rs5370 Asn 30% 17% 
GNB3 C825T rs5443 T 39% 91% (Africans) 
GRK5 Gln41Leu rs17098707 Leu 2% 24% 
NET T-182C rs2242446 C 25% 15% (Africans) 
NOS3 Glu298Asp rs1799983 Asp 22% 7% (Africans) 
SCNN1B Most 
frequent 
haplotype 
N/A N/A 65% N/A 
SCNN1G C4G rs5723 G 28% 24% (Africans) 
SLC12A3 Gly264Ala rs1529927 Ala 8% < 1% (Africans) 
 
A—adenine; ABCB1—P-glycoprotein (ATP-binding cassette, subfamily B, member 1); 
ACE—angiotensin-converting enzyme; ADD1—α-adducin 1; ADRA1D—α-1d adrenergic 
receptor; ADRA2C—α-2c adrenergic receptor; ADRB1—β-1 adrenergic receptor; 
ADRB2—β-2 adrenergic receptor; AGTR1—angiotensin II receptor type 1; Arg—
arginine; ANP—atrial natriuretic peptide precursor; Asn—asparagine; Asp—aspartic 
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acid; C—cytosine; CYP11B2— cytochrome P450, family 11, subfamily B, polypeptide 2; 
CYP2C9—cytochrome P450, family 2, subfamily C, polypeptide 9; Del—deletion; 
EDN1—endothelin-1; G—guanine; Gln—glutamine; Glu—glutamic acid; Gly—glycine; 
GNB3—guanine nucleotide binding protein–β polypeptide 3; GRK5—G protein–coupled 
receptor kinase 5; Ile— isoleucine; Ins—insertion; IVS—intervening sequence; Leu—
leucine; Lys—lysine; Met—methionine; N/A—not available; NET—norepinephrine 
transporter; NOS3—nitric oxide synthase 3; rsID—Reference Sequence Identification; 
SCNN1B—sodium channel non–voltage-gated 1-β; SCNN1G—sodium channel non–
voltage-gated 1-γ; Ser—serine; SLC12A3—solute carrier, family 12, member 3; T—
thymine; Ter—termination; Thr— threonine; Trp—tryptophan; Val—valine 
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APPENDIX III: 
 
Beta-1 adrenergic receptor genotype Ser49Gly is associated with beta-blocker 
Survival benefit in patients with heart failure 
 
Talameh J, Garrand A, Ghali J, Oren RM, Dunlap S, Bakel AV, et al. Beta-1 adrenergic 
receptor genotype Ser49Gly is associated with beta-blocker survival benefit in patients 
with heart failure. J Am Coll Cardiol 2012 3/27;59(13, Supplement):E861. 
 
 
Summary: Although beta-blockers (BB) reduce mortality in patients (Pts) with heart 
failure (HF), genetic differences in neurohormonal activation may limit effectiveness. 
Systematic review identified 3 adrenergic receptor SNPs as primary candidates. We 
report on the beta-1 receptor Gly49 variant that results in agonist-induced receptor down-
regulation in vitro. We hypothesized Gly49-carriers would have reduced response to BB 
compared to Ser49-homozygotes. This hypothesis was tested in the UNITE-HF DNA 
Registry, a prospective, observational, multicenter study of the genomics of HF in US Pts 
seen in HF specialty clinics. Data on BB use and survival (death index) were examined in 
Pts mostly enrolled from 2000-2002. Adjusted Cox models (including race) assessed 
BB*Ser49Gly interaction and the association between BB and survival stratified by 
Ser49Gly genotype. Data were available in 715 Pts on baseline BB use, vital status and 
Ser49Gly genotype (68% Ser49-homozygous and 32% Gly49-carriers). The cohort was 
63% male, 38% African-American (AA) and 44% ischemic etiology. Age of the cohort 
was 57±13 years (mean±SD), LVEF 32±16%, NYHA class 2.5±0.6 and SBP 119±22 
mmHg. Baseline drug use included ACEI or ARB (89%), diuretics (89%) and 
spironolactone (24%). BB utilization was 68% consistent with the enrollment period. 
Baseline characteristics were similar by genotype except AA race (33% Ser49-
homozygotes vs 49% Gly49-carriers, p<0.001). There were 348 deaths (52% Gly49-
carriers, 47% Ser49-homozygotes) at an average follow-up of 6.9±3.6 years. BB use was 
associated with reduced mortality in the overall study population (adjusted HR=0.72, 
95% CI 0.56 − 0.91, p=0.004) and Ser49-homozygotes (adjusted HR=0.56, 95% CI 0.42 
− 0.75, p<0.001) but not Gly49-carriers (adjusted HR=1.28, 95% CI 0.80 − 2.04, 
p=0.31). The adjusted interaction between Ser49Gly genotype and BB association with 
overall survival was p=0.004. These findings were independent of race (AA vs Non-AA). 
In conclusion, BB use was associated with prolonged survival in Ser49 homozygotes, but 
not in Gly49-carriers. This novel hypothesis-generating finding warrants replication in a 
prospective trial. 
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APPENDIX IV: 
PON1 Q192R and Clopidogrel: A case of the winner’s curse or inadequate 
replication? 
 
PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication? 
Talameh JA, McLeod HL. Clin Pharmacol Ther. 2011 Dec;90(6):771-4. 
 
75-word introduction (in place of an abstract) 
 The anti-platelet drug clopidogrel is one of the most commonly prescribed drugs 
in the world, but among patients there is wide variability in its anti-platelet effects. The 
majority of this variation is due to genetic effects, but there is controversy over which 
genetic variants are important and their relative contribution. This controversy may stem 
from the genetic association research paradigm, which casts the “winner’s curse.”  
 
 Coronary artery disease (CAD) is the leading cause of morbidity and mortality in 
the United States. Dual anti-platelet therapy with aspirin and clopidogrel is currently the 
standard of care for patients experiencing an acute coronary syndrome (ACS) who are 
managed either medically or with percutaneous coronary intervention (PCI). Clopidogrel 
inhibits adenosine diphosphate (ADP)–stimulated platelet activation by irreversibly 
binding the P2Y12 receptor, but it must first be enzymatically activated. Inadequate 
platelet inhibition from clopidogrel occurs in approximately 25% of the population and 
leads to recurrent cardiovascular events. This has been attributed to inadequate formation 
of clopidogrel active metabolites, in contrast to pharmacodynamic issues with binding to 
the P2Y12 receptor. However, the issues related to clopidogrel failure are controversial. 
274 
 
 The majority of pharmacogenetic studies for clopidogrel have observed that 
CYP2C19 inactivating variations are associated with decreased clopidogrel activation, a 
decreased anti-platelet effect, and an increased likelihood of a cardiovascular event.(1,2) 
These observations have been confirmed in a genome-wide association study.(1) More 
recently, Bouman et al demonstrated the importance of genetic variation in paraoxonase-
1 (PON1), an esterase synthesized in the liver, in determining clopidogrel efficacy.(3) 
Using a microsomal expression system of metabolizing enzymes, Bouman et al 
determined PON1 to be the rate-limiting step in the formation of the active metabolite of 
clopidogrel. A genetic variant in PON1 resulting in an amino acid change of glutamine 
(Q) to arginine (R) at position 192 (Q192R; A576G; rs662) more efficiently activated 
clopidogrel. This variant is common and varies across population groups, with Q192 
occurring in 60-75% of European-derived groups and 30-40% of Asian or African-
derived populations.(4) In a case-cohort study of 41 CAD patients receiving clopidogrel 
with stent thrombosis and 71 well-matched CAD controls without stent thrombosis, 
PON1 Q192R was significantly associated with PON1 enzyme activity, clopidogrel 
pharmacokinetics, platelet response, and the risk of stent thrombosis. This was confirmed 
in a prospective evaluation of 1,982 ACS patients followed for 12 months with respect to 
several clinical endpoints (Table 1).   
 In this issue of Clinical Pharmacology & Therapeutics, two studies failed to 
replicate the PON1 Q192R and clopidogrel findings (Table 1). Shuldiner et al followed 
227 patients for 12 months that underwent non-emergent PCI and did not find an 
association between Q192R and post-discharge ischemic events. Simon et al followed 
2,170 patients for 12 months after admission for definite myocardial infarction (MI) and 
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did not find an association between Q192R and several in-hospital outcomes  or 1-year 
outcome of death, MI, or stroke in all patients or the hospital survivors. In fact, none of 
the replication studies to date have been able to replicate the finding of an influence of 
PON1 on patient outcome (Table 1). The reason for this is not entirely clear, but it may 
be a case of the winner’s curse.  
 
The problem of the winner’s curse 
 The winner’s curse is a common phenomenon in genetic association literature, in 
which the initial reported genotype-phenotype association is exaggerated relative to the 
estimated effect in follow-up studies or cannot be subsequently replicated at all.(5) Failed 
replication can be due to issues in the initial studies and/or the attempted replication 
studies. Bouman et al, in reporting the initial PON1 Q192R findings, used both biologic 
plausibility and an independent replication cohort to support their findings. However, the 
biologic plausibility of PON1 Q192R, and all other genetic associations, must be 
carefully considered. The use of in vitro experiments remains challenging in the context 
of a complex human physiologic milieu, such as clopidogrel metabolism.  Bouman et al 
used supra-physiologic drug concentrations in in vitro experiments to assess biologic 
impact, which might have given false security of a meaningful finding.  The use of 
existing positive variables was not able to be used to build confidence in the experimental 
system, in that CYP2C19 was not confirmed as a player in clopidogrel metabolism.  
There was also the assumption that any PON1 effect would be via clopidogrel 
metabolism, when PON1 has anti-oxidant and atheroprotective effects (6), and Q192R is 
independently associated with all-cause mortality in cardiovascular disease patients.(7) 
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These possible independent mechanisms of PON1 would not be evident in the subsequent 
biologic replication studies, such as the platelet aggregation tests in Shuldiner et al, Trenk 
et al(8), and Sibbing et al(9), which were well-powered compared to clinical endpoint 
analyses. 
 In addition to demonstrating biologic plausibility, initial reports of genotype-
phenotype associations can be strengthened by replication. This method was also pursued 
by Bouman et al, so is the use of the term ‘failed replication’ justified by the studies of 
Shuldiner et al and Simon et al? The first issue to consider is study power. The study by 
Shuldiner et al was much smaller than Bouman et al. Simon et al had a similar sample 
size and length of follow-up as Bouman et al, but the number of actual patients 
undergoing PCI (n = 1538) was smaller than Bouman et al. Both Shuldiner et al and 
Simon et al were able to confirm the CYP2C19 association, but this doesn’t rule out a 
Type II error for the replication of PON1 Q192R findings.  
 The second issue is study heterogeneity. As shown in Table 1, the studies 
evaluating clopidogrel clinical response and PON1 Q192R are diverse with respect to 
design, patient population, and clinical endpoints. Shuldiner et al included patients 
undergoing non-emergent PCI, which are a lower risk group compared to the ACS 
patients studied by Bouman et al. Thirty-seven percent of the patients in the Shuldiner et 
al study were African-American, compared to Bouman et al that recruited their entire 
patient cohort among the white population of the Netherlands and Northwest Germany. 
Simon et al also studied a white European cohort, but underlying population genetic 
differences may still exist. Specifically, Q192R deviated from Hardy-Weinberg 
equilibrium in the Simon et al patient population, and there was a higher frequency of the 
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QQ192 genotype. Because of the potential anti-oxidant and atheroprotective effects of 
Q192R, there could be pre-existing selective pressure on patients prior to ever receiving 
clopidogrel. The ischemic stroke endpoint was not significantly associated with Q192R in 
Bouman et al, so it is interesting that Simon et al and Shuldiner et al chose to include it in 
their composite endpoints. Stent thrombosis was not a clinical endpoint considered in the 
Simon et al study’s 1-year composite endpoint, nor do they indicate how many of the 
patients received stents. Stent thrombosis has the closest pathophysiologic link to platelet 
aggregation compared to other endpoints such as death, MI, or stroke.  
 One of the greatest challenges in pharmacogenetics is the replication of a 
therapeutic predictor.  Exact replication among genetic association studies is difficult, as 
there is rarely the luxury of multiple study cohorts for the same clinical scenario.  This 
leads to a lack of clarity on whether a subsequent replication failure is due to correction 
of an initial false positive result or represents significant deviations in study design, 
statistical power, and clinical endpoint.  The challenges with identifying replication 
datasets has also strengthened the use of in vitro studies to demonstrate biologic 
plausibility.  However, as demonstrated in the case of PON1 Q192R, it may not always 
translate. Another lesson that can be learned from the PON1 Q192R story is the 
importance of evaluating “new” genetic markers (i.e. PON1 Q192R) in the context of 
“old” genetic markers (i.e. CYP2C19); all of the replication studies in Table 1 failed to 
replicate PON1 Q192R, but each confirmed the association with CYP2C19. The presence 
of a previously observed predictor anchors the results, giving confidence that the patient 
population and clinical context is likely to be consistent with previous reports. 
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 While PON1 does not have a clear clinical use, the PON1 Q192R and clopidogrel 
story is not over. It is possible that all of the variants in the Simon et al and Shuldiner et 
al studies (i.e. PON1, CYP2C19, and ABCB1) are “winners,” with each contributing a 
modest to small effect.  This would not be clearly observed in the study sample sizes 
present in the reports to date.  However to robustly assess genetic markers and optimize 
the use of resources, collaboration among researchers is needed to form well-powered 
and well-characterized clinical cohorts.  A strategy of periodic meta-analyses of genetic 
association studies must be performed to take into account variation in replication study 
design and to find the true winners.(10) 
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Table 1. PON1 Q192R and clopidogrel studies with clinical outcomes  
 
Study 
(reference) 
Design Patient 
population 
Race/ethnicit
y 
n Clinical 
endpoints 
Length 
of 
follow-
up 
Number of 
events (%) 
HR/OR 
(95% CI; 
p-value) 
Bouman et al 
2011(3) 
case-
cohort 
Clinical 
presentation 
of stable 
angina 
pectoris or 
ACS, who 
had 
undergone 
PCI with 
stent 
implantation
. 
White 
population of 
the 
Netherlands 
and 
Northwest 
Germany 
112 Nonfatal stent 
thrombosis 
18 
month
s 
41 cases  
71 
controls 
(RR 
reference
)  
QR = 4.41 
(1.89–
10.20; p = 
0.001)  
QQ = 
12.82 
(4.74–
90.91; 
p<0.001) 
prospectiv
e cohort 
Clinical 
presentation 
of ACS who 
had 
undergone 
PCI with 
stent 
implantation 
Self-reported 
European 
ancestry 
1,98
2 
1) non/fatal 
stent thrombosis  
2) MI  
3) composite of 
vascular death, 
nonfatal MI and 
nonfatal 
ischemic stroke 
4) ischemic 
stroke 
5) nonvascular 
death  
6) major 
bleeding 
12 
month
s 
1) 44 
(2.2%) 
2) 142 
(7.2%)  
3) 216 
(10.9%) 4) 
26 (1.3%)  
5) 15 
(0.8%)  
6) 57 
(2.9%) 
(RR 
reference
) 
QQ = 
1) 10.20 
(4.39–
71.43; p < 
0.001)  
2) 4.93 
(2.16–
11.24; p < 
0.001)  
3) 3.89 
(2.10–
7.19; p < 
0.001)  
4) 2.38 
(0.54–
10.42; p = 
0.250)  
5) 0.98 
(0.20–
4.72; p = 
0.981)  
6) 0.36 
(0.18–
0.75; p = 
0.006)   
Trenk et al 
2011(8) 
prospectiv
e cohort 
Patients 
undergoing 
elective PCI 
with stent 
placement 
Caucasian 
patients in 
Germany 
760 1) death or MI  
2) stent 
thrombosis 
12 
month
s 
1) 24 
(3.2%) 
2) 16 
(2.1%) 
(RR 
reference
) 
QQ = 
1) 0.61 
(0.20-
1.88; p= 
0.390)  
2) 0.28 
(0.08-
1.01; p= 
0.051)  
Sibbing et al 
2011(9) 
post hoc 
analysis of 
prospectiv
e cohort 
and 
registry 
Patients 
undergoing 
PCI with 
stent 
placement 
Enrolled in 
Germany 
1,56
6 
Stent thrombosis 
within 30 days 
n/a 127 cases 
1439 
controls 
(RR 
reference
) 
QQ = 
1.53 
(0.77-
3.05; p = 
280 
 
0.22)  
Shuldiner et 
al Clinical 
Pharmacolog
y and 
Therapeutics 
2011 
prospectiv
e cohort 
Patients 
undergoing 
non-
emergent 
PCI  
Enrolled in 
Baltimore, 
MD, USA; 
140 (62%) 
were 
Caucasian, 83 
(37%) were 
African 
American, and 
4 (2%) were of 
other 
race/ethnicity. 
(self-reported) 
227 Composite of MI, 
ischemic stroke, 
stent 
thrombosis,  
unplanned target 
vessel 
revascularization
,  hospitalization 
for coronary 
ischemia without 
revascularization
, or 
cardiovascular 
death 
 
12 
month
s 
Not 
reported 
(R-carrier 
reference
) 
QQ = 0.46 
(0.20-
1.06; p = 
0.07)  
Simon et al 
Clinical 
Pharmacolog
y and 
Therapeutics 
2011 
registry Patients 
admitted to 
the ICU for 
definite 
acute MI  
Enrolled in 
France; 
99% Caucasian 
2,17
0 
1) in-hospital 
outcomes 
(several 
categories)  
2) 1-year 
outcomes death, 
MI, or stroke in 
all patients  
3) 1-year 
outcomes death, 
MI, or stroke in 
hospital 
survivors 
 
12 
month
s 
1) (several 
categories
)  
2) 296 
(13%) 3) 
191 (10%) 
(RR 
reference
) 
QQ = 
1) NS 
2) 1.03 
(0.66-
1.61; p = 
0.41)  
3) 0.86 
(0.52-
1.44; p = 
0.12) 
ACS = acute coronary syndromes, HR = hazard ratio, ICU = intensive care unit, MI = 
myocardial infarction, NS = not significant, OR = odds ratio, PCI = percutaneous 
coronary intervention
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